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ABSTRACT 
 
Key words: Peripheral neuropathy, HIV/AIDS, Progressive resisted exercise, 
Performance oriented mobility, Quality of life. 
 
Background: Distal symmetrical poly-neuropathy (DSP) has emerged as one of the 
major neurological complication associated with HIV/AIDS and antiretroviral therapy. 
People with DSP commonly have problems with pain, mobility, altered gait and 
balance all which affect their quality of life. While therapeutic strengthening exercise 
has been reported to attenuate these impairments in other co-morbid conditions like 
diabetes mellitus and in HIV/AIDS, there is no evidence available on the effects of 
exercise on DSP in people living with HIV/AIDS (PLWHA).The purpose of this study 
was to determine the effects of progressive resisted exercises (PRE) on performance 
oriented mobility and health related quality of life in (PLWHA) related DSP.  
Objectives of this study were to determine the effects of PRE on gait, balance and 
pain levels and establish if there is a relationship between performance-oriented 
mobility and health-related quality of life in PLWHA related DSP. Methods: In order 
to fulfil the objectives, an assessor-blinded randomized controlled trial was conducted 
over two studies, with a combined sample of 160 participants sourced from two 
family care clinics at two central hospitals and ten anti-retroviral therapy dispensing 
municipal clinics in Harare, Zimbabwe. While the experimental group with 80 
participants had an intervention program of PRE sessions of one hour for the lower 
limbs, done twice per week over 12 weeks, the control group of 80 participants was 
given advice to walk unsupervised at home. Loss to follow up in this study was at 
60% (n=97) and the data was analysed using an intention to treat analysis approach. 
Results: Participants of an average age of 42.2 years (SD=8.5) constituted of 70.6% 
(n=113) female participants. Combination antiretroviral therapy containing stavudine, 
was used by 59% (n=94) of the participants and 59% (n=94) of the participants had 
moderate to severe neuropathy. Proximal muscles exhibited weakness (hamstring 
muscles strength = 3.43 kg force (SD=1.5)) when compared to leg muscles 
(gastrocnemius muscles strength = 12.8 kg force (SD=2.0)). Gait and balance scores 
did not show differences in effect between the intervention and the control group 
(95%CI 0.00-0.02, p = 0.8). Similarly there were no differences of effect for muscle 
strength (95%CI 0.00-0.08, p=0.13-0.8) and pain (95%CI 0.0-0.06, p>0.13). However 
the effect on quality of life changes were significantly different between the two 
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groups (95%CI 0.00-0.12 p= 0.04). Quality of life was positively associated with gait, 
odds ratio 1.01 (95%CI 1.00 – 1.04), moderately associated with balance odds ratio 
0.68, (95%CI 0.52 – 0.93) negatively associated with pain odds ratio 0.98 (95%CI 
0.97 – 0.99). Conclusion: This research study established that progressive resisted 
exercises have positive effects on the health related quality of life in PLWHA related 
DSP. However this study did not show a difference of the effects of progressive 
resisted exercises on performance oriented mobility in PLWHA related DSP when 
compared to advice to exercise at home. The study findings may not be generalized 
to all individuals living with HIV/AIDS who have DSP as the participants were from a 
particular demographic setting. This project may be continued at the participating 
family care clinics as a roll on of the perceived benefits of exercise for people with 
HIV related DSP. 
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CHAPTER 1 
1. INTRODUCTION 
1.1 Background  
 
There are 34 million people living with Human Immunodeficiency Virus and Acquired 
Immunodeficiency Syndrome (HIV/AIDS) globally (UNAIDS, 2011). Of this 
population, the Sub Saharan region has the highest prevalence rate of 68% 
(UNAIDS, 2011). However, prevalence rates declined in Botswana, Rwanda and 
Uganda. In Zimbabwe, the rates declined from 26% in 2002 to 14.3% in 2009 
(UNAIDS, 2011). 
 
While global mortality stood at 1.8 million deaths in 2010 (UNAIDS, 2011) the 
introduction of highly active antiretroviral therapy (HAART) has led to longer life 
expectancy. The complications of HIV infection, opportunistic infections and side 
effects of HAART has emerged as the most common cause of HIV associated 
morbidity (Dudgeon, et al., 2004). One of the common neurological conditions 
associated with HIV complications is peripheral neuropathy (Verma and Simpson 
2007). Peripheral neuropathy can also be caused by diabetes mellitus, alcoholism, 
and neuro-toxic drugs (Keswani, et al., 2003). Distal symmetrical poly-neuropathy 
(DSP) is the most prevalent form of peripheral neuropathy occurring in 50% of cases 
with HIV/AIDS (Simpson, et al., 2006). In Zimbabwe 60% of people living with 
HIV/AIDS are experiencing the complications of peripheral neuropathy (Robertson, et 
al., 2008). Other forms of peripheral neuropathy include mono-neuropathy multiplex, 
inflammatory demyelinating poly-neuropathy (Gullain Barre Syndrome), progressive 
poly-radiculopathy, autonomic neuropathy and mono-radiculopathy (Nicholas, et al., 
2007b). 
 
Distal symmetrical poly-neuropathy is a complex of symptoms that occur as a result 
of peripheral nerve damage (Nicholas, et al., 2007b). The primary damage occurs 
mostly in the sensory neurons leading to axonal degeneration (dying back process) 
and the manifestations of sensory dysfunction (Hahn, et al., 2008). 
Electrophysiological data has been used to confirm peripheral nerve axonal loss, 
demylenation and muscle denervation in HIV infected patients (Schifitto, et al., 2002). 
2 
 
HIV infected macrophages damage dorsal root ganglia by secreting antigens and 
pro-inflammatory cytokines (Hahn, et al., 2008). Stavudine, didanosine and 
zidovudine were part of the standard first line HAART drugs used in Zimbabwe in the 
first decade of the HAART roll-out (EDLIZ 2006). These drugs which are classified as 
dideoxy-nucleoside reverse transcriptase inhibitors (NRTI) are believed to cause 
neuronal damage. Their pharmacological mechanisms interfere with mitochondrial 
oxidative metabolism of the neuronal cell body and growth factors production 
(Keswani, et al., 2007). 
 
While it normally requires technical capacity or specialised medical training to make a 
diagnosis of distal peripheral neuropathy, a brief peripheral neuropathy screen 
(BPNS) can be used in clinical settings (Schiffito, et al., 2003). This test can be used 
by the medical doctor, trained nurses or therapists (Cherry, et al., 2005). Symptoms 
of pain, the presence of distal bilateral symmetrical burning sensation, parasthesia, 
or numbness, cramping in the legs, and muscle weakness in the foot can be used to 
confirm distal symmetrical poly-neuropathy (Schiffitto, et al., 2003). A neurological 
examination will reveal absence of or diminished ankle reflexes compared to knee 
reflexes and distal reduction of vibratory pain or temperature perception in a glove 
and stocking distribution (Cherry, et al., 2005). Further tests which can be used are 
skin biopsy for epidermal nerve fiber density quantitation (Hahn, et al., 2006), nerve 
conduction tests consisting of compound muscle action potentials and sensory nerve 
action potentials (Simpson, et al., 2006). 
 
People with peripheral neuropathy commonly present with pain, altered sensation, 
muscle weakness and increased fatigue (White, Pritchard and Turner-Stokes 2004). 
These impairments may lead to immobility, altered gait, increased risk of fall and 
psychological dysfunction (Dudgeon, et al., 2004).  
 
Distal symmetrical poly-neuropathy impairments may be managed 
pharmacologically, non-pharmacological or by self-care strategies depending on 
severity of symptoms, preference or availability (Nicholas, et al., 2007a). In 
physiotherapy practice, a non-pharmacological approach, these impairments can be 
addressed by use of functional electrical stimulation, transcutaneous electrical nerve 
stimulation (TENS), interferential therapy, heat therapy, ice, massage, acupuncture, 
hydrotherapy and therapeutic exercise (Nicholas, et al., 2007b). Therapeutic exercise 
can be defined as the prescription of a physical activity or program that involves the 
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client to undertake voluntary muscle contraction and or body movement with the aim 
of relieving symptoms or improving, retaining or slowing deterioration of health 
(Taylor, et al., 2007).Therapeutic exercise includes progressive resisted exercise, 
aerobic exercise, individualized exercise programs and general home programme 
(Fillipas, et al., 2006). 
 
The benefits of therapeutic exercise are well documented in randomized clinical trials 
and systemic reviews (Taylor, et al., 2007; O‟Brien, et al., 2008, 2010). Strengthening 
exercises have been reported to improve muscle strength in people with peripheral 
neuropathy (White, et al., 2004; Richardson, Sandman and Vela, 2001). Supervised 
aerobic exercise, done at sub-maximal age predicted maximal heart rate levels of 
70% and resistance exercise program in people with HIV is safe and improves cardio 
vascular fitness (O „Brien , et al., 2008, 2010). The recommended intensity for 
progressive resisted exercise is one to three sets of 8-12 repetition maximum with 
rest of one to three minutes between the sets done two to three times a week 
(ACSM, 2011). Exercise reduces central adiposity, improves metabolic indices 
(Mutimura, et al., 2008) and significantly improves immunology and virology outcome 
measures (Dudgeon, et al., 2004).  
 
Various outcome measures have been used to evaluate mobility and effectiveness of 
intervention used. For the requirements of this study, the modified Performance 
Oriented Mobility Assessment (POMA) was selected (Tinneti 1986; Kegelmeyer, et 
al., 2007; Faber, et al., 2006). It is used for rating gait and balance and a total score 
is derived as an aggregate of the two subscales (Faber, et al., 2006). The value of 
the minimal detectable change (MDC) at 95% confidence level, following an 
intervention for individuals was at least five (5) points and 0.8 points for group scores 
for the change to be considered significant (Faber, et al., 2006). The Euro Quality of 
Life – 5 (Five) Dimensions (EQ-5D) state of health questionnaire was used to assess 
the functional health related quality of life status (Jelsma, et al., 2005). Within its 
domains is a general assessment of pain and mobility. A Shona version of the 
questionnaire was developed by Jelsma, et al., (2001). It is reliable with a high 
measure of agreement range of 0.78 to 1.00 (kappa statistic), for the different 
domains of activity. 
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1.2 Problem statement 
 
There is currently insufficient evidence available to draw the best clinical practice 
guidelines for the management of the effects of DSP in adults living with HIV/AIDS.  
 
1.3 Research question 
 
What is the effect of progressive resisted exercises on the performance oriented 
mobility and health related quality of life of patients with HIV and AIDS related DSP? 
 
1.4 Aim of study 
 
To determine the effects of progressive resisted exercises on performance oriented 
mobility and health related quality of life in patients with HIV/AIDS related (DSP). 
 
1.4.1 Objectives of the study: 
 
1. To determine the effects of progressive resisted exercises on gait in 
patients with HIV/AIDS related DSP. 
2. To determine the effects of progressive resisted exercises on balance in 
patients with HIV/AIDS related DSP. 
3. To determine the effects of progressive resisted exercises on pain levels 
in patients with HIV/AIDS related DSP. 
4. To establish if there is a relationship between performance-oriented 
mobility and health related quality of life in people with HIV/AIDS related 
DSP.  
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1.5 Hypothesis  
 
Research Hypothesis: progressive resisted exercises have positive effects on 
performance oriented mobility and health related quality of life in subjects with 
HIV/AIDS related DSP. 
Null Hypothesis: progressive resisted exercises have no effect on performance 
oriented mobility and health related quality of life in subjects with HIV/AIDS related 
DSP.  
 
1.6 Significance of the study 
 
The number of people living with HIV who are experiencing peripheral neuropathy 
complications (Simpson, et al., 2006) makes it necessary to research the effect of 
exercise therapy on the mobility and quality of life of those affected (UNAIDS, 
2010).The study results may be useful in improving our understanding of how 
progressive exercise may be harnessed for other conditions where peripheral 
neuropathy is a major complaint (White, et al., 2004). 
 
1.7 Justification of study 
 
While the Zimbabwe HIV and AIDS strategic plan 2006-2010 (NAC UNAIDS, WHO 
2006), a policy document, recommends the mainstreaming of nutrition, it is silent on 
physical fitness, wellness and quality of life as a measure to improve the state of 
health in people living with HIV and AIDS. Considering that 60% of people living with 
HIV and AIDS in Zimbabwe, are experiencing the complications of peripheral 
neuropathy (Robertson, et al., 2008), a research study on the effects of therapeutic 
exercise on mobility and the quality of life of the affected is therefore necessary and 
relevant (UNAIDS, 2010).  
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1.8 Procedure, instruments and data analysis 
 
The study was of an assessor-blind randomized controlled clinical trial design. The 
experimental group had an intervention program of progressive resisted exercises 
while the control group was given advice to walk as with the usual method. Whereas 
the initial protocol plan sought to source participants from the three main hospitals, 
when this was done, the study had a high loss to follow-up. Thus the study was 
repeated using the same methodology and a higher sample size with participants 
sourced from antiretroviral dispensing clinics in the community.  
 
Upon pooling of the data from the studies completed, one hundred and sixty 
participants were randomized into these two groups. Eighty participants per group 
had been sourced from the anti-retroviral therapy dispensing clinics and the family 
care clinic at Wilkins Hospital of the Municipal of Harare and family care clinics at 
Parirenyatwa and Harare Central Hospitals in Zimbabwe. Baseline assessments 
consisted of demographic information including HIV measures; CD4+ counts; 
medication; length of time on anti-retroviral drugs and history. The Brief peripheral 
neuropathy screen questionnaires were administered to ascertain diagnosis of 
peripheral neuropathy using scores of neural deficits and symptoms. Muscle strength 
was measured using a hand held dynamometer while pain was assessed using a 
pictorial Likert like scale. While Performance oriented mobility was based on the 
POMA scores, health-related quality of life levels were ascertained using the Shona 
or English EQ-5D questionnaire. The researcher did all assessments and trained the 
research assistants to implement the intervention. 
 
Data was analysed using an intention-to-treat approach. The mean change in all the 
outcomes was analysed with respect to the objectives of the study using the STATA 
v10 statistical software after cutting and pasting into the STATA v10 program from 
data logged in the Excel program. An intention-to-treat analysis captures the real life 
situation, where the participants who may not have been as compliant and adherent 
to the intervention are also included thereby reducing occurrence of possible bias 
about the effectiveness of the intervention (Petroczi, et al., 2010).  
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CHAPTER 2 
2. LITERATURE REVIEW 
 
2.1 Introduction 
 
This review of literature will briefly outline the situation regarding HIV/AIDS and how 
peripheral neuropathy has emerged as a major complication of HIV/AIDS and anti-
retroviral therapy. A focused discussion will be presented on the effects of peripheral 
neuropathy in people living with HIV/AIDS and how the strategies have been 
developed by practitioners involved in managing these effects. Methods chosen to 
assess the effects of peripheral neuropathy will be reviewed, highlighting the reasons 
why these methods were chosen for use in this study. 
 
Articles reviewed in this chapter were sourced from physiotherapy journals, 
publications, Pubmed, the Cochrane collaboration, and Google search engine. 
Keywords in the literature search included HIV, peripheral neuropathy, HAART, 
therapeutic exercise, progressive resisted exercise, balance, gait, pain and quality of 
life.  
2.2 HIV/AIDS situation 
 
There are 34 million people globally who are living with the Human Immunodeficiency 
Virus and Acquired Immunodeficiency Syndrome (HIV/AIDS) (UNAIDS, 2011). Of 
this population, the Sub Saharan region has the highest prevalence of 68% 
(UNAIDS, 2011). Concerted intervention efforts by different organizations and the 
governments have seen a decline in the rates in Botswana, Rwanda and Uganda 
(UNAIDS, 2010). In Zimbabwe, the prevalence rate reduced from 26% in 2002 to 
13.9% in 2009 (UNAIDS, 2010). Although the global mortality rate stood at 1.8 million 
deaths in 2010 (UNAIDS, 2011), widespread availability of highly active antiretroviral 
therapy (HAART) has led to longer life expectancy, transforming HIV from a terminal 
to an episodic chronic illness (Rusch, et al., 2004). Associated HIV co-morbidity has 
emerged as the major medical challenge from the complications of HIV infection, 
opportunistic infections, and the neurotoxicity of some classes of HAART drugs 
(Nicholas, et al., 2007b).  
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2.3 Peripheral neuropathy 
 
Peripheral neuropathy (PN) is the most common neurological complication emerging 
from the era of HAART (Keswani, et al., 2002) with distal symmetrical peripheral 
neuropathy (DSP) being the most common form of peripheral neuropathy (Verma 
and Simpson, 2007). In Zimbabwe, 60% of people with HIV who were yet to 
commence on antiretroviral therapy were found to have peripheral neuropathy 
(Robertson, et al., 2008). 
 
Peripheral neuropathy presents and consists of several patterns and forms namely 
mono-neuropathy multiplex including vasculitis neuropathy, brachial and lumbar 
plexopathy, inflammatory demyelinating polyradiculo-neuropathy (also known as 
Guillain Barre Syndrome), progressive poly-radiculopathy including cytomegalovirus 
polyradiculopathy and myeloradiculopathy, autonomic neuropathy, mono-
radiculopathy,  diffuse infiltrative lymphocytosis syndrome and distal symmetrical 
polyneuropathy (Keswani, et al., 2002; Nicholas, et al., 2007b; Verma and Simpson, 
2007).   
 
Distal symmetrical polyneuropathy is a complex of manifestations of sensory 
dysfunction as a result of peripheral nerve damage (Hahn, et al., 2008). The primary 
damage occurs to nerve structures like the myelin (insulating sheath of the nerve) 
and the axon (the central fibre of the nerve) leading to axonal degeneration (termed 
dying back process) or it may involve both as well as the dorsal root ganglia (White, 
Pritchard and Turner- Stokes, 2004). Damage occurs mostly in the sensory neurons, 
with the resultant sensory dysfunction presentation (Keswani et al., 2002). Motor 
activity may also be affected by the alteration of motor nerve function, leading to 
motor activity dysfunction which presents as cramping in the legs and muscle 
weakness in the foot (Cherry, et al., 2005; Nicholas, et al., 2007b).  
 
Diagnosis of distal symmetrical polyneuropathy (DSP) can be drawn from the most 
commonly observed neurological signs (Schifitto, et al., 2002). On examination there 
are dampened or absent ankle reflexes while the patellar reflexes are usually intact 
(Verma and Simpson, 2007). Pinprick, temperature and vibration are impaired or 
reduced distally (Verma and Simpson, 2007).  While DSP was previously commonly 
associated and prevalent in patients with diabetes mellitus it has been known to 
present concomitantly in patients who have alcohol abuse, cancer, multiple sclerosis, 
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spinal cord disorders, cognitive problems, hypothyroidism, hereditary neuropathy, 
Vitamin B12 and thiamine deficiency, uremia, significant weight loss, low albumin, 
low haemoglobin and neurotoxic agents or drugs like anti-tuberculosis drugs such as 
isoniazide (Verma and Simpson, 2007).   Currently, DSP is strongly associated with 
HIV/AIDS and antiretroviral therapy complications. 
2.4 HIV associated peripheral neuropathy 
2.4.1  The general effects of HIV on body systems 
 
HIV has many effects on the human body and its systems (Dudgeon, et al., 2004). 
Skeletal muscle wasting was the identifying effect of HIV before HAART, (which gave 
HIV/AIDS the name; slimming disease) mainly caused by the catabolic effects of 
increased circulating gluco-corticoid levels (Dudgeon, et al., 2004).  Increased blood 
gluco-corticoid levels slow down protein synthesis while increasing the processes 
that breakdown muscle content (Dudgeon, et al., 2004). Weight loss is influenced by 
the combination of episodes of infection which lead to a significant rise of circulating 
cytokine and gluco-corticoid levels causing an increased level of resting energy 
consumption and reduced food intake as a result of several factors including loss of 
appetite (Dudgeon, et al., 2004). 
 
 While HIV has a well-documented and often cited effect on the immune system, it is 
also generally recognized as having adverse effects on most body systems including 
the nervous, musculoskeletal and cardiopulmonary systems (Cherner, et al., 2004). 
Myezwa, et al., (2009) found that 69% of the participants in a suburban setting study 
in South Africa had mental function impairment. This is consistent with the review 
findings by Wright, et al., (2008) which show that HIV associated neuro-cognitive 
dysfunction (HAND) including dementia was the most commonly observed effect of 
HIV.  
 
HIV associated cardiopulmonary effects were among the first systemic effects to be 
noticed and as shown in Myezwa, et al., (2009)‟s study, respiratory problems were 
reported in 22% of the participants. Most of the opportunistic infections are in the 
form of tuberculosis. Mutimura, et al., (2008) in a random controlled trial, where they 
investigated the use of exercise training to reduce central adiposity, demonstrated 
the negative effects of HIV on the metabolic indices on the baseline measures in 
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lipodystrophy in HAART-treated HIV-positive participants. Furthermore, Gabuzda and 
Wang (2000), in a scholarly review, postulate that HIV tends to have a high affinity for 
the neural cells since it appears to affect the central and peripheral nervous system 
more often. 
 
2.4.2  HIV as a cause of peripheral neuropathy 
 
The pathogenesis of peripheral neuropathy is hypothesised to evolve by two main 
pathways. The first pathway proposes that the HIV glycoprotein 120 (GP120) 
envelope has a toxic effects when it binds to a certain vanilloid receptors on the 
CD4+ receptor of the macrophage thereby interfering with immune responses 
(Keswani, et al., 2002). The second pathway proposes that, HIV infected 
macrophages damage dorsal root ganglia by secreting antigens and pro-
inflammatory cytokines (Hahn, et al., 2008). Chemotactic cytokines (chemokines) like 
the TNF- alpha, Interleukin-1 (IL-1) and IL-6 cathepsin S and fractalkine, which are 
released locally as a result of the presence of macrophages, serve as coordinators of 
the nervous system, signalling and controlling the movements of leukocytes into the 
neural tissues during an inflammatory response process (Abbadie, et al., 2009; 
White, Jung, and Miller 2007; Gabuzda and Wang 2000). An appropriate 
inflammatory response is required for the clearance of pathogens but can become 
pathological if this response is prolonged or excessive (Keswani, et al., 2002).   Thus 
Nicholas, et al., (2007b), in a review, concluded that DSP is a complex of symptoms 
that occurs at any stage of HIV/AIDS and is associated with exposure to viral load 
and mitochondrial toxicity, disease duration and exposure to neurotoxic antiretroviral 
therapy. 
 
2.4.3  Anti-retroviral therapy toxic neuropathy (ATN) 
 
While antiretroviral therapy (ART) is critical in containing the viral load and promoting 
increased CD4+ count, it has been shown that some ART regimens used in 
Zimbabwe and in some developing countries in the first decade of the twenty-first 
century (National Drug and Therapeutics Policy advisory Committee, NDTPAC 2010) 
are neuro-toxic.  
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Anti-retroviral therapy regimens 
 
Below is a summary of the different antiretroviral drugs used in Zimbabwe and their 
side effects on the neuro-musculoskeletal system (NDTPAC, 2010). 
 
Table 1.1 Antiretroviral drugs used in Zimbabwe and their side effects on the neuro-
musculoskeletal system (NDTPAC, 2010) 
Class Drug musculoskeletal/ major side effects  
Nucleoside reverse 
transcriptase 
inhibitors (NRTIs) 
Zidovudine (AZT), Anaemia, myopathy, lactic acidosis 
Didanosine (ddI), Peripheral neuropathy, lactic acidosis 
Zalcitabine (ddC), Peripheral neuropathy 
Stavudine (d4T), Peripheral neuropathy, fatigue, lactic 
acidosis 
Lamuvidine (3TC) Nil  
Abacavir (ABC) Hypersensitivity 
Nucleotide reverse 
transcriptase 
inhibitors (NRTIs) 
Tenofovir (TDF), Renal complications 
Fusion inhibitor Enfuvirtide Nil 
Non- nucleoside 
reverse transcriptase 
inhibitors (NNRTIs) 
Nevaripine (NVP), Fatigue, nausea 
Efavirenz (EFV) Confusion, headache, sleep 
disturbance  
Delavirdine (DLV). Nil 
Protease inhibitors. Saquinavir (SQV), Lipodystrophy, tiredness dizziness 
Ritonavir (RTV), Lipodystrophy 
Indinavir (IDV), Lipodystrophy, muscle pain, 
headache, blurred vision 
Nelfinavir (NFV), Nil 
Amprenavir (APV) Nil 
Lopinavir (LPV) Lipodystrophy 
Atazanavir Headache, nausea 
 
Antiretroviral drugs are classified as nucleoside reverse transcriptase inhibitors, non- 
nucleoside reverse transcriptase inhibitors, and protease inhibitors (Bartlett & Gallant 
2003). The nucleoside/ nucleotide reverse transcriptase inhibitors (NRTIs) are also 
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known as dideoxy-nucleosides (ddN) (Bartlett and Gallant, 2003). These drugs act by 
blocking the HIV reverse transcriptase enzyme and prevent the copying of the viral 
RNA into the DNA of infected host cells by presenting deceptive building blocks of 
the DNA chain (NDTPAC, 2010). The resulting DNA chain is incomplete and 
therefore unable create new viruses (NDTPAC, 2010). The non- nucleoside reverse 
transcriptase inhibitors (NNRTIs) have the same modality of function with more 
resistant profile than the nucleotide analogues and protease inhibitors are not yet 
publicly the available in Zimbabwe (NDTPAC, 2010). The intergrase inhibitor, fusion 
inhibitor and the CCR5 inhibitor classes of antiretroviral drugs are not yet in use in 
Zimbabwe (NDTPAC, 2010). 
 
Mechanisms of neurotoxicity in antiretroviral therapy neuropathy (ATN) 
 
Stavudine (d4T), didanosine (ddI), zalcitabine (ddC) are dideoxy-nucleoside reverse 
transcriptase inhibitors (ddN or NRTI) drugs, which were widely and commonly used 
in the developing world as recommended by World Health Organisation (WHO) 
(NDTPAC, 2003; Bartlett and Gallant, 2003). These drugs have been observed to be 
a cause of toxic neuropathy as shown in Table 1.1. Menez, et al., (2011) in a South 
African study with a large study of 9040 participants on HAART showed that 
Stavudine was associated with co-morbidities which seemed to outweigh the drugs 
benefits. However, Keswani, et al., (2002) in their review of clinical trials and expert -
opinion, feel that since DSP and ATN are similar in their presentation, it may be 
possible that dideoxy-nucleoside only serve to unmask the latent asymptomatic DSP 
thereby worsening the damage to the neuronal cells. Other classes of HAART have 
been trialed to establish their possible contribution to peripheral neuropathy. For 
example, Ellis et al., (2008) showed that, exposure to protease inhibitors drew a 
negligible risk of peripheral neuropathy in a prospective study in North American 
locations involving a sample of 1159 HIV infected participants.  
 
The nucleoside inhibitors‟ become toxic by way of their activity when they interfere 
with the mitochondrial oxidative metabolism of the neuronal cell body as well as with 
growth factor production (Nicholas, et al., 2007b; Hahn, et al., 2008). Keswani, et al., 
(2002) outlines a possible mechanism of how the NRTI interacts with triphosphate 
thereby inhibiting deoxyribonucleic acid (DNA) polymerase gamma leading to 
reduction in mitochondrial DNA levels.  Other mechanisms involves drug toxicity 
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emanating from anti-retroviral drug interference in the activity of adenylate kinase, an 
enzyme responsible for catalyzing the oxidative phosphorylation of adenosine 
diphosphate, a nucleoside diphosphate to adenosine triphosphate (Keswani, et al., 
2002).    This process is critical for the energy requirements of a cell (Keswani, et al., 
2002). The NRTI is also thought to actively interfere with the activity of other 
respiratory complexes that form the electron transport chain thereby impairing the 
process of oxidative phosphorylation, which is required in the formation of energy 
(Keswani, et al., 2002). This reduces the available energy levels for cellular activity 
leading to a cascade of other harmful corrective processes leading to neuronal cell 
death (Keswani, et al., 2002). 
 
Anti-retroviral therapy in Zimbabwe is based on WHO guidelines (NDTPAC, 
2010).The first line of treatment for adults in Zimbabwe in the first decade of the HIV 
pandemic after the introduction of HAART consisted of stavudine, lamivudine and 
nevirapine (NDTPAC, 2003).  This was normally given as a combination product 
Stalanev or Triviro with cotrimoxazole prophylaxis (NDTPAC, 2003).  However this is 
in the process of being phased out with a new regime of first line therapy now 
consisting of a first line of tenofovir and zidovudine combined with lamivudine and 
nevirapine (Zidolan) (NDTPAC, 2010). This is consistent with the findings in 
Griensven, et al., (2010)‟s study, where in a cohort in which 2190 participants who 
had used stavudine were re-assessed after its substitution for a variety of toxic 
effects. They found that one of the major side-effects of stavudine was DSP thus 
concurring with the WHO position.  
  
Hence while HIV may have initiated the DSP through pathological inflammation and 
macrophage activation in the peripheral nerves and dorsal root ganglia, the use of 
dideoxy-nucleoside in antiretroviral therapy worsens the DSP, unmasking its 
presence (Keswani, et al., 2002). It remains to be established if the peripheral 
neuropathy experienced in diabetes mellitus and co-morbidities is phenotypically 
identical to the HIV- associated peripheral neuropathy.  
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2.5 The effects of HIV-associated peripheral neuropathy 
2.5.1  Introduction 
 
Effects of DSP consist of various degrees and forms of sensory impairments, pain, 
gait dysfunction and imbalance, fatigue, muscle weakness and impaired health 
related quality of life (Nicholas, et al., 2007b). The International classification of 
function (ICF) is going to be used to describe the presentations of the effects of HIV-
associated peripheral neuropathy found in the literature.  
 
The ICF is a classification system developed by the World Health Organization 
(WHO) to improve communication between stakeholders, who include health 
professionals and people with disabilities (Hwang and Nochajski, 2003). Dimensions 
of human function are considered as different domains, thereby capturing the factors 
which allow for wholistic approach to assessment and intervention. Impairments are 
defined by the ICF (WHO, 2001) as problems in body function or structure such as a 
significant deviation or loss (WHO, 2001). Major impairments in PLWHA occur in 
mental, neuro-musculoskeletal and movement related functions (Myezwa, et al., 
2009). Activity limitations are seen as the difficulties an individual may have in the 
performance of activities, previously termed disability (WHO, 2001). Furthermore, 
participation restrictions are problems an individual may have in the manner or extent 
of involvement in life situations and these were previously termed handicaps (WHO, 
2001). 
  
2.5.2  Sensory impairments related to peripheral neuropathy  
 
As already identified, one of the major impairments for PLWHA, is neuro-
musculoskeletal function. Hahn, et al., (2008) and White, Pritchard and Turner- 
Stokes, (2004) explain that primary damage in peripheral neuropathy occurs mostly 
in the sensory neurons, leading to axonal degeneration and alteration of nerve 
function. The major manifestations of sensory impairment as outlined by Cherry, et 
al., (2005) include pain, aching, symmetrical distal burning, numbness (loss of feeling 
of an area), pins and needles (paraesthesia) and loss of perception of vibration. 
While pain will be reviewed in the next section, numbness is an equally important 
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sensory impairment with serious implications on activity limitations. As shown by 
Tannenburg, (2009) in a review, peripheral neuropathy can present as a 
contradiction of painful neuropathy or painless neuropathy (numbness). Nerve 
function alteration also results in allodynia where PLWHA with DSP become overly 
sensitive to touch, and cannot tolerate contact with blankets/ covers during sleeping 
time and to socks or shoes (Simpson, et al., 2006; Keswani, et al., 2002). Sensation 
to temperature becomes impaired with the affected PLWHA with DSP being unable 
to tell hot from cold, often denoted by inability to tell a hot bath/shower from a cold 
one (Verma and Simpson, 2007).   Cherry, et al., (2005) clarify that these sensations 
may be of sharp stabbing, lancinating or shooting pain quality with the legs 
sometimes experiencing electric shock like pain. The physiology of pain will be briefly 
explained in the section on neuropathic pain. 
2.5.3  Neuropathic pain  
 
Pain is a complex symptom of the sensory impairments which occur as a result of 
injury to the sensory neurons. As such pain is defined as a sensation of unpleasant 
feeling indicating potential or actual damage to some body structure and is classified 
as impairment by the ICF (WHO, 2001).  
 
Pain is primarily a subjective symptom based on mostly an individual experience 
which requires a multidisciplinary approach to comprehend its complex presentation 
(Campbell, Clauw, and Keefe, 2003). It may also be defined using the biomedical or 
the bio psychosocial model or a combination medical-psychosocial approach 
(Campbell, Clauw, and Keefe, 2003). In the biomedical framework, pain perception is 
modulated by nociceptors through a neurone network to the thalamus and to the 
somatosensory centres in the cortex (White, Jung and Miller, 2007). A feedback loop 
in the pathways initiates a pain withdrawal reflex while an efferent impulse leads to a 
local release of neuropeptides which is believed to offset an inflammatory response 
which is augmented by the immune response (White, Jung and Miller, 2007).  
 
In neuropathic pain the initial inflammatory response activates spinal sensitisation 
through involvement of other nociceptive mediators and pathways still being 
investigated (Abddie, et al., 2005).  Once spinal sensitization has occurred a 
phenomena involving chemokines and the immune mediators is set in motion, where 
pain continues to be propagated in the absence of a pain stimulus (White, Jung and 
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Miller, 2007). While the biomedical model assumes that pain is equivalent to noci-
ception, it fails to fully explain phantom limb pain, pain in the absence of pathology or 
pathology without pain (Abddie, et al., 2005).   
 
Hence a more integrative conceptual model with a multi-disciplinary understanding is 
required to explain chronic pain which has proved to be a difficult symptom to 
manage leading to concerted attempts to understand its propagation (Campbell, 
Clauw, and Keefe, 2003). Chronic pain, which is similar to neuropathic pain, is 
associated with depression which may manifest as maladaptive coping responses for 
example catastrophizing, perceived helplessness, and low self-efficacy and pain 
related fear and anxiety (Keefe, et al., 2004).  
 
Considering that people adjust themselves to pain in different ways Keeffe, et al., 
(2004), found that an adjustment response to chronic pain was dependent on factors 
like: self-efficacy, acceptance, coping mechanisms, and the readiness to change. 
Group support and interaction are known to be as effective management approaches 
for adjustment to chronic situations like pain (Lucey, et al., 2011).  Keeffe, et al., 
(2004) explains that differing coping mechanisms to persistent pain also yield 
different perceptions to pain. Catastrophizing is occasionally used as a coping 
mechanism where one may take advantage of their pain with the hope that society 
members might help them (Lucey, et al., 2011). Ownby and Dune (2007), applying a 
grounded theory approach concur with these findings adding that there is need for 
the health care workers to research more on the problems associated with DSP so 
as to develop effective strategies for reducing associated activity limitation and 
participation restrictions.  The study by Ownby and Dune (2007) also suggest that 
activity in the form of exercise may be used to mediate chronic neuropathic pain. As 
shown in a study covering three continents done by Nicholas, et al., (2007a), PLWHA 
who had DSP and experiencing neuropathic pain, tried all self-help activities or 
available methods to control pain.  
 
2.5.4  Gait 
 
One of the major complaints received from participants in studies for the effects of 
peripheral neuropathy is that of gait instability (Ites, et al., 2011).  The factors 
involved in the quality of gait include, proprioception, numbness, balance, muscle 
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strength and co-ordination (Bensoussan, et al., 2008; Tannenburg, 2009). Mobility is 
defined as the muscles ability to initiate movement, and the flexibility in movement 
thereafter (American College of Sports Medicine (ACSM), 2006). It can be 
maintained by postural stability which may be improved by muscle strengthening of 
postural muscles (Bensoussan, et al., 2008). Strength is defined as the force to 
propel or withstand against force and to lift a mass and is measured using 
electromyography, myometry or dynamometers (ACSM, 2011). Whereas mobility 
generally refers to the ability to walk with or without the assistance of walking aids,  
the ICF (WHO, 2001) defines walking  as moving along a surface on foot step by 
step  so that one foot is always on the ground such as when standing (WHO, 2001). 
This includes; walking short distance; long distance walking on different surfaces 
domain [d4502] or walking around obstacles [4503] (WHO, 2001). Mobility is a d4 
domain of activities and participation. It is essential for people with peripheral 
neuropathy to remain mobile as this is also accepted as one of the palliative 
modalities for neuropathic pain (Nicholas, et al., 2007a).   
 
Walking is a cycle of feedback loops as a skill and in adults, supraspinal control 
mechanisms are utilized in generalized motor programmes (Gates and Dingwell, 
2007). During normal gait, central processing mechanisms control the stride over 
long range walking; however in the elderly people, people with Huntington‟s disease 
and people with Parkinson disease, long range striding is affected (Gates and 
Dingwell, 2007). Long range factors in stride intervals are believed to be controlled by 
supraspinal control mechanisms. Thus where there is central control deterioration 
gait stride becomes uneven (Gates and Dingwell, 2007). 
 
Gates and Dingwell (2007) carried out a comparative study with a sample of 14 
participants with severe peripheral neuropathy and 12 gender, age, height and 
weight matched non-diabetic controls. Gates and Dingwell (2007) hypothesised that 
if loss of long range correlation indicates that inability has been caused by central 
control of gait then peripheral change would have no effect. However if loss of long 
range correlation indicated general inability to regulate gait cycle timing then similar 
loss of long range timing would occur in patients with peripheral movement disorders 
ability to regulate gait. They found that there was no difference in stride times 
between the peripheral neuropathy and control subjects p=0.95 and 0.97 
respectively. However participants with peripheral neuropathy also exhibited a slower 
gait speed, which is a cognitive adaptive coping strategy (Gates and Dingwell, 2007). 
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2.5.5  Balance 
 
Factors known to influence balance namely; decreased sensation, proprioception, 
reflexes and strength in the lower limbs, are all negatively affected by DSP (Ites, et 
al., 2011). Hess and Woollacott (2005) demonstrated in their study on an elderly 
population that strength training can improve their balance by improving muscle 
strength of the lower limb muscles especially ankle stabilizers.  In their discussion, 
Hess and Woollacott (2005) demonstrate how by eccentric contraction, the 
hamstrings, gastrocnemeius, tibialis anterior and the quadriceps all act in symphony 
to reduce sway and maintain the centre of gravity.  
 
On the other hand, Kanekar, Santos, and Aruin, (2008) investigated how the body 
responds to fatigued muscles and found that there was also cognitive compensation 
in form of anticipatory postural adjustment to this effect. Although their sample was 
small (n=9), they used the deltoid anterior and hamstring muscle to determine how 
adjustment occurs, and concluded that there existed effective mechanisms which can 
easily be employed (Kanekar, Santos, and Aruin, 2008).   Hence while balance 
dysfunction is a result of factors which include decreased sensation, proprioception, 
reflexes and strength in the lower limbs (Ites, et al., 2011) it may be attenuated by 
cognitive processes.  
 
2.5.6  Muscle dysfunction 
 
Muscle dysfunction which presents as cramping in the legs and muscle weakness in 
the intrinsic muscles of the foot occurs as a result of the alteration of motor nerve 
function (Cherry, et al., 2005; Nicholas, et al., 2007b).This is explained by the 
changes in the metabolic functions of muscle and primary lactate accumulation which 
occurs as a result of HIV and as a side effect of ART depending on the type being 
used Dungeon, et al., (2004) In people with peripheral neuropathy this does not 
necessarily translate to reduced muscle strength for the affected muscles (White et., 
al). In their review of studies where PRE was employed as a method of management 
and intervention in PLWHA, Dungeon, et al., (2004) indicate that muscle adapt to the 
stress loads and type of training it is exposed to.  
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2.5.7  Health related quality of life 
 
When there is activity limitation and participation restriction, health related quality of 
life is compromised.  Bril, et al., (2010) feel that health related quality of life is a 
relevant dimension of functional outcomes which should be investigated to acquire a 
better evaluation of the effectiveness of intervention in the management of conditions 
which affect the activity of PLWHA. Considering the multi-faceted context of quality of 
life Rusch, et al., (2004), several dimensions/domains, form the integral part of 
quality of life (Miners, et al., 2001).   
 
In their review, Hwang and Nochajski (2003) outline the major areas of activity 
limitation and participation restriction for PLWHA as mobility, self care and domestic 
life. People with peripheral neuropathy commonly present with pain, altered 
sensation, loss of proprioception, muscle weakness, and increased fatigability and 
psychological dysfunction (White, Pritchard and Turner- Stokes, 2004). These 
impairments may lead to immobility, altered gait and increased risk of falling 
secondary to impaired balance, as explained by Ites, et al., (2011) and also by 
Hwang and Nochajski (2003).  Activity limitations commonly experienced by persons 
with peripheral neuropathy are walking, activities of daily living like bathing, sleeping 
and other usual activities, factors which all may change the quality of life (Myezwa, et 
al., 2009). Limitation in aspects of health related quality of life as drawn up by the 
European Quality of Life group  include; mobility, self-care and usual activities 
(Miners, et al., 2001). O‟Brien, et al., (2008b) demonstrated how episodes of activity 
limitation eventually lead to participation restriction and ultimately disclose to the 
employer and colleagues and the community, the possible status of an individual, 
leading to stigmatization. The main areas of possible participation restriction include 
role fulfillment, like being at work, being a parent or spouse (Miners, et al., 2001). 
(Hwang and Nochajski, 2003) using the ICF explains that the major environmental 
barriers for human function are found in the attitudes and beliefs of the society. The 
available services, systems and policies create an enabling environment upon which 
performance is based (Hwang and Nochajski, 2003).   
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2.6 Management of peripheral neuropathy 
2.6.1  Introduction 
 
Distal symmetrical poly-neuropathy impairments may be managed using 
pharmacological, non-pharmacological or self-care strategies depending on the 
severity of symptoms, preference, or availability of approach (Nicholas, et al., 2007b). 
Pharmacological approaches include analgesics and some of the ARV drugs. Non 
pharmacological approaches include physiotherapy, which addresses these 
impairments by way of electrotherapy, massage, acupuncture and therapeutic 
exercise (Verma and Simpson, 2007). Therapeutic exercise includes progressive 
resisted exercise, aerobic exercise, individualized exercise programs and 
generalized home exercise programs including walking (Philipas, et al., 2006). 
2.6.2  Pharmacological management 
 
While analgesics are the commonly used approach, certain anti retroviral therapy 
drugs are also known to alleviate DSP symptoms. These therapeutic drugs include 
zidovudine, which has been shown to ameliorate symptoms of DSP (Keswani, et al., 
2002).The main approach utilized is symptomatic relief of pain based on the WHO 
ladder of pain management (Verma and Simpson, 2007; Nicholas, et al., 2007b). Anti 
convulsants like carbazapine has shown good relief of neuropathic pain while drugs 
like lamotrigine and gabapentin are used internationally but are not available locally 
(Verma and Simpson, 2007). The American Association of neuromuscular and 
electrodiagnostic medicine, the American Academy of neurology and the American 
Academy of Physical Medicine and Rehabilitation approved a report by Bril, et al., 
(2011). This report recommends the use of anti-convulsants, especially pregabalin as 
treatment of painful diabetic neuropathy where clinically appropriate as they are 
equally effective in relieving pain (Bril, et al., 2011). The same report also 
recommends that Gabapentin and sodium valproate should be considered. However 
they do not recommend Oxcarbazepine, lamotrigine and lacosamide. Bril, et al., 
(2011) reviewed the use of antidepressants and recommend that amitrypyline, 
venlafaxine, and duloxetine be considered based on their review of well-designed 
clinical trials. 
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2.6.3  Non -pharmacological management 
 
Electrotherapy 
 
Physiotherapists commonly manage pain using electrotherapy agents which include 
functional electrical stimulation, trans-cutaneous electrical nerve stimulation (TENS), 
interferential therapy, heat therapy and cryotherapy (Pieber, Herceg and Partenostro-
Sluga, 2010). There is limited evidence from clinical studies conducted to establish 
the effectiveness of electrotherapeutic agents in reducing HIV related neuropathic 
pain. However patients have been shown to use heat in warm baths and cold water 
as a form of cryotherapy in self-management of their chronic pain (Nicholas, et al., 
2007b). Most literature linked to neuropathic pain management using electrotherapy 
is cited in the management of painful diabetic neuropathy (Pieber, Herceg and 
Partenostro-Sluga, 2010; Bril, et al., 2011). In a review of fifteen studies done to 
determine the efficacy of electrotherapeutic modalities, Pieber, Herceg and 
Partenostro-Sluga, (2010) found that transcutaneous electrical nerve stimulation was 
consistently beneficial in three of the large randomized controlled trials  studies. Bril, 
et al., (2011), also recommend the application of percutaneous electrical nerve 
stimulation based on a review of one well designed clinical trial. Frequency 
modulated electromagnetic neural stimulation registered clinical important reduction 
of pain in the other reviewed studies (Pieber, Herceg and Partenostro-Sluga, 2010). 
Nonetheless conflicting results emerged from studies where pulsed and static 
electromagnetic fields were trialed thereby leaving a need for further studies in this 
arena (Pieber, Herceg and Partenostro-Sluga, 2010). Bril, et al., (2011) concurs with 
this finding and recommends that electromagnetic field treatment should probably not 
be considered for treating painful diabetic neuropathy. More work has been done by 
acupuncturists and alternative medicine practitioners in showing evidence of 
providing relief for neuropathic pain as discussed in the next section. 
 
Massage 
 
It is estimated that there are over 100 types of massage (Hillier, et al., 2010). The 
most commonly used form of massage in the western world is the Swedish or 
muscular massage which comprises of different techniques used to manipulate the 
soft tissues (Hillier, et al., 2009). These include slow rhythmic stroking; effleurage, 
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circular compressions also known as kneading, forceful skin/tissue rolling also called 
petrissage, and penetrating pressure from finger tips with circular or transverse 
movements like trigger point or friction massage and tapotment where there is rapid 
striking of the tissues by the hand (Ashton and Cassel 2002). However in a study to 
establish the effects of massage in 30 participants, who had cold induced pain with 
no known pathology, Kessler, Marchant and Johnson (2006), showed that there was 
a trend towards significance when the massage effect was compared to touch where 
soft tissue below it was not manipulated. When discussing their results, Kessler, 
Marchant and Johnson (2006), suggest that massage reduces transmission of pain 
impulses as mediated by the stimulation of mechano- receptors. Swedish massage 
or western massage has been shown to have an effect on peripheral neuropathy 
when used with topical agents like lidocaine or capsaicin (Wolfe and Trivedi, 2004). 
The results of the review by Hillier, et al., (2010) suggest that massage may be used 
with other modalities like acupuncture, Tai Chi, meditation and relaxation to improve 
the quality of life and deal with stress associated with pain in PLWHA (Galantino, et 
al, 2005). 
 
Acupuncture and Tai Chi 
 
Whereas acupuncture has been used extensively in the alleviation of pain, it is only 
recently that research has sought for evidence on how acupuncture works and if it 
works for symptoms of pain in PLWHA. Phillips, Skelton, and Hand (2004) examined 
the effect of acupuncture on pain associated with HIV by carrying out a pre-test /post 
test pre-experimental study designed to assess the effects of acupuncture in a group 
setting on subjective pain and symptoms of peripheral neuropathy in PLWHA. A 
certified acupuncturist performed the acupuncture to twenty one participants over a 
five week period and all scores of pain showed significant reduction post acupuncture 
of between 39% to 50% points (Phillips, Skelton, and Hand, 2004). The results show 
that the Subjective Peripheral Neuropathy Screen (SPNS) score was reduced by 
between 43% to 56% points in the intervention group (Phillips, Skelton, and Hand, 
2004). However the intervention did not address muscle weakness associated with 
peripheral neuropathy. All measures used in the study were subjective and placebo 
factors were not controlled for (Phillips, Skelton, and Hand, 2004). Other forms of 
therapy have been researched with some progress. Galantino, et al., (2005) 
compared the effects of group aerobic exercise and Tai Chi done twice per week for 
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eight weeks, with a sample of thirty eight participants in an outpatient setting at two 
clinics. They found that aerobic exercise and Tai Chi improved flexibility, balance, 
endurance, the quality of life and some physiological measures. Some of the 
interventions used by individual PLWHA are remedies recommended traditionally by 
relatives or friends, which have been utilised as self-care strategies (Nicholas, et al., 
2007a). 
 
Self- care strategies  
 
Nicholas, et al., (2007a) carried out a study with a sample of 450 participants in 
American, European, Caribbean and Asiatic cities so as to establish the patterns of 
self-care activities PLWHA use to manage peripheral neuropathy. Their study found 
that 292 of participants took a hot bath, while others strategies included staying off 
the feet (n=258), rubbing the feet with cream (n=177, walking (n=262), elevating the 
feet (n=236). These results concur with findings by Ownby and Dune (2007) who 
found that people with peripheral neuropathy tended to develop individual strategies 
to manage their symptoms.  In a grounded theory approach, they interviewed 19 
people with peripheral neuropathy and listed the categorized strategies as follows: 
humor, exercise, massage and lotion, heat and cold modalities, rest, environmental 
/personal changes, herbal/ marijuana, prescribed medications, TENS, prayer, 
meditation and guided imagery (Ownby and Dune, 2007). However, Nicholas, et al., 
(2007) is of the opinion that some of the management behaviors which were 
employed by participants in his study including, use of marijuana, cigarette smoking 
and street drugs may be deemed unhealthy. As shown by these findings some form 
of exercise, e.g. walking was adapted by the participants of these studies as a 
strategy to manage peripheral neuropathy (Ownby and Dune, 2007). In the following 
section, therapeutic exercise will be explored as a management approach to 
peripheral neuropathy. 
 
Therapeutic exercise 
 
Therapeutic exercise can be defined as the prescription of a physical activity or 
program where the client carries out voluntary muscle contraction and or body 
movement with the aim of relieving symptoms or improving, retaining or slowing 
deterioration of health (Taylor, et al., 2007). However medical practitioners advise 
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their clients to avoid physical exertion and therefore will not refer them for exercise 
for fear of further immune-compression arising from over-exertion and fatigue (Bopp, 
Philips and Fulk, 2003). Nonetheless there is compelling evidence in well 
documented randomized clinical trials to the benefits of therapeutic exercise without 
excessive effects on immunity (O‟Brien, et al., 2008, 2010; Taylor, et al., 2007). 
Strengthening exercises have been shown to improve muscle strength in people with 
peripheral neuropathy (White, Pritchard and Turner-Stokes 2008). Supervised 
aerobic exercise done at sub-maximal age predicted maximal heart rate levels of 
70% and resistance exercise programs in PLWHA has been shown to be safe and is 
known to improve cardiovascular fitness (O‟ Brien, et al., 2010). Exercise reduces 
central adiposity, improves metabolic indices (Mutimura, et al., 2008) and 
significantly improves immunology and virology measures as defined by CD4+ 
counts (Dudgeon, et al., 2004). 
 
Muscle strengthening programmes involve progressive resisted exercise utilising 
repetitions of specific muscle contractions. These can be isometric (performed 
against maximal resistance where no associated joint movement is possible), 
isotonic (performed against a sub maximal known resistance, this is typically greater 
than 70% of the maximal load possible, where joint movement and limb excursion is 
permitted) or isokinetic (performed against variable resistance but where the speed 
of contraction is constant) ACSM (2011). Endurance programmes involve gradually 
increasing the duration and intensity of aerobic activity for example cycling, running, 
or walking. Specific muscle endurance programmes may also involve the use of low 
load high repetition muscle contractions (White, Pritchard and Turner-Stokes, 2006) 
 
Taylor, et al., (2007) conducted a systematic review on the use of therapeutic 
exercise on a variety of conditions as commissioned by the Australian Physiotherapy 
Association, They found 47 trials which confirmed that therapeutic exercise can 
improve muscle performance and mobility in people with multiple sclerosis and 
reduce pain and improve activity levels in people with chronic osteoarthritis of the 
knee, and chronic low back pain (Taylor, et al., 2007). Therapeutic exercise is 
beneficial in conditions which include heart conditions, geriatric, and peripheral 
neuropathy and in HIV (Taylor, et al., 2007). Meanwhile O „Brien, et al., (2010) in a 
Cochrane review, carried out a meta analyses of all studies they had retrieved using 
Rev Man 4.2.2 software and showed that exercise improves cardio vascular fitness 
and is safe. However, the results of O „Brien, et al., (2010)‟s study review showed no 
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significant changes in immunology or virology outcome measures. Weight, body 
composition, body mass index, strength, amount of weight resisted were analysed in 
most studies which were male dominated (O „Brien, et al., 2010). This meta-analysis 
reveals that most studies had a high loss to follow-up of more than 15% withdrawals 
and data in the studies was analysed using a per protocol analysis whereas an 
intention to treat analysis would add value. 
 
Fillipas, et al., (2006) carried out a single blind, randomised, controlled trial to 
determine the effects of two six month supervised aerobic and resistance exercise 
programs for HIV infected participants. Outcome measures in this trial by Fillipas, et 
al., (2006) included a self-efficacy scale, cardiovascular system fitness using Kasch 
pulse recovery test which tests fitness by checking the recovery rate of the 
cardiopulmonary system after exertion and they used the Medical Outcomes Study 
HIV Health Survey to evaluate Health related quality of life.  Participants‟ health 
status was ascertained using CD4+ count and viral load values. This study confirmed 
the known effects of exercise which include improved self-efficacy and 
cardiovascular fitness. Results from this study by Fillipas, et al., (2006) remind 
researchers that the need for supervision in exercise is important and reveals that a 
twice weekly program can be comparable in effects to a thrice weekly program. The 
exercise was run by an experienced therapist with knowledge in HIV and therefore 
counseling in an exercise setting may have been an extenuating factor value adding 
to the exercise. White, Pritchard and Turner-Stokes (2004) also performed a review 
of three clinical trials done on the use of exercise in the management of peripheral 
neuropathy in diabetes mellitus. In three studies they found suitable, White, Pritchard 
and Turner-Stokes (2004) observed that the methodological quality of two of the 
studies was poor.  Less than eight weeks of intervention had been used while the 
outcomes and diagnostic groups of these studies were not similar therefore could not 
be compared (White, Pritchard and Turner-Stokes 2004). One of the studies found to 
be methodological proper, was done by Richardson, Sandman and Vela (2001) and 
had a sample size of 20 participants, ten in the control and ten in the experimental 
group. This study used an exercise program which focused on strengthening the 
lower limb muscles without using a proper PRE. Their findings indicated that a 
focused strengthening programme was effective in increasing muscle strength and 
improving balance Richardson, Sandman and Vela (2001). 
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Progressive resisted exercises (PRE) 
 
Progressive resisted exercise is defined as an exercise regimen where physical 
resistive activity is performed at least three times per week for at least four weeks 
(O‟Brien, et al., 2008).  In their meta-analysis, O‟ Brien, et al., (2008) demonstrates 
by the results of different clinical trials that an effective exercise regimen must ideally 
be at least six weeks long. The ACSM (2011) paper, in a review of studies, found that 
PRE has positive effects on muscle strength, balance and quality of life in apparently 
healthy adults. This is consistent with the findings by O‟Brien, et al., (2008), where 
the studies reviewed reveal that PRE is similarly effective in improving muscle 
strength, balance and quality of life in PLWHA. However these studies had small 
samples sizes, and were of predominantly male constitution, and did not include 
quality of life in their outcomes. A small number of the studies reviewed by O‟Brien, 
et al., (2008) analysed the data using an intention to treat analysis approach. In a 
study done by Bhasin, et al., (2000), where only male participants were used, PRE 
was compared with PRE augmented with testosterone, testosterone only and a 
control group. They found that PRE was effective in improving muscle strength and 
quality of life without the need for augmentation with testosterone. This concurs with 
the findings by Agin, et al., (2001)‟s study that tested PRE on a women only sample 
in PLWHA and compared PRE and PRE with whey protein supplements. The study 
by Agin, et al., (2001) found that PRE improved muscle strength and quality of life in 
a similar manner as when supplemented with protein. Some studies have used 
different forms of nutritional supplements to augment exercise based on muscle 
hypertrophy physiology as done in a study by Hess and Woollacott (2005). However 
the results of other studies seem to defy this generalization. Agin, et al., (2001) using 
whey protein in female participants to augment exercise and found that there was no 
value addition. Sakkas, et al., (2009) in a study where they used creatinine 
supplements found results similar to the study done by Agin, et al., (2001). 
Furthermore, Hess and Woollacott, (2005) showed that PRE increases strength and 
improves balance in 27 elderly men and women after carrying out a high intensity 
PRE program over ten weeks. Both studies by Agin, et al., (2001) and Hess and 
Woollacott, (2005) looked at the effects of PRE on other variables including 
immunological and virological indices and found that these indices were improved by 
PRE. On the other hand Dolan, et al., (2006) also used a women only sample to 
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show that when combined with aerobic exercise PRE was effective in improving 
muscle strength and the body composition. 
 
 On the other hand literature on people with diabetic DSP which is believed to be 
similar to DSP in PLWHA was reviewed in a study by White, Pritchard and Turner-
Stokes, (2004).This review cites flaws in methodology used, but concludes that  
strengthening exercise moderately improve the functional abilities of people with 
diabetic DSP (White, Pritchard and Turner-Stokes, 2004). 
 
Progressive resisted exercise protocol 
 
Literature was reviewed to establish the recommended procedures for PRE and 
found that the intervention exercise program consists of warm up, stretching and 
progressive resisted exercise (ACSM, 2006).  Participants carried out exercise 
sessions based on the established baseline strength. While several protocols may be 
used, Hess and Woollacott, (2005) used a simple protocol where the weights are 
then increased for each participant as the participant could tolerate every two weeks 
to allow for adaptation. The sets were increased to three (3) on the following week 
while the weight was maintained. A resting period of 2 minutes was allowed between 
the sets so that the muscles could recover (ACSM, 2011). 
 
While the studies reviewed by O‟Brien, et al., (2008) used a regimen of three 
sessions per week, other studies have used the twice per week regimen. Fillipas, et 
al., (2006), in a study with PLWHA used the twice weekly regimen over a period of 
six months equally and found that the regimen was equally effective. Furthermore the 
ACSM, (2011) position paper concurs and states that a twice to thrice per week 
regimen is effective for the purpose of muscle strengthening (ACSM, 2011).  
 
Adherence to exercise 
 
Adherence to exercise can influence the actual results of the study as with findings 
by Petrozsci, et al., (2010) that the perception of well-being, lifestyle and cultural 
beliefs are major contributors to compliance in studies. The withdrawal rates in the 
studies reviewed by O‟ Brien, et al., (2008), range from 0 -76 % and  different 
reasons including, employment, illness, relocation, loss of interest, transportation 
difficulties, personal issues, lack of motivation, lack of time, economic reasons. 
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Basta, Reece and Wilson (2008), in their study propose the use of the trans-
theoretical model to predict how PLWHA adjust to an exercise program. They used 
this model of approach in a study and found that this model may explain how PLWHA 
go through the stages of change to become compliant to management (Basta, Reece 
and Wilson, 2008). Using such a model implies the factoring in of motivation as a 
crucial factor in behavior modifications and as such, so as to exercise PLWHA need 
to have a good reason to commit to this undertaking. 
 
2.7 Methods of Assessment of the Effects of HIV-associated 
Peripheral Neuropathy 
2.7.1  Introduction 
 
An outcome measure is a test or scale administered and interpreted by the therapist 
that has been shown to measure accurately any aspect of interest, which is expected 
to respond to an intervention (Hammond, 2000). As such, this study required 
instruments to measure the effect of the intervention that had been set.  
The choice of instrumentation is dependent on reason for measuring, the preference 
and need of the outcome measure and who the end user of the information 
(Hammond, 2000). An instrument may be discriminative, predictive or evaluative in 
nature. Occasionally diagnostic relevance and specifity does not necessarily reflect 
the result of specific intervention (Hammond, 2000). Outcome measures need to be 
standardized to allow for comparison of results from different intervention studies 
(White, Pritchard and Turner-Stokes 2004).  
The measure should be reliable, valid and responsive to changes. It should be 
convenient to use by the clinician while being comfortable and painless to the subject 
(Hammond, 2000). In the literature, the participants‟ health status was one of the 
outcomes measures assessed and the outcomes include: the participants‟ health 
status outcomes were assessed using body composition changes like the body mass 
index while immunology was measured using CD4+ count. Physical performance 
tests include cardiovascular system fitness and muscle strength assessment. 
Chester step test and force transducers like the dynamometer are used. Functional 
performance measures are the clinician‟s choice for assessment as they have to be 
relevant. In this study there was need to choose a suitable assessment tool to 
measure the appropriate changes which would occur as a result of the intervention. 
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2.7.2  Definitions 
 
Some of definitions considered important in the process of choosing the assessment 
tools for this study included: 
Validity indicates whether the instrument does indeed measure what it is intended to 
measure; therefore the right questions have been asked (Faber, et al., 2006). 
Reliability is how uniformly the test can be repeated when administered on more than 
one occasion that is stability overtime (test-rater reliability). Reliability also refers to 
the extent to which the measurements can be objectively administered (inter-rater 
reliability) (Bruton, Conway and Holgate, 2000).  
Responsiveness is defined as the ability of an instrument to accurately detect true 
change in subjects when it has occurred (Hammond, 2000).   
Predictive validity was expressed in terms of sensitivity and specificity where 
sensitivity, is defined as the probability that an event is indeed predicted to occur, 
whereas specificity is defined as the probability that a non-event is indeed a non-
event (Faber, et al., 2006).  
Ceiling effect is a measurement limitation of an instrument which renders the 
instrument unable to determine an increased performance beyond a certain level. 
As the process of choosing the tools is reviewed in the following section, these terms 
defined will be used accordingly. 
 
2.7.3  Dynamometry and muscle strength assessment  
 
While manual muscle tests like the Oxford scale may be used, they are highly 
subjective and unreliable (Bohannon, 1997). A one-repetition maximum (1RM) is the 
weight as adjusted to ensure that the participant can only lift that weight once through 
a full range of motion (ACSM, 2006). The 1RM is established by asking the 
participant to lift a weight. If the person can barely lift the weight, it is adjusted until 
the person can just lift it through range of motion (ACSM, 2006). Dynamometry may 
also be used in the place of 1RM as its values are equivalent to 1RM as established 
by Verdjk, et al., (2009), in a randomized controlled trial, The make test (Bohannon, 
1997) is performed when the assessor holds the dynamometer and matches the 
participant‟s maximal force exertion until the joint gives in (Bohannon, 1997).  This is 
to allow the weakened participant to initiate and exert a force they can generate and 
each movement is repeated three times and the mean recorded (Bohannon, 1997). 
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The Jamar Dynamometer was used in the assessment of muscle strength and it 
features a strain gauge mechanism while allowing for digital output. 
 
O‟Brien, et al., (2008) explains that using isometric testing for muscle strength, may 
underestimate muscle strength. This position is consistent with the results from five 
out of the seven of the studies reviewed by O‟Brien, et al., (2008) which had used 
isotonic muscle strength testing.  
 
 Studies have shown that people living with HIV and AIDS have a physiologic 
performance level of 70% of usual level which is equivalent to a 12RM and 
approximately 75% of a 1RM (ACSM, 2006). Use of the 12 repetition maximum also 
reduces the risk of injury to the person.  
 
2.7.4  Performance Oriented Mobility Assessment  
 
While functional performance tests have been used to evaluate mobility and 
effectiveness of clinical interventions, for the requirements of this study, the modified 
Performance Oriented Mobility Assessment (POMA) (Faber, et al., 2006) was 
selected. The Performance Oriented Mobility Assessment, also referred to as the 
Tinnetti Mobility Test (TMT) was developed by Mary Tinnetti in 1986 for use with the 
elderly population who are at risk of falling.  
 
The TMT can be administered in less than five minutes making it easier than the 
Berg balance scale (BBS) which takes 15 to 20 minutes. It may be used as 
proficiently by experienced physiotherapists as by physiotherapy students (Faber, et 
al., 2006). The POMA is an easily administered task-oriented test that consists of 
eight items of gait and eight items on balance. (Faber, et al., 2006).It requires basic 
equipment including a hard armless chair, Stopwatch or wristwatch and a 6 meter 
walkway (Faber, et al., 2006). It is used for rating gait (POMA- G) and balance POMA 
–B and a total score POMA-T is derived as an aggregate of the two subscales. 
Balance Score = 16, Gait Score = 12 and the Total Test Score = 28. The 
Performance Oriented Mobility Assessment is interpreted as: 25-28 = low fall risk 19-
24 = medium fall risk < 19 = high fall risk. There is no literature found showing the 
use of the POMA in a study involving participants with peripheral neuropathy and 
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HIV/AIDS hence while the POMA has been used for other conditions it has not been 
applied or validated for peripheral neuropathy. 
 
The studies found in literature sought to establish the POMA as a predictor of the 
risks of falls in the elderly for geriatric participants (Tinnetti, 1986, 1988; Lin, et al., 
2004; Baloh, et al., 2006; Faber, et al., 2007; Panzer, et al., 2011). Kegelmeyer, et 
al., (2007) used the POMA to assess the risk of falls as well as the testing the 
reliability and the validity of the POMA in participants with Parkinson‟s disease. 
Kloos, et al., (2010) carried out a study to also assess the responsiveness of the 
POMA in participants with Huntington‟s chorea Kloos, et al., (2010).  However, other 
studies were done to determine the reliability and validity of the POMA against the 
tools considered gold standards when used for different neurological conditions. 
 
Reliability and validity of the Tinnetti Mobility Test for individuals with mobility 
dysfunction was tested for in two studies by Kegelmeyer, et al., (2007) and Faber, et 
al., (2006). In a study which had a sample size of 30 individuals from a movement 
disorders clinic, Kegelmeyer, et al., (2007) found that the Tinnetti Mobility Test has 
the best predictive validity with reference to falls in the elderly. Kegelmeyer, et al., 
(2007) also detailed the validity and reliability of the POMA against the other gold 
standard tests and in different populations which showed good reliability levels and 
showed that the TMT was a valid measure of balance. In another randomised clinical 
trial to investigate the effects of exercise on elderly with participants drawn from 15 
self-care and nursing care residences Faber et al 2006, found a similar outcome. 
Faber, et al., (2006) assessed the POMA for validity, reliability and responsiveness 
against gold standard test/ reference tests which included the timed „„Up and Go‟‟ test 
(TUG), the six minute walk, the balance test from Frailty and injuries Co-operative 
studies of Intervention Techniques (FICSIT). Other comparable physical performance 
and functional tests include gold standard tests like: the functional Reach Test (FRT) 
for balance, sit and reach test for flexibility, the sit up test for endurance (Galatino, et 
al., 2004),  the Dynamic Gait Index, the Berg Balance Scale and the Groningen 
Activity Restriction Scale GARS and the Southampton Mobility Assessment.  The 
Spearman correlations between the scores when it was tested for intra rater and inter 
rater reliability on the POMA scales and the scores on the reference test indicate 
moderate current validity of scores for the scales Spearman‟s rho score of .74 to .93 
with levels of agreement at -4 to 4 points (Faber, et al., 2006).The value of the 
minimal detectable change (MDC) at 95% confidence level, following an intervention 
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for individuals was at least five (5) points and 0.8 points for group scores for the 
change to be considered significant (Faber, et al., 2006). However while the POMA is 
sensitive to fallers it is not specific enough with a sensitivity of 64% and specificity of 
66%, (Faber, et al., 2006). This is interpreted as a moderate predictive validity for the 
POMA (Faber, et al., 2006). This tool was therefore recommended for use in the 
study to assess gait and balance in participants as it was the most suitable for the 
requirements of the study as shown by studies by Faber, et al., (2006), Kegelmeyer, 
et al., (2007) detailing the validity and reliability of the POMA against the other gold 
standard tests in different populations. 
2.7.5  Wong Baker faces  
 
One of the recommendations by Bril, et al., (2011) in their report, is that non-
ambiguous pain rating scales for use in clinical trials should be developed. Different 
scales have been used before in the assessment of pain and the Likert scales are 
the most popular. Wong Baker faces were found useful when assessing young 
participants of three years of age and also suitable for people who are older and 
illiterate as the concept of a scale using numbers may not be reliable (Jackson, et al., 
2006; Wong, et al., 2001). This pictorial visual analogue scale is modelled along the 
six point Likert scale from no pain to worst pain imaginable and employs a 
representative face for each level of pain (Wong, et al., 2001). The respondent then 
chooses the face which best matches how they would describe their pain. Their 
pictorial presentation of pain using expression faces reduces confusion associated 
with interpretation of visual analogue scales which use numbers (Jackson, Kersten 
and Turner- Stokes 2006). Using the Wong Baker is therefore recommended as it is 
simple clear and reduces the misunderstanding and bias which may arise with 
illiterate or cognitively impaired participants. 
 
2.7.6  Brief Peripheral Neuropathy Screen (BPNS)  
 
While it may be difficult to make a diagnosis of distal peripheral neuropathy, a brief 
peripheral neuropathy screen (BPNS) can be used in clinical settings (Cherry, et al., 
2005). Symptoms of shooting pain, the presence of distal bilateral symmetrical 
burning sensation, parasthesia, or numbness, cramping in the legs, and muscle 
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weakness in the foot can be used to confirm distal symmetrical poly-neuropathy 
(Nicholas, et al., 2007b). This is a non-invasive method of diagnosis, which is fast 
and easy to perform and has excellent sensitivity to DSP (Hahn, et al., 2006). This 
study did not differentiate the underlying cause of neuropathy but demonstrated the 
tools‟ sensitivity to small fiber evoked potentials/ pain fibers, which indicate the 
presence of DSP (Hahn, et al., 2006). Non-neurologist clinicians, like a general 
practitioner, trained nurses or therapists could use the Brief Neuropathy Screen Test 
to diagnose peripheral neuropathy (Cherry, et al., 2005); (Schifitto, et al., 2006). 
Severity of neuropathy is assessed using the neural deficit score and the neuropathy 
symptom score (Cherry, et al., 2005). The study correlated sensory neuropathy with 
the symptoms of pain in HIV associated sensory neuropathy and found (Schiffito et al 
2002). It is reliable in identifying symptomatic peripheral neuropathy (Cherry et al., 
2005). Cettamoi, et al., (2010) piloted the use of the BPNS against quantitative 
sensory testing and found that using only one of the questions (do you feel numb in 
your feet) as a single question neuropathy screen was 83% sensitive in identifying 
DSP in PLWHA. Hence this tool was found to be suitable and cost effective in 
identifying participants for this study.  
 
2.7.7  The European Quality of Life in 5 Domains (EQ-5D) Questionnaire 
 
O‟Brien, et al., (2010) observed that the studies in their Cochrane review lacked a 
standard outcome measure of the health related quality of life.  Bril et al., (2011) in 
their review of the management of painful diabetic neuropathy concurred and 
recommended that health related quality of life should be included in clinical trials 
with standardized measurements (Bril, et al., 2011). As this measure focuses on 
individual PLWHA understanding of their own quality of life, a thematic approach was 
been used by previous studies to construct this measure, successfully providing 
researchers with choice of tools tailor-made for the requirement of the research 
(Robberstad and Olsen, 2010).  
 
Robberstad and Olsen, (2010) in a review of the studies on quality of life in Southern 
Africa found that the EQ5D was the most appropriate instrument used recently to 
evaluate the quality of life in PLWHA in this region. In a study with PLWHA Miners, et 
al., (2001) sought to validate the European Quality of Life in 5 Domains (EQ-5D) 
state of health questionnaire against the Medical Outcomes Survey HIV (MOS-HIV), 
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which is accepted as a gold standard in the evaluation of quality of life in PLWHA. 
The Medical Outcomes Survey HIV Health Survey is a 35 item self-administered 
questionnaire with 10 dimensions of health and eight subscales physical health 
summary which include pain, health perception, physical role and social function, 
mental health summary, with mental health, health distress, overall quality of life, 
cognitive function and energy or fatigue scale (Miners, et al., 2001). The EQ-5D is a 
simplified and practical form of a health related quality of life which explores and 
summarizes the ten dimensions of living included in the Medical Outcomes Survey–
HIV into five domains (Miners, et al., 2001).  These domains include mobility with 
regards to being able to walk about or being confined to bed. Other domains are self-
care, where one may have problems with washing or dressing self; problems with 
usual activities (e.g. work, study, housework, family or leisure activities); 
pain/discomfort measuring levels of pain or discomfort and anxiety/depression 
(Jelsma, et al., 2001). Miners, et al., (2001), in across sectional study, compared the 
use of the Medical Outcomes Survey HIV Health Survey (MOS –HIV) with the use of 
the Euro-Quality of life questionnaires in a developed country setting with a sample of 
128 participants. Their findings indicate that EQ-5D can be used effectively to assess 
the level of quality of life in PLWHA. Jelsma, et al., (2005) assessed the quality of life 
in 117 participants in a resource poor setting who had been commenced on highly 
active anti-retroviral therapy and found that the EQ-5D was a valid instrument for 
evaluating quality of life in PLWHA. They found that quality of life was an important 
measure of the possible effects of a HAART intervention. 
 
A Shona version of the questionnaire which was developed a by Jelsma, et al., 
(2001) using the Euro-Qol group protocol, which involved translation and back 
translation, showed a high level of reliability with a level of agreement of 0.78 to 1.00 
using kappa statistic for the different domains of activity (Jelsma, et al., 2001). Hence 
the EQ5D was chosen for use in this study as it had already been translated into 
Shona using the required methods by Jelsma, et al, (2001) and shown that it was 
comparable to the MOS-HIV which is regarded as the gold standard in evaluating the 
health related quality of life by Miners, et al, (2001). 
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CHAPTER 3 
3. METHODOLOGY 
3.1 Introduction 
 
In this chapter the research design, instruments, the procedure and statistical 
analysis of the study will be discussed. Discussed, are the most suitable measuring 
instruments, and the reason why they were used. The validity and reliability of all the 
measuring instruments in this study were assessed according to the literature.  
3.2 Study design 
 
The study was an assessor-blinded randomized controlled clinical trial. The 
participants in the experimental group underwent an intervention program of 
progressive resisted exercises while the participants in the control group were given 
advice as usual by the doctors and nurses to walk as a home exercise program. 
 
3.2.1 Study population 
 
Participants for the pilot study were sourced from the family care clinics (FCC), 
previously known as opportunistic infections (OI) clinics at Wilkins Hospital of the 
Municipal of Harare and family care clinic clinics at Parirenyatwa and Harare Central 
Hospitals in Zimbabwe. The participants for study 1 were sourced from the same 
sites as for the pilot study. However the participants for study 2 were sourced from 
ten selected antiretroviral therapy dispensing local clinics of the Municipality of 
Harare. (The research team had to do Study 2 because the Study 1 had experienced 
a high loss to follow-up rate and therefore a Study 2 was essential to achieve the 
required sample size as calculated in the initial protocol). 
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3.2.2 Sample selection and size 
  
Inclusion Criteria 
 
Both female and male residents in Harare aged between 18 to 70 years were 
recruited by way of an invitational English or Shona Brief Peripheral Neuropathy 
Screen (BPNS) questionnaire. Participants who had been on first line antiretroviral 
therapy (including d4T / Stavudine) for at least six months were selected. CD4+ 
counts of any level were included in the study as they were not reliable or in some 
cases current. The strength of knee and ankle muscles on quick assessment was 
expected to be grade 3 (antigravity) or greater by the manual muscle testing. The 
assessors required participants to be able to walk without assistance or with a 
walking aid. Willing and able participants signed consent forms before the diagnosis 
of distal symmetrical peripheral neuropathy was reached at by use of a Brief 
Peripheral Neuropathy Screen Test (BNST). 
 
Exclusion criteria 
 
Participants with a history of central nervous system dysfunction, hemiparesis, 
myelopathy or cerebellar ataxia (Richardson, Sandman and Vela, 2001), were 
disqualified. Alternative causes of distal symmetrical neuropathy – alcohol, other 
drugs, other chronic illnesses like diabetes were screened for. Participant on 
isoniazide, either as prophylaxis or as part of TB treatment were excluded. Other 
exclusion factors as noted by Richardson, Sandman and Vela, (2001), included: 
musculoskeletal deformity, amputation, scoliosis and inability to actively and 
functionally move ankle and knee joints lower extremity arthritis or pain that limited 
standing and foot ulcers at the time of assessment. 
 
All those who had already been receiving physiotherapy prior to the study were not 
considered. 
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3.2.3 Sample size determination  
 
The sample size was calculated using the Microsoft Excel Sample size calculator (v4 
draft). Assuming a standard deviation of 5.5, (Faber, et al., 2006), in study 1, a 
sample of 34 participants per group gave 90% power to detect a 5 point change on 
the POMA scores with a confidence interval of ±1.54. A 25% potential loss due to 
follow up was factored into this calculation. However in the second study while still 
assuming a standard deviation of 5.5, a sample of 58 participants per group had 90% 
power to detect a 5 point change on the POMA scores with a confidence interval of 
±1.54. A 45% potential loss to follow up and 10% to noncompliance was considered.  
 
3.2.4 Randomisation 
 
A computer generated randomization system of numbers was used to allocate the 
participants to their respective intervention groups in the pilot phases. In the main 
study, the selected clinics were paired by cross matching the participants at the 
clinics for sex and age of within five years of each other. The research assistant was 
then given the matched clinic pairs which were then randomly allocated for each pair 
by picking from a hat, into either intervention group or control group. Each clinic 
drawn first from each hat was taken as the intervention clinic. The second drawn 
clinic was the control clinic. 
 
3.2.5 Assessor blinding 
 
The principal investigator, who was the assessor, was blinded to the allocation of 
participants by a qualified registered physiotherapist, appointed to work as the 
research assistant at each phase through the study. The research assistant kept the 
names of the randomised participants in a centrally locked drawer, coded them and 
passed the coded participants on to the assessor without informing him which of the 
groups a participant belonged to. During the intervention period, the research 
assistants carried out the progressive resisted exercise program and did not allow 
the assessor access to any of the clinics. Thus on reassessment of the participants, 
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the researcher was not aware if the participants had been in the experimental group 
or control group. 
3.3 Study instruments 
3.3.1  Study instruments and procedures 
 
The study instruments, the outcome variable to be tested, the procedure or the tool 
and the instrument validity and reliability will now be summarised in the tables 
according to the variable they test. 
 
Brief Peripheral Neuropathy Screen (BPNS) (Appendix A1, A2 and A4)  
 
The Brief Peripheral Neuropathy Screen, is summarized below in Table 3.1 
 
Table 3.1 Brief Peripheral Neuropathy Screen (BPNS)  
Study instrument: Outcome 
Variables tested: 
Tool/Procedures:  
Brief Peripheral Neuropathy Screen 
(BPNS)  
 
(Appendix A1 and A4)   
Level of severity 
of peripheral 
neuropathy 
symptoms in 
participants 
Invitational Questionnaire 
Potential participants 
were invited to contact the 
researcher if they answer 
yes to more than 4 of the 
15 questions.  
Brief Peripheral Neuropathy Screen 
(BPNS) (Appendix  A2)   
 
Demographics 
including age, 
sex, marital 
status, education 
and HIV related 
information  
Questionnaire to identify 
patients with or without 
peripheral neuropathies 
related to ART. Used to 
screen participants for 
exclusion 
 
A self-administered modified Brief Peripheral Neuropathy Screen (BPNS) (AIDS 
Clinical Trials Group 2004) questionnaire (Appendix A1, A4) was used as an 
invitational questionnaire. As there was no Shona version of the questionnaire 
(Appendix A4), the research team translated the English version into Shona. The 
Shona version was then back translated into English. It is a checklist for muscular 
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cramping, numbness, tingling sensation inability to tell hot from cold especially when 
bathing, burning or aching pain, sharp, stabbing, shooting or sudden electric shock 
like pain and allodynia during sleep. It checks for foot sensation patterns when 
walking and if the skin becomes so dry it cracks. 
 
The Questionnaire for Screening of Peripheral Neuropathies related to HIV and ART 
(Appendix A2), was used to provide demographic history of the participants among 
those showing willingness to participate in the study. It is an informational nurse-aide 
administered questionnaire which also serves to screen for exclusion criterion. 
Demographic characteristics consisted of gender, age, and highest level of 
education, occupation, marital status. General health status of the participant 
included HIV diagnoses period, the CD4+ count, the specific type(s) of anti-retroviral 
drug, duration of treatment and presence of common co-morbidities. The 
questionnaire also established when the symptoms commenced (before start or after 
starting ARVs), based on the participant memory or records on the hospital cards. If it 
was after starting ARVs, clarification on after how long on ARVs the symptoms had 
commenced was made.  
 
Brief peripheral neuropathy screen tool (BNST) (Appendix A3). 
 
The Performance Oriented Mobility Assessment, is summarized below in Table 3.2 
 
Table 3.2 Brief peripheral neuropathy screen tool (BNST) (Appendix A3). 
Study 
instrument: 
Outcome 
Variables tested: 
Tool/Procedures:  
Brief peripheral 
neuropathy 
Screen Tool 
(BNST) 
(Appendix A3). 
 
Level of severity 
of peripheral 
neuropathy in 
participants 
Diagnosis of peripheral neuropathy by 
physical examination. Symptoms rated on a 
VAS and location 
128 Hz tuning fork was used to evaluate 
perception of vibration as rated by duration of 
vibration felt. - Reflex hammer was used to 
strike the Achilles tendon so as to evaluate of 
tendon reflexes in the ankle.  
 
While the subjective part of the BPNS was used to invite participants into the study, 
the Brief Neuropathy Screen Test (BNST) of the BPNS was used in confirming the 
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diagnosis of peripheral neuropathy. The examiner scored for neuropathy symptoms 
by checking for muscular cramping, numbness and abnormality in sensing of 
temperature, tingling sensation, burning pain, aching pain and irritation by bedclothes 
in the lower legs and feet (Cherry, et al., 2005; Schifitto, et al., 2006). The subject 
rated the severity of each symptom of pain, aching, or burning, “pins and needles” 
and numbness (lack of feeling) in feet; legs. These were graded using subjective 
elicited symptoms to form the subjective sensory neuropathy score. Location of 
symptoms was used to score depending on where the symptoms were e.g. feet, legs. 
Neuropathy deficit score focused on presence of the ankle tendon reflex and the 
vibration sensation (128Hz tuning fork) (Simpson, et al., 2006). The neurologist at 
Parirenyatwa Hospital (there was only one at the time of study), concurred with the 
findings from literature that clinicians besides the neurologists could use the Brief 
Neuropathy Screen Test (Cherry, et al., 2005; Schifitto, et al., 2006) 
 
The Wong Baker Faces (Appendix E) 
 
The Wong Baker faces are presented below in Table 3.3 
 
Table 3.3 The Wong Baker faces 
Study instrument: Outcome 
Variables tested: 
Tool/Procedures:  
The Wong Baker Faces (Appendix E), 
 
Pain as viewed 
subjectively by the 
participant on a 
Likert scale 0-5 
Visual analogue scale 
Representative faces 
used for each level of 
pain. Participant 
chooses the best 
descriptive face 
 
Performance Oriented Mobility Assessment (POMA) (Appendix B) 
 
The Performance Oriented Mobility Assessment, is summarized below in Table 3.4 
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Table 3.4 Performance oriented mobility assessment tool 
Study 
instrument: 
Outcome Variables 
tested: 
Tool/Procedures:  
Performance 
Oriented 
Mobility 
Assessment 
(POMA)  
 
Tinnetti, 1986 
 
(Appendix B)  
Level of gait 
performance score out 
of 12 and level of 
balance performance 
score out of 16, the 
total Mobility 
Assessment is 
interpreted as:  
25-28 = excellent 19-
24 = good  
< 19 = poor mobility.  
 For gait  
poor (<9)  
good (9-10) Excellent 
(11-12) 
For balance 
Poor (<10)  
Good (11-13) Excellent 
(14-16) 
When assessing gait, the subject stands 
with the examiner, walks down the 
hallway or room at the usual pace. The 
subject is asked to walk down the 
walkway, turn, and walk back after being 
instructed to go. The subject should use 
the usual walking aid. The 
characteristics scored:   
-Initiation of gait  
-Step length, continuity and symmetry. 
-Turning while walking (180°)  
-Height clearance  
and path deviation  
-Trunk sway and walking stance. 
When assessing balance  
the subject is seated on a hard, armless 
chair and the manoeuvres tested are:  
-Sitting balance posture, ability to arise 
smoothly, immediate standing balance. 
-Standing balance and when balance 
when nudged on the sternum. 
-Standing balance with eyes closed  
-Turning 360º or 180° continuity of steps. 
-Safety in the manoeuvre to sit. 
 
 
The Performance Oriented Mobility Assessment also referred to as the Tinnetti 
Mobility Test (TMT) was developed by Mary Tinnetti in 1986 for use with the elderly 
population who are at risk of falling. The POMA is an easily administered task-
oriented test that consists of eight items of gait and eight items on balance. It 
requires basic equipment, which includes a hard armless chair, stopwatch or 
wristwatch and a 6 meter walkway (Faber, et al., 2006).  
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Health related quality of life. 
The health related quality of life EQ5D questionnaire is summarized below in Table 
3.5 
Table 3.5 The EQ5D questionnaire (Appendix C and D) 
Study instrument: Outcome Variables 
tested: 
Tool/Procedures:  
EQ-5D questionnaire 
(Appendix C English, 
Appendix D Shona) 
Health related quality of  
life, on five dimensions 
-mobility 
- usual activity 
- self care 
-pain or discomfort 
-anxiety or depression 
It is a questionnaire with five 
dimensions where participant rate 
level of problem in domain: 
mobility (ability to walk about or 
being confined to bed), self-care 
problems like with washing or 
dressing oneself, problems with 
usual activities (e.g. work, study, 
housework, family or leisure 
activities), levels of pain or 
discomfort and anxiety or 
depression. 
The participant indicates in their 
opinion their state of health on that 
day using a scale on which the 
best state imaginable is marked 
100 and the worst state 
imaginable is marked 0.  
 
 
 
This questionnaire has undergone rigorous validation and reliability tests by the 
European quality of life group and the Shona version was coined by Jelsma, et al., 
(2001), following the European quality of life group protocol for translations. 
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Muscle strength assessment 
 
Hand held dynamometer (Appendix I) 
 
Table 3.6 below summarises the details of process of using the hand held 
dynamometer. 
 
Table 3.6 Details of the dynamometer 
Study 
instrument: 
Outcome Variables 
tested: 
Tool/Procedures:  
Dynamometer 
(Appendix I)  
The muscle strength 
assessment (measured in 
kilograms of force) of  
quadriceps , the hamstring, 
the tibialis anterior  and the 
gastrocnemius  
 
Jamar® hand held dynamometer 
Each tested movement was repeated 
three times and the mean recorded. 
The make test used requires the 
assessor to hold  the dynamometer 
and match the participant‟s maximal 
force exertion until the joint gives 
 
 
 
In the main assessment, muscle strength was measured using dynamometry by way 
of the Jamar Dynamometer. It has a strain gauge mechanism and allows for digital 
output. The make test (ACSM) which was used allows the weakened participant to 
initiate and exert a force they can generate (Bohannon, 1997). In the initial quick 
screen test, participants were tested using the manual muscle test as a criterion for 
entry.  
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Table 3.7 below summarises the assessment positions, Bohannon (1997) used when 
assessing muscle strength using a dynamometer. 
 
Table 3.7 assessment positions for muscle strength dynamometry 
Muscle group 
and action 
Limb joint 
position 
Dynamometer 
placement 
Stabilization of 
participant 
(quadriceps 
muscles) knee 
extensors 
 
Hips and knees 
flexed at 90° hand 
resting on lap 
2cm proximal to 
malleoli 
Stabilized at 
shoulder by 
assistant 
(hamstring 
muscles) knee 
flexors 
Hips and knees 
flexed at 90° hand 
resting on lap 
2cm proximal to 
malleoli 
Stabilized at 
shoulder by 
assistant 
 
(tibialis anterior 
muscles) ankle 
dorsiflexors 
Hip and knee and 
ankle at 0° 
2cm proximal to 
metatarsophalangeal 
joints 
Foot is just off 
the couch and 
the leg is 
stabilized by 
assistant 
(gastrocnemius 
muscles) ankle 
plantarflexors 
Hip and knee and 
ankle at 0° 
2cm proximal to 
metatarsophalangeal 
joints 
Foot is just off 
the couch and 
the leg is 
stabilized by 
assistant 
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3.4 Intervention  
3.4.1  Introduction 
 
The intervention exercise program consisted of warm up, stretching and progressive 
resisted exercise. Participants carried out exercise sessions based on the 
established baseline strength assumed to define the one repetition maximum (1RM) 
value. As the programme assumes to use moderate exertion, an eight repetition 
maximum (8RM) to twelve repetition maximum (12RM) was used. A calibrated set of 
sandbags ranging from 500g, 1kg, 2kgs and 5kgs were combined to make up the 
required weight. 
 
Description of intervention exercises 
 
The procedure for progressive resisted exercises is summarised below in Table 3.8 
  
Table 3.8 Summary of a progressive resisted exercise sessions  
 
Procedure week Frequency Progression 
Week one (Load less) 10 reps by 2 sets No Load 
Week two  Increase to 10 reps by 3 sets  
Week three  10 reps by 2 sets Start with 2kg/Ikg  load 
Week four  Increase to 10 reps by 3 sets 
Week five 10 reps by 2 sets Increased load by 1 kg 
Week six  Increase to 10 reps by 3 sets 
Week seven 10 reps by 2 sets Increased load by 1 kg 
Week eight  Increase to 10 reps by 3 sets 
Week nine 10 reps by 2 sets Increased load by 1 kg 
Week ten  Increase to 10 reps by 3 sets 
Week eleven 10 reps by 2 sets Increased load by 1 kg 
Week twelve  Increase to 10 reps by 3 sets 
 
The exercise sessions were done twice a week such as on Mondays and Thursdays 
or Tuesdays and Fridays. The weights were increased as the participant could 
tolerate at increments of 1kg per after every two weeks (ACSM, 2006). On the week 
the weight was increased, two (2) sets of repetition were used. The sets were 
increased to three (3) on the following week while the weight was maintained.  
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Session format 
 
Table 3.9 below highlights the phases followed within a session. 
 
Table 3.9 Summary of an exercise session  
 
Procedure Duration Progression 
Warm up and general static 
stretching 
5 min Easy walking 
Arm swinging 
Walking sideway and backwards 
Specific  static stretching to 
the lower limb described in 
Table 3.9 
10 min As described in stretching a hold of 
30 seconds at the point of mild 
discomfort per stretch. 
Progressive resisted exercises 30 min As described in PRE section 
Warm down 5 minutes Walking around the gym and 
combined stretching. 
 
 
Warm up 
 
The specific static stretching to the lower limb is summarised in Table 3.10. 
 
Table 3.10 Specific static stretching to the lower limb   
 
Muscle Starting 
position 
Movement/ name of stretch 
Hamstring 
muscles 
Sitting modified hurdlers stretch 
Quadriceps side lying Upper leg is self-stretched by bending the knee 
and pulling the leg back. 
Calf stretches Standing Lunge forward keeping the feet firm on the floor 
Tibialis anterior in standing front of leg stretches- lift the leg bending it back 
The back muscle in side lying using the back curls/ knees to chest tuck 
 
 
A general warm up activity was done before participants commenced on the specific 
static stretching to the lower limb.  
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Main progressive resisted exercises 
 
The progressive resisted exercise session procedure is summarized in Table 3.11 
below 
 
Table 3.11 Progressive resisted exercise session procedure 
Muscle group Starting position Activity 
Quadriceps 
femoris muscles 
Seated on a plinth, weight fixed 
at the ankle. Feet must clear the 
ground with the knee bending. 
Knee extensions – 
straightening the knee 
Hamstring 
muscles 
 
Lying in prone on mat, weight 
fixed at the ankle. 
Legs will be straight on the mat 
with a pillow under the ankle. 
 Knee flexion – (bending 
the knee) as per 
schedule   
Tibialis anterior 
muscles 
Seated on a plinth, weights fixed 
near the toes. 
Feet must clear the ground with 
the knee bending. 
Foot lifting as per 
schedule ankle dorsi-
flexors 
Gastrocnemius 
muscles 
Lying in prone on mat, weight 
fixed near the toes. 
Knees bent at 90. 
the ankle plantar-flexors 
Foot pushups getting 
toes to point up to 
ceiling  
 
The core muscles underwent a general strengthening exercise programme using self 
body weight. The Erector Spinae muscles were exercised in prone on mat, while the 
abdominals were exercised in supine crook lying on the mat. The core muscles were 
exercised generally to stabilize the trunk; however no assessment was done as this 
was not objectively feasible in our setting or primarily part of the objectives. On 
commencing sessions, each muscle group in the lower limbs was taken through two 
sets of ten (10) repetitions using the mean weight at 12RM. The weight was fixed in a 
safe manner on the participants‟ body with Velcro or crepe bandage depending on 
movement to be performed. A resting period of 2 minutes was allowed between the 
sets so that the muscles could recover (ACSM, 2006). Non- compliance was defined 
as not attending more 50% of the sessions, which in this case is twelve sessions. 
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3.5 Data collection and recording procedure 
3.5.1 Introduction 
 
The procedure of how the data were collected, recorded and analysed as well as the 
intervention procedure will be outlined in the following section. 
 
Ethical considerations: / ethical clearance (Appendix J and Appendix K) 
 
Approval and ethical clearance of the protocol was sought from both the Human 
Research Ethics committee of the University of the Witwatersrand registration No: 
M090214 and the Human Medical Research Council of Zimbabwe registration No: 
MRCZ/B/62 through application for registration of protocol after approval by the 
school. Approval and ethical clearance of the research protocol was sought from the 
Joint Parirenyatwa Hospital and College of Health Sciences Research Ethics 
registration No: JREC/23/09, through application for permission. Permission to 
access the municipal clinics was sought from the Medical Director of City of Harare. 
Permission to access the Municipality of Harare clinics was granted in December 
2010 by the Medical Director. Permission by the Medical Research Council of 
Zimbabwe was granted in September 2009, after approval and ethical clearance of 
the research protocol by the responsible ethical boards and councils. Participant‟s 
written consent to participate in the study was sought using an information sheet 
(Appendix K). Participants in the control group were switched to do the experimental 
intervention at the end of the trial. Confidentiality was maintained to address 
HIV/AIDS associated stigma. An annual renewal of ethical clearance with the Joint 
Parirenyatwa Hospital and College of Health Sciences Research Ethics Zimbabwe 
and Medical Research Council of Zimbabwe was observed in 2010 and 2011.  
 
3.6 Pilot study  
3.6.1 Pilot study objectives 
 
The main purpose for the pilot study was to establish the intra-rater reliability of the 
Performance Oriented Mobility Assessment tool and of the hand held dynamometer. 
The study sought to establish the usual treatment method used while allowing the 
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principal researcher and research assistant to familiarise with the study process and 
to adjust logistical preparations. 
3.6.2 Procedure of pilot study 
 
The pilot study was completed in four weeks using a sample of seven (7) participants 
determined by using the equivalent of 10% of total sample required for main study so 
as to determine the intra-rater reliability.  
 
The pilot was commenced in January 2010 with prospective participants being invited 
in person by the researcher using the Brief Peripheral Neuropathy questionnaire. All 
the invited persons had an initial assessment done immediately on the day, or when 
they presented at the physiotherapy department. A reassessment for all the 
participants was carried out within 48 hours for intra rater reliability tests. The 
research assistant took the experimental group of four participants through a 
program of four progressive resisted exercises sessions as described in the 
intervention method. Seven of the participants were reassessed at the end of the 
experimental groups four sessions of progressive resisted exercises. 
3.6.3 Results of  pilot study 
 
The results intra rater reliability tests are summarised in Tables 3.12 and Table 3.13 
below. The results intra rater reliability tests for muscle strength are summarized in 
Table 3.12. 
 
Table 3.12 Correlation of muscle strength scores 
 
Muscle Spearman Rho  p value 
right quadriceps 0.87 0.01 
left quadriceps 0.80 0.03 
right hamstrings 0.96 0.001 
left hamstrings 0.70 0.08 
right gastrocnemius  0.88 0.01 
left gastrocnemius 0.53 0.22 
right tibialis anterior 0.33 0.47 
left tibialis anterior 0.46 0.30 
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Intra-rater reliability of the dynamometer was high for the quadriceps, hamstring and 
right gastrocnemius muscles with Spearman rho range of 0.70 to 0.96.with p= 0.08 to 
p=0.001. Both tibialis anterior muscles and left gastrocnemius muscle were poorly 
correlated p=0.2, p=0.29 and p=0.47.  
 
Table 3.13 Correlation of POMA gait and balance and pain scores  
 
 
Variables  Spearman Rho P value 
Wong Baker faces   
Pain 0.94 0.002 
POMA   
 Balance score 0.82 0.03 
 Gait score 0.37 0.42 
Total score 0.58 0.17 
 
 
The Performance Oriented mobility assessment balance scores showed a reliability 
quotient, Spearman‟s rho = 0.82, which is significant p= 0.03. The gait score had a 
Spearman‟s rho = 0.37, p=0.42 and the total mobility score was Spearman‟s rho =    
0.58, p= 0.17. The Wong baker faces pain score showed a reliability quotient, 
Spearman‟s rho = 0.94, (p= 0.002). 
 
3.6.4 Implications for the study 
 
 
The pilot study showed that inviting participants by using the first part of the BPNS 
was more efficient in recruiting participants. The analysis of the results suggested 
that instruments were reliable as shown by high correlation co-efficient realised. The 
dynamometry measurements were appropriate for determining muscle strength. 
However the dynamometer needed a cushion pad to be used to reduce contact pain 
during testing. The pilot study revealed that not all participants who attended at the 
central hospitals were residents of Harare; they had only sought accommodation with 
their relative‟s resident in Harare while they accessed drugs which were more readily 
available at these centers. The CD4+ count was unreliable as most of these clinical 
results were more than one year old since an actual test had been done making 
these results stale.  A high percentage of the participants were employed and once 
they felt better they stopped attending and went back to work in Harare or other 
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towns while others were self-employed and therefore could not afford to attend as 
many sessions. Eligible numbers were lowered by co-morbidity especially 
tuberculosis which made them ineligible for the study. The working space in the gym 
for the exercise classes would be able to accommodate only 15 clients per session. 
 
Study setting 
 
The experience we had when sourcing for our participants showed that our approach 
of assessing patients at source sites was time consuming and unfriendly to the 
prospective participants.  On corresponding with the medical consultants responsible 
at the family care clinics, we were advised that the local doctors would be too busy to 
assist in the diagnosis of poly-neuropathy for the study. We therefore had to use a 
different approach in recruitment, where participants were invited to attend a full 
assessment using an invitation questionnaire for main study compared to the pilot 
study approach.  
 
Performance oriented mobility assessment and dynamometry reliability 
 
The gait scoring showed volatility consistent with its ability to discriminate change 
and a possible training effect from the first session.  The results show that the 
dynamometer and the performance oriented mobility assessment are reliable 
instruments when assessed by the same assessor. 
 
Usual method of treatment 
 
Most participants interviewed showed that the usual treatment method used by 
clinics was to be advised by the nurse or doctor to go and do exercises like walking 
while at home. Pain was managed using medication usually in the form of 
amitryptiline.  Rarely were these participants referred to the physiotherapist for 
exercise prescription.  Participants had knowledge of the need to exercise but not the 
information on how to exercise or they would go to the gym or taking walks. The 
study found that some participants with symptoms of peripheral neuropathy had been 
referred for physiotherapy to address the neuropathic pain and activity limitation 
emanating from the impairments of pain weakness and numbness. However, when 
they presented at the Physiotherapy department they were asked to pay US$10 for 
each session. The participants did not have the money to pay for this service as they 
were getting the antiretroviral drugs for a token fee or for free. These participants 
were included in the study because they had not received therapy as they were 
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unable to pay for the service. This may be one of the reasons why the usual method 
used advice from the doctor or nurse for the patient to exercise at home.  
3.7 Main Study 
 
The main study was fulfilled in two phases; Study 1 and Study 2 because the Study 1 
had experienced a high loss to follow-up rate and therefore a Study 2 was essential 
to achieve the required sample size as calculated in the initial protocol. 
3.7.1  Study 1 
 
Study 1 was completed over thirty weeks from March to August 2010.  Participants 
were invited for baseline assessments using the English and Shona versions of the 
BPNS at Wilkins clinic and Opportunistic Infections clinics at Parirenyatwa and 
Harare Central Hospitals. Baseline assessments as per pilot study were carried out 
on a sample of forty six participants over eleven weeks, at the physiotherapy 
department at Parirenyatwa Hospital. The control group was advised to exercise 
using walking at home. The selected experimental group participants were informed 
by phone call to attend exercise sessions by the assistant. The research assistant 
took the experimental group of participants through of twenty four sessions of 
progressive resisted exercises as described in the intervention method. After the 
twelve weeks reassessments were done for both the control group and the 
experimental group.  
3.7.2  Study 2 
 
The researcher selected ten clinics with functional support groups from the ART 
dispensing local clinics of the Municipality of Harare. Baseline assessment of the one 
hundred and fourteen participants was completed over fifteen (15) weeks as they are 
identified using the BPNS questionnaire at the local clinics. The baseline 
assessments were completed in the same manner as in the pilot study. The ten 
groups were cross matched for sex and age and then randomized to five (5) 
interventional groups and five (5) control groups. The experimental group of fifty 
seven participants in their five different home support groups (eleven+/-two 
participants per group) was taken through a program of progressive resisted exercise 
sessions described earlier in the intervention method by a research assistant. The 
other five (5) control groups‟ participants were given advice to walk as a home 
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exercise programme. All the participants were then reassessed within three weeks at 
the end of twelve weeks of trial intervention. The reassessments also included focus 
group discussions to get insight on the reasons for failing to attend the exercise 
sessions. Participants who could not attend the reassessments sessions were 
interviewed on the phone to get insight on the reasons for failing to attend the 
exercise sessions. The participants were asked the question:  
What are/were your reasons for failing to attend the assessment exercise sessions?  
 
3.8 Data analysis 
 
Each participant was given a unique identifying code number so that they are 
identified on their result forms and questionnaires. All raw data was recorded on 
these prepared assessment forms and questionnaire forms and logged using a 
prepared Excel software spread sheet. The data logged into the Excel program was 
analysed after cutting and pasting into the Stata V10 statistical software program.  
 
The statistical tests used on this data are summarised in Table 3.14 and Table 3.15. 
  
Table 3.14 Variables analysed and the tests applied. 
Variables analysed: Test  
 
Intra-rater reliability of the Performance Oriented 
Mobility Assessment tool. 
 
Spearman rho 
The intra-rater reliability of dynamometer Pearson r 
Differences in the mean change in the muscle 
strength scores within groups 
Paired t-test 
Differences in the mean change  in the 
performance oriented mobility gait scores 
Paired t-test 
Differences in the mean change in  the 
performance oriented mobility balance scores  
Paired t-test 
Differences in the mean change in the pain scores 
within groups 
Wilcoxon‟s rank sum test 
Differences in the mean change in  the health 
related quality of life scores within groups 
Paired t-test 
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Table 3.15 Variables analysed and the tests applied for between group and 
association analysis. 
 
Intention to treat analysis was applied to the raw data. The EQ5D-utility score was 
analysed using pre-calculated tables from the results of the EQ5D –profile scores. 
Upon analysis, the EQ5D profile scores defines 243 states of health pre-calculated 
using a regression analysis to produce Euro-quality of life a utility scores (Appendix 
F). The outcomes were then multiplied by 100 to give a percentage rating which 
allows for ease of analysis. Baseline similarities were determined using unpaired t-
tests for muscle strength and quality of life utility scores, while Wilcoxon Rank sum 
tests were used for gait, balance and pain. The results of the study was analysed to 
establish the effect of progressive resisted exercises on the different variables as 
outlined in the objectives. The levels of difference between the change in the scores 
in the experimental group and the control group after intervention were analysed 
using analysis of variance on a logistic regression model generated using a 
generalized estimating equations. The association levels between variables were 
analysed using univariate models, temporal and group adjusted models and 
multivariate logistic regression models. 
Variables analysed: Test  
Differences in the mean change in the muscle 
strength scores between groups 
Analysis of variance 
Differences in the mean change in the 
performance oriented mobility gait scores 
between groups 
Analysis of variance 
Differences in the mean change in the 
performance oriented mobility balance scores 
between groups 
Analysis of variance 
Differences in the mean change in the pain scores 
between groups 
Analysis of variance 
The mean change in the health related quality of 
life between groups 
Analysis of variance 
Relationships between muscle strength changes, 
the mobility level change and the health related 
quality of life. 
Logistic regression 
model using generalised 
estimating equations  
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CHAPTER 4 
4. RESULTS 
4.1 Introduction 
 
In this chapter the results of the data collected as well as the outcomes of the 
intervention will be presented and analysed according to the study objectives. The 
aim of the study was to determine the effects of progressive resisted exercises (PRE) 
on performance oriented mobility and on health related quality of life in people with 
HIV/AIDS related distal symmetrical poly-neuropathy (DSP). The first objective in the 
study sought to determine the effects of PRE on the aspect of gait in participants with 
HIV/AIDS related DSP. The second objective was to determine the effects of PRE on 
balance in the above same participants. The third objective sought to determine how 
PRE affect the pain levels in the said participants. The fourth objective was to 
establish if there is a relationship between the levels of performance-oriented mobility 
and health related quality of life in participants with HIV/AIDS related DSP.  
 
4.2 Pilot Study Results 
 
In summary, the purpose of the pilot study was to establish the feasibility and intra-
rater reliability of the Performance Oriented Mobility Assessment (POMA) tool and 
that of the hand held dynamometer. It also sought to establish the usual method used 
to treat peripheral neuropathy in Zimbabwe. The POMA balance scores showed a 
high intra-rater reliability, Spearman rho (rho = 0.82, p= 0.03) while gait score was 
low, (rho = 0.37, p=0.42). Intra-rater reliability of the dynamometer was high for the 
quadriceps, hamstring and right gastrocnemius muscles with Pearson r of 0.7 to 0.96 
and p= 0.07 to p=0.001. The pilot study showed that the usual treatment for 
peripheral neuropathy was advice given by doctor or nurse to exercise at home and 
medication for pain. The full results of the pilot study are reported in detail in Chapter 
Three under section 3.10. 
 
 
56 
 
4.3 Main study results 
4.3.1 Introduction 
 
The main study was conducted in two separate studies as Study 1 and Study 2. 
Study 1 was conducted during the period March to August 2010. This study was 
completed and experienced very high dropout rates of above 33% (n=16).  Due to 
the high dropout rate the researcher undertook to repeat the study using the same 
methodology but located the study closer to the participants. Hence Study 2 sought 
to recruit a sample size of 120 participants calculated using a dropout rate of 45% 
and the same power  at 90% (as described in Section 3.4.3) so as to take into 
account the high dropout experienced in Study 1. Study 2 was conducted during the 
period January to September of 2011. 
 
The per protocol analysis is presented as Appendix G and Appendix H. The results 
using an intention to treat analysis approach will be presented under the following 
headings  
 
i) Description of the study participants 
ii) Baseline assessments results of main study. 
iii) Post intervention results between the control group and the experimental 
group.  
iv) Post intervention results within the control and within the experimental group.  
v) Correlation and associations between the study variables. 
vi) Reasons for non-compliance or withdrawal from study 
 
4.3.2 Description of the study participants 
Flow of participants  
Figure 4.1 is a flow diagram of the participants through the combined Study 1 and 
Study 2 using the Consolidated Standards for Reporting Trials (CONSORT) template 
for flow diagrams recommended for reporting outcomes of trials (Moher et al 2010). 
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Figure 4.1 Flow of participants through the main study showing loss to follow-up      
(n =160) 
 
Baseline assessments in Study 1 were carried out on 80 participants, eight were 
excluded from the study for being non-resident in Harare n=8, declined to participate 
n=6, diabetic n=3, period on ART less than six months n=6, were moving n=5, 
getting employed n=3 or were pregnant n=3. Therefore 46 participants were 
randomised for the Study 1, 23 in the control group and 23 in the experimental group. 
Reassessments were done on follow-up for thirty-one participants, 15 controls and 
16 in the experimental group. Baseline assessments in Study 2 were carried out on a 
sample of one hundred and fourteen (114) participants at sites at the selected city of 
Harare clinics, over eleven weeks. Participants were excluded for not being residents 
of Harare n=16, declining to participate n=6, being diabetic n=4, less than six months 
Identified and invited 
n=350(100+250)  
Presented for assessment 
n=240 (80+160) 
 
Excluded 
(n=46)    
 Allocation at week 0 
Randomised (n=160) 
(46+114) 
   
  
Allocated to Control 
n= 80 (23+57) 
Received Intervention 
n=80 (23+57) 
Analysed n=29 
(15+14) 
Did not respond 
Study 2 n=90 
Lost to follow-up 
n=50 (8+43) 
Lost to follow-up 
n=45 (7+38)  
Analysed n=35 
(16+19) 
FOLLOW -UP     
Week 12 
Excluded 
(n=26) 
               
Did not respond 
Study 1 n=20 
 
 Pilot (n=8) 
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on ART n=12, planning to move n=1, being too ill and requiring hospitalisation n=1, 
getting employed n=2 and being pregnant n=4. Reassessments were done for 33 
participants, 14 controls and 19 participants from the experimental group. Of the 114 
participants who were randomised, 71% (n=81), were lost to follow up.  
 
Demographic information of Study 1 and Study 2 
 
The demographic characteristics of the participants in the study is described below in 
Table 4.1  
 
Table 4.1 Demographic characteristics of the participants (n=160) 
Characteristic Control group (n=80)  
n (%) 
Experimental group (n=80) 
 n (%) 
Gender   
Females 56 (70) 57 (71.3) 
Males 24 (30) 23(28.7) 
Marital status   
Single 11 (13.7) 11 (13.9) 
Married 45 (56.3) 43 (54.4) 
Divorced 6 (7.5) 3 (3.8) 
Widowed 18 (22.5) 22 (27.9) 
Age   
<30 years 6 (7.5) 5 (6.3) 
31-40 years 29 (36.3) 30 (37.5) 
41-50 years 30 (37.5) 32 (40) 
>51 years 15 (18.7) 13 (16.2) 
Occupation   
Unemployed 12 (15) 7 (8.8) 
Self employed 33 (41.3) 32 (40) 
Employed 35 (43.7) 41 (51.2) 
Education (years)   
Nil  1 (1.2) 1 (1.2) 
1-7 (primary) 22 (27.5) 21 (26.3) 
8-11 (secondary) 53 (66.3) 57 (71.3) 
12+ (tertiary) 4 (5) 1 (1.2) 
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The above results show that 55% (n=88) participants were married and female 
participants constituted 70.6% (n=113) of the total study sample.  
 
HIV related information of the participants  
 
Table 4.2 shows HIV related information of the participants in the main study. 
 
Table 4.2 HIV related information of the participants (n=160)  
HIV Information Control group (n=80) 
n (%) 
Experimental group (n=80)  
n (%) 
Period after diagnosis 
6-12 months 47 (58.7) 45 (56.3) 
13-24 months 6 (7.5) 8 (10) 
25-36 months 6 (7.5) 7 (8.7) 
>37 months 21 (26.3) 20 (25) 
CD4+ count (cells per mm3 ) 
>100 27 (33.7) 16 (20) 
101-200 18 (22.5) 24 (30) 
201-300 11 (13.8) 7 (8.8) 
301-400 4 (5) 5 (6.3) 
>401 11 (13.7) 11 (13.7) 
Missing values 9 (11.3) 17 (21.2) 
Type of Antiretroviral Therapy 
Stalanev 59 (73.7) 59 (73.7) 
Combivir/coviro 12 (15) 7 (8.8) 
Zidolan  9 (11.3) 14 (16.5) 
Period on Antiretroviral Therapy 
6-12 months 32 (40) 26 (32.5) 
13-24 months 11 (13.7) 9 (11.3) 
>25 months 37 (46.3) 45 (56.2) 
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The results above show that 70 % (n=112) had a CD4+ count of less than 300 cells 
per cubic mm. Combination antiretroviral therapy of Stavudine, Lamivudine and 
Nevirapine was used by 59% (n=94) of the participants. 
 
Levels of peripheral neuropathy in the participants 
 
The levels of peripheral neuropathy in the participants, using the subjective 
peripheral neuropathy screen (PNS) scores are shown in Table 4.3 below.  
 
Table 4.3 Subjective peripheral neuropathy screen (PNS) scores in the participants 
(n=160) 
PNS score Control group (n=80) 
n (%) 
Experimental group (n=80) 
n (%) 
minor (1-3) 5 (6.3) 4 (5) 
mild (4-7) 25 (31.3) 32 (40) 
moderate (8-11) 43 (53.7) 30 (37.5) 
severe (12-15) 7 (8.7) 14 (17.5) 
 
The subjective peripheral neuropathy screen score show that 59% (n=94) of the 
participants had moderate to severe neuropathy. The results highlight the similarities 
in severity of neuropathy between the control and the experimental groups. 
 
Numbness 
 
During the assessments of peripheral neuropathy the signs and symptoms required 
further clarification.  Participants reported having problems with numbness a 
symptom of peripheral neuropathy where participants did not have pain but could not 
feel their feet. Participants described not feeling their feet and losing their footwear 
and walking for a distance before realizing they had forgotten their footwear. Five of 
them were public vehicle drivers and related experiences associated with the loss of 
feeling in the feet. These drivers indicated that they had difficulty feeling the clutch 
and brake pedals during driving. One of participants was a haulage truck driver who 
occasionally had to rely on visual check when braking. Two of the participants were 
public commuter or taxi drivers. They reported that the numbness was worse as the 
day progressed and as they got tired. All of the participants walked over two 
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kilometers per day and they complained of fatigue as the day progressed. All the 
research assistants reported that during the exercise sessions participants would 
discuss their problems with pain and numbness while sharing ideas on how to 
manage these problems. 
 
Comparison of participants’ demographic and clinical characteristics between 
the control and experimental groups 
 
Table 4.4 compares the demographic and clinical characteristics between the control 
and experimental groups. 
 
Table 4.4 Comparison of the participants at baseline (n=160) 
Characteristic 
 
Control  
group (n=80) 
mean (SD) 
Experimental 
group (n=80) 
mean (SD) 
Mean 
Difference   
(SE) 
p 
value 
(95%) 
Confidence 
intervals  
Age (yrs) 42.4 (8.5) 42.2 (8.0) 0 (1.3) 1.0 -2.6 – 2.6 
Education (yrs) 9.3 (2.3) 9.1 (2.7) 0.25 (0.4) 0.5 -0.5 – 1.0 
Period of 
diagnosis 
(months) 
26.6 (30) 26.6 (23) 0 (4.2) 1.0 -8.4 – 8.4 
CD4+ count (per 
mm3) 
211.4 (193) 222.9 (198) -11.5 (33.8) 0.7 -78.4 – 55.5 
Peripheral 
neuropathy 
score 
8.2 (2.8) 8.1 (2.9) 0.15 (0.5) 0.7 -0.7 – 1.1 
 
The participants in the experimental group and the control group showed similarities 
in most characteristics tested for including: gender, age, education level, period of 
diagnosis and if on ARVs, CD4+ count and peripheral neuropathy scores with a (p 
>0.5).  
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4.3.3 Results of baseline assessments  
 
The baseline assessment results for muscle strength, gait, balance and health- 
related quality of life the participants in the study will be presented in Tables 4.5 – 
4.7b.  
 
Baseline muscle strength  
 
A comparison of the muscle strength means between the control groups and the 
experimental group is presented in Table 4.5. 
 
Table 4.5 Muscle strength means comparing the control groups and the experimental 
groups (n=160) 
 
Muscles in kg 
of force 
Control  
group (n=80) 
mean (SD) 
Experimental 
group (n=80) 
mean (SD) 
Difference  
mean (SE) 
Confidence 
intervals 
(95%) 
p 
value 
Rt quadriceps 7.96 (4.6) 7.99 (3.6) -0.03  (0.7) (-1.3 – 1.2) 0.96   
Lt quadriceps 7.25 (3.65) 7.55 (4.4) -0.30 (0.6) (-1.4 – 0.8) 0.60 
Rt hamstrings 3.43 (1.5) 3.65 (2.0) -0.23 (0.74) (-0.8 – 0.3) 0.41 
Lt hamstrings 3.49 (1.7) 3.54 (1.9) -0.05 (0.3) (-0.6 – 0.5) 0.87 
Rt gastrocs 12.84 (2.0) 12.88 (5.3) -0.58 (0.8) (-2.1 – 1.0) 0.47 
Lt gastrocs 12.11 (4.4) 12.26 (4.7) -0.15 (0.7) (-1.6 – 1.3) 0.84 
Rt tib anterior 8.2 (3.5) 8.6 (4.3) -0.39 (0.6) (-1.6 – 0.8) 0.53 
Lt tib anterior 7.71 (3.2) 7.95 (4.0) -0.24 (0.6) (-1.6 – 0.9) 0.68 
 
Abbreviations:  Rt = right, Lt = Left, gastrocs = gastrocnemius, tib = tibialis 
  
 
The muscle strength profile showed that the hamstring generated the least mean 
force at 3.43 (1.5) kilograms of force in contrast to the right gastrocnemius muscles 
which exhibited the highest mean muscle strength at 12.8 (2.0) kilograms of force.  
Mean muscle strength of the control group were not statistically different to the mean 
muscle strength of experimental group at baseline, (p=0.41 – 0.96). 
 
Gait, balance and pain baseline scores 
 
The gait and balance scores at baseline assessed using the POMA reported in Table 
4.6 below. 
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Table 4.6 Gait, and balance scores at baseline in the participants (n=160) 
 
Score 
Control  
group (n=80) 
mean (SD) 
Experimental 
group (n=80) 
mean (SD) 
Difference  
mean (SE) 
(95% 
confidence 
interval) 
p value 
Gait  11.5 (1.0) 11.4 (0.9) 0.06 (0.2) -0.23 – 0.36 0.68 
Balance   14.4 (1.2) 14.3 (1.6) 0.05 (0.2) -0.39 – 0.49 0.82 
Total 25.7 (2.3) 25.8 (2.1) 0.04 (0.4) -0.73 – 0.60 0.91 
 
 
The mean difference in the gait score of 0.06 (p=0.68) and in the balance score of 
0.05 (p=0.17) show there was no difference statistically between the two groups 
When pain was tested using Wilcoxon‟s rank sum test, the results showed similarity 
between the control group and the experimental group (p=0.96). 
 
Health related quality of life levels at baseline 
 
The health related quality of life levels at baseline assessed using the EQ-5D scores 
in the participants in the study are shown in Table 4.7a below. 
 
Table 4.7a Health related quality of life (EQ-5D) scores at baseline in the participants 
(n=160) 
Scores 
 
Control  
group (n=80) 
mean (SD) 
Experimental 
group (n=80) 
mean(SD) 
Mean 
Difference  
(SE) 
p 
value 
(95% 
confidence 
interval) 
EQ5D VAS  63.5 (15.1) 66.8 (14.5) -3.30 (2.3) 0.16 -7.93 – 1.33 
EQ5D utility  57.5 (29.9) 50.8 (30.9) 6.63 (4.8) 0.17 -2.86 – 16.1 
 
The EQ-5D visual analogue score mean difference of -3.3 (SE 2.3) p=0.16 and the 
health related quality of life utility score mean difference of 6.6 (SE=4.8) p=0.17, 
showed similarity between the control group and the experimental group. Table 4.7b 
is a profile of the EQ-5D health related quality of life levels results showing the scores 
in the five domains at baseline for the participants. 
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Table 4.7b EQ-5D profile scores at baseline (n=160) 
EQ5D scores 
 
Control group (n=80) 
 n (%) 
Experimental group (n=80)  
  n (%) 
ED-5D mobility 
No problems 51 (63.7) 42 (52.5) 
Some problems 29 (36.3) 36 (45) 
Confined to bed 0 2 (2.5) 
EQ-5D self-care 
No problems 71 (88.7) 74 (92.5) 
Some problems 9 (11.3) 6 (7.5) 
Unable 0 0 
EQ-5D usual activity 
No problems 43 (53.7) 47 (57.8) 
Some problems 29 (36.3) 19 (23.7) 
Unable 8 (10) 14 (17.5) 
EQ-5D pain or discomfort 
None 13 (16.3) 10 (12.5) 
Moderate 56 (70) 51 (63.8) 
Extreme 11 (13.7) 19 (23.7) 
EQ-5D anxiety/depression 
None 32 (40) 40 (50) 
Moderate 38 (47.5) 30 (37.5) 
Extreme 10 (12.5) 10 (12.5) 
EQ-5D state of health level  
Better 61 (76.2) 56 (70) 
Much the same 10 (12.5) 16 (20) 
Worse 9 (11.3) 8  (10) 
 
The health related quality of life profile shows that 42% (n=67) of the participants had 
some problems with mobility and completion of usual activities. Self-care was a 
problem in 9 % (n=14) of the participants. The study showed that 20% (n=32) of the 
participants reported extreme pain. Participants perceived themselves to be in a 
better state of health, where state of health median score was one (1). 
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4.3.4 Post intervention results between the experimental group and the 
control group  
 
Introduction 
 
The results of the study were analysed to establish the effect of progressive resisted 
exercises on gait, balance and pain as outlined in the objectives. The analysis 
determined if there was a difference in the muscle strength change between the 
control and the experimental groups prior to establishing the effects of progressive 
resisted exercise. 
 
Muscle strength difference between the control and experimental groups 
 
The difference in mean muscle strength between the combined control group and 
experimental group post intervention is summarized in Table 4.8 below. 
 
Table 4.8 Mean muscle strength difference between the control group and 
experimental group after intervention (n=160) 
Muscle F ratio Standard error (95% confidence interval) p value 
Right quadriceps 0.07 0.01 (0.00 – 0.02) 0.80 
Left quadriceps 1.59 0.02 (0.00 – 0.04) 0.20 
Right hamstrings 2.22 0.03 (0.00 – 0.06) 0.13 
Left hamstrings 0.13 0.01 (0.00 – 0.02) 0.70 
Right gastrocnemius  0.59 0.01 (0.00 – 0.02) 0.44 
Left gastrocnemius  0.11 0.01 (0.00 – 0.02) 0.73 
Right tibialis anterior 2.78 0.03 (0.00 – 0.08) 0.09 
Left tibialis anterior 1.23 0.01 (0.00 – 0.03) 0.26 
 
There was a trend towards a significant difference between the control and 
experimental group, p=0.09 in the right tibialis anterior muscles. There was no 
difference in the mean muscle strength change between the control group and the 
experimental group in the other muscles tested (p= 0.13 – 0.80).  
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Gait, balance, pain and quality of life differences between the control and 
experimental groups after intervention 
 
Objectives 1, 2 and 3 of the study focus on the effects of progressive resisted 
exercises on gait, balance and pain.  The differences in the gait, balance, pain and 
quality of life utility score between the control group and the experimental group after 
intervention are summarized in Table 4.9. 
 
Table 4.9 Difference in the gait, balance, pain and quality of life (QOL) utility scores 
and state of health between the control group and the experimental group post 
intervention (n=160) 
Variable F ratio Standard error (95% confidence interval) p value  
Balance 0.00 0.01 (0.00 – 0.02) 0.95 
Gait 0.01 0.01 (0.00 – 0.02) 0.94 
Pain  2.36 0.03 (0.00 – 0.06) 0.13 
QOL Utility score 0.07 0.01 (0.00 – 0.02) 0.79 
QOL State of health 4.24 0.05 (0.00 – 0.12) 0.04 
 
There was no difference in the changes in the gait scores of the POMA between the 
experimental and control groups p=0.94. The change in the balance scores of the 
POMA between the experimental and control group after the intervention were similar 
p=0.95.  There was a trend towards significance in the pain score change between 
the control group and the experimental group p=0.13. The health related quality of 
life changes in the experimental group and control groups after the intervention 
measured using the utility score showed no differences between the groups p=0.79. 
However the health related quality of life changes in the experimental group and 
control groups after the intervention measured using the state of health showed there 
was a difference between the groups p=0.04. 
 
Within group changes for these same variables were analysed using paired t-tests 
and Wilcoxon‟s rank sum test and the results are outlined next.  
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4.3.5 Within group results pre and post intervention (experimental 
group and the control group) 
 
Introduction 
 
This section of the results presents the change in the muscle strength, gait, balance 
and pain within the control group and the experimental group.  
 
Muscle strength change within the control group 
 
The mean muscle strength changes within the control group are shown in Table 4.10 
below. 
 
Table 4.10 Mean muscle strength change in the control group (n=80) 
 
Muscle  Mean muscle strength 
change 
95% (confidence 
interval) 
Standard 
Error 
p 
value 
Right quadriceps 0.8 0.17 – 1.43 0.31 0.01 
Left quadriceps 1.0 0.29 – 1.71 0.35 0.006 
Right hamstrings 0.95 0.52 – 1.38 0.25 0.0001 
Left hamstrings 0.8 0.41 – 1.20 0.20 0.0001 
Right gastrocnemius  1.75 0.90 – 2.60 0.43 0.0001 
Left gastrocnemius  1.36 0.57 – 2.16 0.40 0.001 
Right tibialis anterior 1.18 0.45 – 1.89 0.36 0.002 
Left tibialis anterior 1.14 0.45 – 1.83  0.35 0.002 
 
The mean muscle strength changes within the control group were significant ranging 
from p=0.0001 to p=0.01. The highest mean difference occurred in the right 
gastrocnemius muscle =1.75 kg (95% CI 0.90 – 2.60). The least mean difference of 
0.8 kg (CI = 0.41 – 1.2) occurred in the left hamstring muscle and right quadriceps 
muscle. 
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Muscle strength change within the experimental group 
 
The mean muscle strength changes within the experimental group are shown in 
Table 4.11 below. 
 
Table 4.11 Mean muscle strength change within the experimental group 
Muscle  Mean muscle 
strength change 
Standard 
Error 
p value  (95% confidence 
interval) 
Right quadriceps 1.75 0.35 < 0.0001 1.05 – 2.45 
Left quadriceps 2.16 0.35 < 0.0001 1.47 – 2.86 
Right hamstrings 1.39 0.23 < 0.0001 0.94 – 1.83 
Left hamstrings 0.93 0.21 < 0.0001 0.51 – 1.34 
Right gastrocnemius  2.25 0.51 < 0.0001 1.23 – 3.27 
Left gastrocnemius  2.00 0.48 0.0001 1.04 – 2.96 
Right tibialis anterior 2.39 0.47 < 0.0001 1.48 – 3.30 
Left tibialis anterior 1.78 0.42 0.0001 0.93 – 2.61 
 
The mean muscle strength changes within the experimental group were significant 
ranging from p<0.0001 to p=0.0001. The highest change in muscle strength occurred 
in the right tibialis anterior muscle with 2.39 kg (95% CI 1.48 – 3.30) and the least 
change occurred in the left hamstrings, 0.93 kg (95% CI 0.51 – 1.34). 
 
 
Gait, balance and pain changes within the groups 
 
The level of changes in the gait, balance and pain scores of the performance 
oriented mobility scores within the experimental groups and the control groups are 
summarised in Table 4.12 below. 
 
Table 4.12 The POMA gait score change within the control group and within the 
experimental group 
Study Group (n=80) Mean gait 
score change 
Standard Error  (95% confidence 
interval) 
p 
value 
Control group  0.36     0.14     -0.27 – 0.34 0.81 
Experimental group  0.25     0.17    -0.1 – 0.6 0.16           
 
There was no difference in the change in the gait scores for both the experimental 
and the control groups p=0.16 and p=0.81 respectively. 
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Table 4.13 The POMA balance score change within the control group and within the 
experimental group 
Study Group (n=80) Mean balance  
 score change 
Standard 
Error 
 (95% confidence 
interval) 
p 
value 
Control group  0.8      0.25     0.3 – 1.3 0.003 
Experimental group  0.48      0.21    0.6 – 0.9 0.03          
 
 
Both the control group and the experimental group had a significant difference in the 
balance score change p=0.003 and p=0.03 respectively.  
 
 
Table 4.14 The POMA total score change within the control group and within the 
experimental group 
Study Group (n=80) Mean POMA Total  
 score change 
Standard 
Error 
 (95% confidence 
interval) 
p 
value 
Control group  0.78      0.36     0.03 – 1.54 0.003 
Experimental group  0.55      0.27    -0001 – 1.1 0.05          
 
Both the control group and the experimental group had a significant difference in the 
balance score change p=0.003 and p=0.05 respectively.  
 
Table 4.15 Level of changes in the gait, balance and pain scores of the performance 
oriented mobility scores within the experimental groups and the control groups 
Variable Control group (n=80) Experimental group (n=80) 
 z-score p-value z-score p-value 
Pain  1.97 0.05 3.20 0.001 
 
There was a significant change in the pain scores for both the experimental and the 
control groups p=0.001 and p=0.05 respectively. 
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Health-related quality of life 
 
Table 4.16 below, shows the quality of life utility score change within the control 
group and experimental group. 
 
Table 4.16 Quality of life utility score change within the control group and utility score 
change within the experimental group 
Study Group (n=80) Quality of life utility 
 score change 
Standard 
Error 
 (95% confidence 
interval) 
p 
value 
Control group  -11.7      7.5     -27 – 0.36 0.13 
Experimental group  11.3      3.07    -0.60 – 11.60 0.08           
 
The change in the quality of life utility scores of 11.3 for the experimental group 
trended to be significant p=0.08 while the control group‟s quality of life utility scores 
of -11.7 did not show significant change p=0.13. 
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4.3.6 The relationships between the gait, balance, pain and quality of 
life in the study 
 
Introduction  
The fourth objective sought to establish if there was a relationship between the levels 
of performance-oriented mobility and health related quality of life in participants with 
HIV/AIDS related DSP will be reported in this section.  
 
Relationship of gait, quality of life, level of neuropathy and muscle strength  
 
The relationship between gait and health related quality of life is presented below. 
Gait also has relationships with the level of neuropathy and muscle strength of the 
right tibialis muscle as presented in Table 4.17a and Table 4.17b below. 
 
Table 4.17a Univariate model showing the relationship between gait and quality of 
life, level of neuropathy and strength of the right tibialis muscle (n=160) 
Variable Odds ratio 95% confidence interval  z score p value 
Right tibialis anterior 
muscle strength 
1.30 1.10 – 1.58 2.95 0.003 
Quality of life 1.01 1.00 – 1.04 1.94 0.05 
Level of neuropathy 0.76 0.61 – 0.96 -2.31 0.02 
 
Table 4.17b Time and group adjusted model showing the relationship between gait 
and quality of life, level of neuropathy and muscle strength of the right tibialis muscle 
(n=160). 
Variable Odds ratio 95% confidence interval z score p value 
Right tibialis anterior 
muscle strength 
1.29 1.11 – 1.63 2.97 0.003 
Quality of life 1.01 1.00 – 1.04 0.99 0.05 
Level of neuropathy 0.76 0.61 – 0.95 -2.38 0.02 
 
The results of the models depicted in Table 4.17a and Table 4.17b demonstrate a 
strong positive relationship between the changes in gait and health related quality of 
life, odds ratio 1.01, p=0.05. There is also a strong positive relationship between gait 
and muscle strength of the right tibialis anterior muscle, odds ratio 1.29, p=0.003. 
The change in the level of neuropathy is moderately related to the change in gait 
scores, odds ratio 0.76, p=0.02.  
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Table 4.18c Multivariate model showing the relationship between gait and level of 
neuropathy and strength of the right tibialis muscle (n=160). 
Variable Odds ratio 95%  confidence interval z score p value 
Right tibialis anterior 
muscle strength 
1.31 1.07 – 1.61 2.66 0.008 
 
The time and group adjusted model results are similar to the results of multivariate 
model above. Gait is strongly positively related to the muscle strength of the right 
tiabialis muscle, odds ratio 1.31, p=0.008.  
 
Balance and quality of life relationship 
 
The correlation between balance and the level of pain, and muscle strength of the 
right and left hamstring muscle and quality of life are described in Table 4.19a and 
Table 4.19b. 
 
Table 4.19a Univariate model showing the correlation between balance and the level 
of pain, and muscle strength of the right and left hamstring muscle and quality of life 
(n=160). 
Variable Odds ratio 95% confidence interval z score p value  
Right hamstring muscle strength 1.19 1.00 – 1.42 1.95 0.05 
Left hamstring muscle strength 1.19 0.99 – 1.44 1.86 0.06 
Level of pain 0.62 0.46 – 0.83 -3.17 0.001 
Quality of life 0.68 0.52 – 0.93 2.76 0.06 
 
Results show that there was a trend towards significance in the association between 
balance and quality of life odds ratio 0.68, p=0.06. There was significant positive 
relationship between the level of balance and the level of pain, odds ratio 0.62, 
p=0.001, muscle strength of the right hamstring muscle odds ratio 1.19, p=0.05 and a 
trend towards significance in the muscle strength of the left hamstring muscle, odds 
ratio=1.19, p=0.06. 
 
Table 4.19b Adjusted model showing the relation between balance and level of pain 
(n=160)  
Variable Odds ratio 95% confidence interval z score p value 
Level of pain 0.64 0.47 – 0.87 -2.84 0.005 
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There was significant correlation between the change in balance and the level of 
pain, odds ratio 0.64 p=0.005 as depicted by the group and time adjusted model. The 
multivariate model showed a significant positive relationship between balance and 
the level of pain, odds ratio 0.64 p=0.01. 
 
Pain, quality of life and other relationships 
 
The relationship between pain and the quality of life and the level of neuropathy is 
shown in Table 4.20a and Table 4.20b. 
 
Table 4.20a Univariate model showing the correlation between pain and the quality of 
life, level of neuropathy (n=160). 
Variable Odds ratio 95% confidence interval z score p value 
Quality of life 0.98 0.98 – 0.99 4.35 <0.0001 
Level of neuropathy 1.21 1.08 – 1.36 3.36 0.001 
 
The relationship between pain and the quality of life was significant odds ratio=0.98, 
p= 0.005.  The results also show that pain was significantly related to the level of 
peripheral neuropathy, odds ratio=1.21, p=0.001. 
 
Table 4.20b Multivariate model showing the relationship between pain and the quality 
of life, and the level of neuropathy (n=160). 
Variable Odds ratio 95% confidence interval z score p value 
Quality of life 0.98 0.97 – 0.99 -4.03    <0.0001      
Level of neuropathy 1.17 1.04  - 1.31 2.71    0.007       
Time 0.45 0.22 – 0.92 -2.19 0.03 
Experimental group 0.50 0.26 – 0.96 -2.07 0.04 
 
The relationship between pain and the quality of life was significant, odds ratio 0.98, 
(p<0.0001), time, odds ratio 0.45, p=0.03, exercise group, odds ratio 0.50, p=0.04 
and the level of neuropathy was also significant, odds ratio 1.17, p= 0.007 for both 
the adjusted and the multivariate model.   
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Health related quality of life relationships with other variables. 
 
The relationship between the quality of life and pain, the level of neuropathy, level of 
education level of health, muscle strength of the left quadriceps muscles is shown in 
Table 4.21a Table 4.21b below. 
 
Table 4.21a Univariate model showing the relationship between the quality of life and 
pain, level of neuropathy, level of health and muscle strength of the left quadriceps 
muscles (n=160). 
Variable Odds ratio 95% confidence interval z score p value 
Muscle strength left 
quadriceps 
1.06 0.99 – 1.14 1.79 0.07 
Pain score 0.62 0.49 – 0.77 -4.18 <0.0001      
Level of health  0.45 0.29 – 0.69 -3.58 <0.0001      
Level of  neuropathy 0.91 0.82 – 1.01 -1.81 0.07 
 
There were significant relationships between quality of life and pain, odds ratio 0.62, 
p<0.0001 and the level of health, odds ratio 0.45, p<0.0001. There was a trend 
towards significance in relationships between quality of life and the level of 
neuropathy, odds ratio 0.91, p=0.07 and muscle strength of the left quadriceps 
muscles, odds ratio 1.06, p=0.07. 
 
Table 4.21b Multivariate model showing the relationship between the quality of life, 
level of health and pain (n=160). 
Variable Odds ratio 95% confidence interval z score p value 
Level of health 0.50 0.31 – 0.80 -3.86 <0.0001      
Pain 0.68 0.53 – 0.87 3.04 <0.0001      
 
The relation between quality of life and pain was significant, odds ratio 0.68 
p=<0.0001, as with the level of health, odds ratio 0.50 p=0.004 and muscle strength 
of the left quadriceps muscles, odds ratio 1.06, p=0.05 in the temporal and group 
adjusted. The relation between quality of life and pain was significant, odds ratio 0.68 
p<0.0001, and with the level of health, odds ratio 0.50 p<0.0001 in the multivariate 
model. 
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Relationship structural equation model  
The relationships between health-related quality of life and balance, pain, gait, time 
and level of neuropathy are presented in Figure 4.2. These relationships were 
generated from structural equation models using Stata v12 and are illustrated by 
lines of which indicate the p values association between the different related 
variables.  
 
Figure 4.2: The relationships between health-related quality of life and time,  
        gait, pain, balance and level of neuropathy 
 
The structural equation model also shows associations between health-related 
quality of life and pain, gait and peripheral neuropathy. Pain is associated with quality 
of life, balance and peripheral neuropathy. This model demonstrates the relationship 
between the right tibialis anterior muscle and gait as well as the association between 
balance and the right and left hamstring muscles. 
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4.3.7 Results of the interviews on participants reasons for withdrawal 
and non-compliance.  
 
Following a 33% (n=) dropout in study 1 and a 71% (n=) dropout in study 2 (average 
60%) and non-compliance participants had failed to attend follow-up assessment 
sessions or failing to attend their exercise sessions were invited to give their reasons. 
A total of 20 participants responded to an open ended question. 
The reasons given by the participants for withdrawal from the study or non-
compliance are listed below in table 4.22. 
 
Table 4.22 Reasons given by participants for withdrawal from study or non-
compliance (n=20). 
Concept Specific reasons 
Transportation - Had difficulties getting to the site 
- Could not afford taxi fare 
- Can only walk short distances of less than two kilometers 
- Average taxi fare five rand 
Expected incentives - Had been involved in another study before which provided food and 
goodies. 
- This study did not provide goodies/food = no reason for attending.  
- „„These researchers have lots of money they are making money using us.‟ 
- What do I benefit by being in this study? 
Livelihood 
pressures 
- They were trying to earn a living in a very tough economic time  
- I would rather be at my vegetable and fruit stall making money.‟ 
- They were busy with living chores, cooking, laundry and tending to the 
family, e.g. the widowed or separated women. 
Greater 
expectations of 
study 
- The equipment being used in this study was not new so there was nothing 
to “expect” from study. 
- Had seen what was being done at the exercise sessions and continued 
doing so at home.  
Mistrust - There have been few cases of unethical research and some participants 
felt they were being used “again”.  
Stigma - Afraid to be seen in the group as other people would know their status and 
stigmatise them in the community. 
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Participants withdrew commonly for transportation expected incentives livelihood 
pressures greater expectations of study mistrust stigma socio-economic reasons. 
Stigma was also a threat to participants because a few clinics still had “special days” 
for ART medication collection, while some clinics have integrated the ART 
medication as any other chronic condition, like diabetes mellitus. 
 
4.4 Conclusion   
 
Baseline assessments were carried out on a sample of 160 participants sourced from 
family care clinics in Harare and randomized for the clinical trial with 80 in the control 
group and 80 in the experimental group for intervention using PRE. After the twelve 
weeks, reassessments were done for 63 participants, 14 controls and 19 participants 
from the experimental group with 60% (n=97) of the participants lost to follow up.  
 
While the participants‟ demographic results highlight similarities in the control and 
experimental groups, female participants constituted 70.6% (n=113) of the sample. 
The results show that 70 % (n=112) had a CD4+ count of less than 300 cells per 
cubic mm and the combination antiretroviral therapy of stavudine, lamivudine and 
nevirapine was used by 59% (n=94) of the participants. The subjective peripheral 
neuropathy screen score show that 59% (n=94) of the participants had moderate to 
severe neuropathy. The participants in the experimental group and the control group 
showed similarities in most characteristics tested for including: age, education level, 
period of diagnosis and on ARVs, CD4+ count and the peripheral neuropathy scores 
with a p value range of 0.5 -1.0. 
  
The muscle strength profile showed that the hamstring generated the least mean 
force at 3.43 (1.5) kilograms of force in contrast to the right gastrocnemius muscles 
which exhibited the highest mean muscle strength at 12.8 (2.0) kilograms of force. 
The baseline mean muscle strength of the control group was similar to the baseline 
mean muscle strength of experimental group, p value range of p=0.41 to p=0.96. The 
gait score mean difference was 0.06, p=0.68 and the balance score mean difference 
of 0.05 p=0.17, showed similarity between the control group and the experimental 
group. The pain scores show similarity between the control group and experimental 
group at baseline, p=0.96. The EQ-5D visual analogue score mean difference of -3.3 
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p=0.16 and the health related quality of life utility score mean difference of 6.6 
p=0.17, showed similarity between the control and the experimental groups.  
 
The results of the study were analysed to establish the effect of progressive resisted 
exercises on muscle strength, gait, balance and pain as outlined in the objectives. 
There was a trend towards a significant difference between the control and 
experimental group, p=0.09 in the right tibialis anterior muscles. There was no 
difference in the mean muscle strength change between the control group and the 
experimental group in the other muscles tested p value range 0.13 – 0.80. There was 
no difference in the changes in the gait scores of the performance oriented mobility 
assessments between the experimental and control groups p=0.94. The change in 
the balance scores of the performance oriented mobility between the experimental 
and control group after the intervention were similar p=0.95.  There was no difference 
in the pain score change between the control group and the experimental group 
p=0.13. The health related quality of life changes in the experimental group and 
control groups after the intervention measured using the utility score showed no 
differences between the groups p=0.79. However the health related quality of life 
changes in the experimental group and control groups after the intervention 
measured using the visual analogue score showed a difference between the groups 
where p=0.04. 
 
Relationship results will be presented as odds ratios with the 95% confidence interval 
shown in brackets. The results demonstrate a significant relationship between the 
changes in gait and health related quality of life, odds ratio 1.01 (1.00 – 1.04). There 
is also an association between gait and muscle strength of the right tibialis anterior 
muscle, odds ratio 1.31 (1.07 – 1.61). The change in the level of neuropathy is also 
related to the change in gait scores, odds ratio 0.76 (0.61 – 0.95). There was 
significant relationship between the level of balance and the level of pain, odds ratio 
0.64 (0.46 – 0.83), muscle strength of the right hamstring muscle, odds ratio 1.19 
(0.99 – 1.44), muscle strength of the left hamstring muscle, odds ratio 1.19 (1.00 – 
1.42). There was relationship between balance and quality of life was significant, 
odds ratio 0.68, (95%CI 0.52 – 0.93). The relationship between pain and time, odds 
ratio 0.45 (0.22 -0.92) and exercise group was significant, odds ratio 0.50 (0.26 – 
0.96) using both the univariate model and the time and group adjusted model.  Pain 
was significantly related with the level of peripheral neuropathy, odds ratio 1.17 (1.04 
– 1.13). There were significant relationships between quality of life and pain, odds 
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ratio 0.98 (0.97 – 0.99), the level of neuropathy, odds ratio 0.91 (0.82 – 1.01) with 
some adjustments using the different models. 
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CHAPTER 5 
5. DISCUSSION 
5.1 Introduction 
 
Chapter 5 will discuss the results of the data collected and the outcomes of the 
intervention based on the research question, the objectives of the study and the 
hypothesis. Therefore the aim of this study was to determine the effects of 
progressive resisted exercises on performance oriented mobility and on health 
related quality of life in patients with HIV/AIDS related distal symmetrical poly-
neuropathy (DSP) and the specific objectives of the study included: 
 
1.  Determine the effects of progressive resisted exercises on gait in 
participants with HIV/AIDS related DSP. 
2. Determine the effects of progressive resisted exercises on balance in 
participants with HIV/AIDS related DSP  
3. Determine the effects of progressive resisted exercises on pain levels in 
participants.  
4. Establish if there is a relationship between the level of performance-
oriented mobility and health related quality of life in participants with 
HIV/AIDS related DSP.  
 
5.2 Discussion of results 
 
While the research hypothesis stated that progressive resisted exercises (PRE) have 
positive effects on performance oriented mobility and health related quality of life in 
participants with HIV/AIDS related distal symmetrical poly-neuropathy, the null 
hypothesis stated that PRE have no effect on performance oriented mobility (POMA) 
and health related quality of life in subjects with HIV/AIDS related distal symmetrical 
poly-neuropathy. POMA was used to assess gait and balance on a sample of 160 
participants and their characteristics are discussed here. With a seventy percent 
70.6% (n=113) female composition, this study was similar to Mutimura, et al., 
(2008)‟s and Jelsma, et al., (2005)‟s studies which had high female compositions of 
68% and 74.5% respectively. On the other hand these percentages differed from 
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earlier studies reviewed by O‟Brien, et al., (2008) in which women comprised less 
than 30% (n= 87)  of the participants. However in studies done by Dolan, et al., 
(2003) and Agin, et al., (2001), purposeful targeting of women participants only was 
practiced to fulfill the aims of these studies. The participants in this study were 
educated to a high school exit level (which is Ordinary Level in Zimbabwe) 
comparable to Basta, Reece and Wilson (2008)‟s study.  Composition of this study 
also shows an equal proportion of formally employed, not employed and self-
employed participants (33% each, n=53). Objectives one and two will be discussed 
first as they assessed the first two elements. 
 
Progressive resisted exercises effect on the elements in POMA and HRQOL 
 
Although POMA includes balance and gait, muscle strength and pain were also 
assessed as they are closely linked to the outcomes of POMA and the effects of 
progressive resisted exercises. Progressive resisted exercises on, gait and balance 
scored using the POMA did not show differences in effect between the intervention 
and the control group (CI 0.00-0.02 p = 0.8). Similarly there were no differences of 
effect for muscle strength (CI 0.00-0.08) p=0.13-0.8) and pain (CI 0.0-0.06 p>0.13). 
However the effect on quality of life changes were significantly different between the 
two groups (CI 0.00-0.12 p= 0.04). While PRE has been tested for its effects on 
muscle strength, gait, balance, pain and quality of life in studies outlined in a recent 
Cochrane review (O‟Brien et al., 2008), no single study testing these variables in 
combination was found. Similarly no study was found that tested for mobility using 
the POMA in people living with HIV/AIDS (PLWHA). The results cannot therefore be 
compared as a unit (POMA) with other studies. Nevertheless, the literature was 
examined and studies that tested the individual variables were reviewed and will be 
discussed under each single variable namely muscle strength, gait, balance, pain 
and quality of life.  
 
The literature was therefore examined for studies in HIV that used PRE as an 
intervention.  ACSM (2011), in a review of studies, found that PRE has positive 
effects on muscle strength, balance and quality of life in healthy adults ACSM (2011). 
This is consistent with the findings by O‟Brien, et al., (2008), where the studies 
reviewed reveal that PRE is similarly effective in improving muscle strength, balance 
and quality of life in people living with HIV/AIDS (PLWHA). However these studies 
had small samples sizes, and were of predominantly male constituted, and did not 
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include quality of life in their outcomes. A small number of the studies reviewed by 
O‟Brien, et al., (2008) analysed the data using an intention to treat analysis 
approach. One of these studies done by Bhasin, et al., (2000), in which male 
participants only were used had four groups. PRE only was compared with PRE 
augmented with testosterone, testosterone only and a control group. They found that 
PRE was effective in improving muscle strength and quality of life without the need 
for augmentation with testosterone. This concurs with the findings by Agin, et al., 
(2001)‟s study that tested PRE on a women only sample in PLWHA and compared 
PRE and PRE with whey protein supplements. The study by Agin, et al., (2001) 
found that PRE improved muscle strength and quality of life in a similar manner as 
when supplemented with protein. These studies both looked at the effects of PRE on 
other variables including immunological and virological indices. In a different 
approach, Fillipas et al., (2006) combined supervised PRE and aerobic exercises 
over six months and compared this intervention to an unsupervised walking program 
for PLWHA. They found that there was an improved quality of life and cardiovascular 
fitness but did not look at muscle strength as a variable. If muscle is loaded as 
opposed to aerobic training it will adapt to the load and type of training by 
hypertrophying through increased protein synthesis (Dungeon, et al., 2004).  In 
addition the muscle function (e.g. contraction speed and endurance), mediated by 
neural factors, will improve. PRE utilizes anaerobic ways of Adenosine Tri-phosphate 
formation where lactic acid is one of the end products (Dungeon, et al., 2004). On the 
other hand Dolan, et al., (2006) also used a women only sample to show that when 
combined with aerobic exercise PRE was effective in improving muscle strength and 
the body composition (Dolan, et al., (2006) . 
 
No literature could be found that looked at the effects of PRE on peripheral 
neuropathy in PLWHA. On the other hand, available literature relating to the effects 
of exercise on peripheral neuropathy focuses on people with diabetic DSP, which is 
similar to DSP in PLWHA, (Richardson, Sandman and Vela 2001). In their study, 
Richardson Sandman and Vela (2001) carried out a muscle strengthening program 
specifically targeting muscles on the lower limb over three weeks using a sample of 
twenty participants and found that exercise had a positive effect on muscle strength 
and balance. Furthermore, Hess and Walcott (2005) showed that PRE increases 
strength and improves balance in 27 elderly men and women after carrying out a 
high intensity PRE program over ten weeks. While these effects are not questionable 
even in healthy people (ASCM 2011), Richardson, Sandman and Velas (2001) study 
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was a controlled pre and post intervention study that used only 10 participants per 
group over three weeks. Therefore it can be considered to have a small sample size 
with a short follow up period and the study would need to be repeated with a 
randomized control trial and sample size calculated in order to be credible for effect 
of treatment. Another interesting difference with Richardson, Sandman and Velas 
(2001)‟s study is that they deviated from the recommended protocol for  PRE 
implementation ( ASCM 2011) by doing PRE daily as opposed to three time weekly.  
Hess and Walcott (2005) conducted a study in with a sample size of 27 over a longer 
period of ten weeks and found that PRE had an effect on balance in the elderly 
population. However their sample size still remains relatively low though larger than 
Richardson, Sandman and Vela (2001)‟s study.  
 
In spite of calculating a sample size of 34 participants per group and repeating the 
study to try and obtain the appropriate sample size this study still experienced very 
high dropout rates and non-compliance. Possible reasons for this outcome include 
the factors involved in the methodological approach to the study and contextual 
factors. The contextual factors were explored by following up patients who dropped 
out and were non-compliant and conducting focus groups discussion to explore the 
reasons for dropping out. Newly qualified therapists, who were engaged as research 
assistants to conduct the exercise intervention were trained by the researcher to 
ensure uniformity of implementation approach. However as a safety precaution to 
ensure patients were not over exerted, the research assistants were given the 
autonomy to adapt the exercise program according to the principles of exercise 
therapy prescription after evaluating the participant‟s condition and ability to complete 
each session they attended.  
 
This study, one of the first to use PRE in addressing the physical and HRQOL effects 
of  DSP in PLWHA, experienced a high loss to follow-up rate of 53% (n=85) on 
average. This is higher than similar studies in a Cochrane review by O‟Brien, et al., 
(2008). These studies showed high loss to follow up of between three to 35% (n=60). 
Some of the reasons attributed to a high dropout rate in this study and non-
compliance were related to socio-economic difficulties, problems with transportation, 
expectation of incentives and greater expectations of study, livelihood pressures, 
mistrust and stigma.  Some of the factors reported by the patient group related to 
pressures that affected the PLWHA lifestyle and health beliefs. This is consistent with 
findings by Petrozsci, et al., (2010) who found that the perception of well-being, 
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lifestyle and cultural beliefs are major contributors to compliance in studies. In 
comparison O‟Brien, et al., (2008), reported similar reasons such as, employment, 
illness, relocation, loss of interest, transportation difficulties, personal issues, lack of 
motivation, lack of time, economic reasons. Part of the reason for enhanced 
socioeconomic difficulties in this study is that it was implemented during the period 
2010 to 2011 when the country from which the participants of this study are habitant 
was going through a recovery period after the economic meltdown of 2006 -2009, 
unprecedented in history (Ministry of Health and Child Welfare (MoH&CW) 2009). 
Most of the population was unemployed with rates quoted at 80% (MoH&CW 2009) 
and most people reporting inability to eat more than one meal a day. 
 
Methodological issues that may have contributed to the reduced effect on the 
experimental group is that in this study, the researcher decided to conduct two 
exercise sessions in view of the economic capacity and the participant‟s potential to 
exercise. While the studies reviewed by O‟Brien, et al., (2008) used a regimen of 
three sessions per week, using the twice per week regimen is acceptable as 
stipulated by the ACSM (2011) position paper. Fillipas, et al., (2006), in a study with 
PLWHA used the twice weekly regimen over a period of six months and found that 
the regimen was equally effective for the purpose of muscle strengthening.  
 
While the results comparing the control and intervention groups did not show any 
differences, further analysis to establish within group changes and association 
between the muscle strength, pain, gait and HRQOL showed significant effects of 
PRE and significant association between the variables as shown in the structural 
equation model in figure 4.2. found similar results in, in group analysis when they 
tested for the effect of PRE on gait, balance and pain in participants with DSP (Ites, 
et al., 2011). As such the results of the individual variables pre-intervention, within 
group and their associations will be discussed.   
 
Muscle strength 
 
When the study participants‟ mean muscle strength was tested for differences 
between the control group and the experimental group there was a trend towards  
significance, p=0.09 in the right tibialis anterior and right hamstring muscle muscles 
as summarized in Table 4.8. However the differences in the experimental and control 
group in the other muscles tested was not significant p > 0.13.  Meanwhile the 
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baseline muscle strengths values in this study were lower than the normative values 
(Bohannon 1997) and in other studies reviewed by (O‟Brien, et al., 2008). Moreover 
the results from five out of the seven of the studies reviewed by O‟Brien, et al., (2008) 
which had used isotonic muscle strength testing, yielded high muscle strength 
values. O‟Brien, et al., (2008) attributes low values in muscle strength to the use of 
isometric testing, which was also done in this study.   Even though this study used 
isometric muscle strength testing, moderate muscle strength levels were still 
observed in the participants when compared to the reference normative values for 
extremity muscle strength dynamometry in a healthy population in a developed 
country (Bohannon, 1997). Similarly, Dolan, et al., (2006) whose study focussed on 
female participants only showed higher muscle strength levels for the quadriceps and 
the hamstring muscles than in this study. 
 
Interestingly, at baseline, the left hamstring muscles generated the least mean force 
at 3.43 (SD 1.5) kilograms of force in contrast to the right gastrocnemius muscles 
which exhibited the highest mean muscle strength at 12.8 (SD 2.0) kilograms of 
force. Participants therefore exhibited weaker proximal muscles as shown by the 
hamstring values of 3.43 kilograms of force. The leg muscles had better strength with 
the calf muscles being the strongest.   Proximal muscle weakness which was also 
reported in Myezwa, et al., (2009)‟s study done in PLWHA in a mining and inpatient 
community is different from the findings in Bohannon‟s (1997)‟s for normative values, 
Hess and Woollacott (2005)‟s  elderly participants and from O‟Brien, et al., (2008)‟s 
review where the proximal muscle showed greater strength. Furthermore, 
participants who had problems with proximal weakness especially in the hamstring 
muscle in this study had low balance scores as shown by the association between 
left and right hamstring muscle strength scores and  balance.  
 
Hess and Woollacott (2005) in a study on an elderly participants sample argued that 
the effectiveness of PRE on muscle strengthening may need to be augmented by 
nutritional supplementation. However findings in studies with PLWHA appear to 
contradict this generalisation, as shown by Agin, et al., (2001) where the use of whey 
protein in female participants to augment exercise brought no added benefits to the 
participants Agin, et al., (2001). While the possible reason for the similarity between 
the groups may be that participants in the experimental group exhibited poor 
adherence to exercise, the effects of PRE on muscle strength are clear in the within 
group results. Although muscle strength results had not shown an effect difference 
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between the control and experimental group, within group analysis comparing the pre 
and post intervention muscle strength showed a significant difference (p<0.01.) and 
(p<0.0001) in the control and experimental groups respectively. However one cannot 
also ignore that all these participants were walking long distances as a mode of 
transport and consistent walking is recorded in the literature as an effective 
intervention for general muscle increase and fitness (ACSM, 2011). These results 
support the hypothesis that PRE, as an exercise program has an effect on muscle 
strength, as reported in other studies reviewed by O‟Brien, et al., (2008). Further 
analysis also showed a significant association between the muscle strength increase 
of both the left and right hamstring muscle with balance (p=0.05) in both 
experimental and control groups. 
 
Balance 
 
As already stated in the introduction, change in the balance scores of the 
performance oriented mobility showed that there was no difference between the 
experimental and control group after the intervention p=0.95. There was however, 
significant change in balance within the control group (p=0.002) and the experimental 
group (p=0.04) which suggests that the usual method and the progressive resisted 
exercises had a similar effect on balance. All the participants in the study were 
mobile, where none of them used a walking aid. 
 
The usual method was further augmented as noted before by the long distances that 
patients were walking (an average of one and half kilometres per day per patient). 
Most patients could not afford transport costs and thus had to walk. Walking has 
been reported in the literature as a potentially effective intervention to improve 
strength, endurance and cardiovascular fitness (ACSM, 2011). 
 
As discussed previously PRE are closely related with increased and balanced 
muscle strength contributing to maintenance of posture (Zagyapan et al 2011). 
Related to balance and muscle strength is mobility.  In this study, mobility, assessed 
using POMA was good to excellent (mean score = 25.7(SD=2.3)) as shown in Table 
4.6 for all the participants. Literature searches for studies in HIV and peripheral 
neuropathy which had used the POMA to assess gait and balance in participants with 
peripheral neuropathy did not yield comparable results. Hess and Walcott (2005) 
found that an increased muscle strength score improved the balance in the elderly 
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sample. However Hess and Walcott (2005) used the Berg Balance Scale as their 
outcome measure for balance instead of the POMA which limits comparability with 
this study. 
 
Studies found in literature used the POMA as a predictor of the risk of falling in the 
elderly (Tinnetti 1986, 1988; Lin, et al., 2004; Baloh, et al., 2006; Faber et al 2007; 
Panzer, et al., 2011). However, other studies were done to determine the reliability 
and validity of the POMA against the tools considered gold standards when the 
POMA was used for different neurological conditions. Kegelmeyer, et al., (2007) used 
the POMA to assess the risk of falls as well as the reliability and the validity of the 
POMA in participants with Parkinson‟s disease. Similarly, Kloos, et al., (2010) carried 
out a study to also assess the responsiveness of the POMA in participants with 
Huntington‟s chorea.  These studies while assessing gait and balance, differed with 
this study as the cause of both Parkinson‟s disease and Huntington‟s chorea are 
impairments to central nervous system level whereas this study looked at 
impairments to the peripheral nervous system. However these studies experience of 
using the POMA shows that it is a valid and reliable measure of the factors 
influencing the quality of gait and balance which can be impaired in peripheral 
neuropathy and therefore it would be the appropriate tool to use. 
 
Considering that the function of the hamstring muscle is mainly to prevent forward 
sway, an important facet of balance (Hess and Woollacott 2005), it would have been 
expected that the low strength values found in the hamstring would have also 
translated into low balance scores. However the results only showed a mild change 
in the balance scores obtained using the POMA of 14 out of a possible 16 on 
average to 15.5 out of 16.  In contrast, when Kanekar, Santos, and Aruin (2008) 
investigated how the human body responds to fatigued muscles, their results show 
that the body may compensate cognitively by form of anticipatory postural adjustment 
to this effect. Although their sample was small (n=9), they tested the deltoid anterior 
and hamstring muscle to determine how adjustment occurs, and concluded that there 
existed effective mechanisms which can easily be employed (Kanekar, Santos, and 
Aruin 2008).   Hence while balance dysfunction is a result of factors which include 
decreased sensation, proprioception, reflexes and strength in the lower limbs (Ites, et 
al., 2011) cognitive processes also have a role to play. In fact during this study, the 
participants appeared to be unaware that they had problems with balance until they 
were tested. Balance was also found to be associated with level of pain, odds ratio 
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0.64 (0.46 – 0.83).  Taking the previously mentioned fact that the quality of balance is 
affected by elements which include decreased sensation or proprioception may 
explain the relationship between balance and pain. Considering that the pain was 
concentrated in the foot, it follows that pain sensation would interfere with 
proprioceptive feedback and possibly gait. 
 
Gait 
 
No difference in the changes in the gait scores of the POMA between the 
experimental and control groups p=0.94 was found. Considering that the scores of 
gait were already excellent at baseline for this sample, the results of gait scores may 
have had a ceiling effect, as a result of the small margin for improvement possible for 
already high scores. As with the between group results, the within group results post 
intervention also showed no statistically significant difference with the pre-
intervention score (p=0.26). 
 
When compared with the results of the gait scores reported in Faber, et al., (2007) 
and Baloh et al.,‟s (2006) with elderly participants, this study‟s baseline results had a 
higher level of scores. In Kegelmeyer, et al., (2007)‟s study, the participants with 
Parkinsons‟ disease had lower gait scores when compared to this study. These 
findings are consistent with the activity limitations associated with the impairments 
arising from the central nervous system lesion in comparison with a peripheral nerve 
lesion (Kegelmeyer, et al., 2007). 
 
Lack of statistically significant differences in the changes in gait between the control 
and the experimental group may also be attributed to other factors. These factors, 
which contribute to the quality of gait include, proprioception, balance, co-ordination 
and muscle strength (Bensoussan, et al., 2008). It is therefore not surprising that the 
results showed a relationship between gait and muscle strength of the right tibialis 
anterior muscle, odds ratio 1.31 (1.07 – 1.61). During the swing phase of gait, the 
tibialis anterior muscle is responsible for ensuring that the foot clears the ground 
(Bensoussan, et al., 2008). The change in the level of neuropathy, which also 
assesses proprioception is also significantly associated with the change in gait 
scores, odds ratio 0.76 (0.61 – 0.95). These associations are not surprising because 
the function of the tibialis anterior muscle is more energy efficient than its 
contemporary muscles which use compensatory gait like high stepping gait. Using a 
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high stepping gait would increase energy expenditure as the use of hip flexors which 
lift the whole lower limb for clearance, would then be required. 
 
Another reason for the difference in gait scores between these studies is found in the 
difference in demographic and socio-economic status of this sample to the samples 
in Kegelmeyer, et al., (2007)‟s, Faber, et al., (2007)‟s and Baloh et al., (2006) studies. 
Participants in this study only used public transport when they had to travel distances 
longer than two kilometers. For example to get to their local clinic 20% (n=4) would 
use public transport. The other 80% (n=16) walked to the clinic and to all local 
amenities and social visits. The ACSM (2011) position paper recommends that 
people who walk at least one and a half kilometers a day, which is equivalent to 
about 2 000 steps a day, lead a reasonably active lifestyle. Gait results indicate that 
the assessments were therefore carried out on participants who have an active 
lifestyle. Furthermore earlier results indicate that the participants had stronger distal 
leg muscles which include the tibialis anterior, a result that is confirmed by the 
excellent gait scores posted by the participants.  
Gait results also seem to indicate that walking as a home exercise programme even 
without supervision has a reasonable effect on gait measures, balance, pain and 
quality of life. This implies that where there are no practitioners to implement an 
exercise programme, advice given by the health worker to PLWHA who have DSP 
exercise at home, may be an effective community based intervention to improve 
mobility and pain. Furthermore all health workers must be trained to advise PLWHA 
on simple methods of exercising at home, or at least to encourage PLWHA to 
continue an active lifestyle even when in pain from DSP. Pain was often cited as a 
reason for reduced activity at times by the participants in this study. 
Pain 
 
 There were no differences in pain score changes between the control group and the 
experimental group as reported previously however the within group change in pain 
for the experimental and in the control groups was significant (p= 0.001 and 0.05) 
respectively. It is possible that the lack of differences between the experimental and 
the control groups is a result of the different coping mechanisms employed by 
participants including self-care strategies in dealing with pain symptoms (Nicholas, et 
al., 2007a). However taking note of the significant within group changes, we may 
argue that PRE has an effect on pain but the difficulties discussed earlier may have 
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impacted on the between group differences.  In addition to this Basta, Reece and 
Wilson (2008)‟s study, where they used the trans-theoretical model to predict how 
PLWHA go through the stages of change when complying with an exercise program 
allude to motivation as a crucial factor in behavior modification. Correspondingly, 
Keefe, et al., (2004), found that an adjustment response to chronic pain was 
dependent on factors like: self-efficacy, acceptance, coping mechanisms, and the 
readiness to change. Therefore, a greater change would have been expected in the 
experimental group which offered group support and interaction, both known as 
effective management approaches for adjustment to chronic situations like pain 
(Keefe, et al., 2004). However this was not the case and therefore it is possible that 
the participants‟ pain got better as they might have used self-care strategies in a 
manner similar to PLWHA in the study by Nicholas, et al., (2007a).    
 
The majority of participants in this study with the help of the medical practitioners 
also tried several approaches including amitriptyline prescriptions (Wolfe and Trivedi 
2004; Bril, et al., 2010) as this was not controlled for, but the pain especially the 
allodynia type, continued to disturb their sleep. Lack of sleep in turn, affected their 
ability to work on the following day as they would be tired and irritable from. The 
results are a subjective measure and therefore bias by for example using a 
catastrophizing coping approach may not be dismissed (Lucey, et al., 2011). 
Nicholas, et al., (2007b), reported similar findings in an extensive study covering 
three continents indicate a tendency by people experiencing neuropathic pain to use 
various available methods to combat their pain. Considering that people adjust 
themselves to pain in different ways Keeffe, et al., 2004), it is not surprising that there 
were novel approaches by different participants in this study and the study had no 
control with regard to pain management practiced by the participants. 
 
While it is debatable to ascertain the effects of PRE on pain from the results of this 
study, these results may be useful for making inferences on the factors which might 
contribute to the reduction in the symptoms of pain. We may hypothesise that time 
lapse; being in a group; PRE and the reduction in peripheral neuropathy levels are 
associated with change in pain levels. These associations may also be because the 
instruments that assess pain, the Wong -Baker faces; level of neuropathy and the 
brief peripheral neuropathy screen; have domains which actually assess the levels of 
pain. Therefore these results are not surprising as the same evaluation has been 
repeated, as part of the whole in each assessment. However these arguments do not 
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explain the association between time that had lapsed between pre and post-
intervention, and the association of being in the experimental group. Association 
between pain and belonging to the experimental group agrees with literature which 
states that being active group support approaches were used effectively in managing 
neuropathic pain (Keefe, et al., 2004). 
 
As pain is  a subjective measure there is risk of bias related to the social context in 
which the assessments were carried out in bearing in mind that, differing factors 
contribute to the individual perception of pain (Keeffe, et al., 2004). Hence a 
participant may catastrophize their pain with the hope that the clinician might help 
them. The level of self-efficacy may also be inferred from the participant rating of 
their own pain (Campbell, Clauw and Keefe, 2003). For example during the 
assessments, a participant who had avoided walking barefoot was asked to remove 
their shoes for observation. They were surprised that they were able to walk on the 
floor without shoes and believed they had been given a miracle cure! The participant 
explained that before this assessment she was in so much pain she had always used 
shoes with thick socks each time when walking to avoid the pain. Similar responses 
were expressed by participants in Ownby and Dune (2007)‟s study. In this study 
Ownby and Dune (2007) sought to analyse the concepts involved in neuropathic pain 
in interviews with 19 PLWHA and form themes for a neuropathic pain management 
strategies classification. Their findings concur with Nicholas, et al., (2007) in 
classifying some of the strategies as for example; activities, exercise and prescribed 
medications. 
 
The results as shown by the generalized equating models show that peripheral 
neuropathy levels are closely related to pain odds ratio 1.17 (1.04 – 1.13). The 
results of the brief peripheral neuropathy screen in this study, show that 59% (n=94) 
of the participants had moderate to severe peripheral neuropathy (score range 8-15) 
as shown in Table 4.3. Schifitto, et al., (2002) and Cherry, et al., (2005) described 
similar scores in their study where they sought to establish the risk factors of 
peripheral neuropathy and evaluate the instrument respectively. In this study the 
subjective peripheral neuropathy screen was used only as a diagnostic confirmation 
tool as it had been established as a sensitive tool in identifying peripheral neuropathy 
(Cherry, et al., 2005). Whereas the association between the severity of peripheral 
neuropathy and pain may be assumed, it is not clear why this is so since peripheral 
neuropathy also shows numbness symptoms, which is the opposite of pain. Further 
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research studies may all the involved partners to understand the fine line between 
painless and painful neuropathy.   
 
Experiences from using the tools will be discussed briefly as the issues noted are 
important for future research. Nonetheless the pictorial presentation of the Wong 
baker faces reduced confusion associated with interpretation of visual analogue 
scales using numbers (Jackson, Kersten and Turner- Stokes 2006). An interesting 
fact noted during assessments using the VAS on the BPNS, was that participants 
would invert the interpretation of the scale. Whereas a ten (10) on the scale means 
the worst pain, participants would say ten (10) means that “my pain is very good 
/excellent”, therefore if I am not in pain my score is a ten (10). The assessor had to 
repeat the explanation and ask the participant what they understood by the score. 
Furthermore a score of one (1) or zero (0) would be taken to mean that “my pain is 
very bad/ (poor) therefore its score must be one (1).  Furthermore, using the terms 
employed in the the brief peripheral neuropathy screen they also describe their pain 
as being constantly worst at night and fluctuating during the day when they are busy 
and active. This experience shows that the assessor needs to be aware of the 
different interpretations of Likert scales and the influence of context and past 
experience when assessing pain. 
 
While pain management was not the focus of this study, participants showed that 
pain and numbness were of major concern to them and discussed these problems 
during their exercise sessions. Numbness has important implications for the 
participants, as it is a critical safety issue both at home and at work especially in the 
circumstances where the PLWHA is a driver as it showed that they can injure 
themselves easily if due protective care is not taken. There is need to protect the feet 
and to give advice to people with peripheral neuropathy who are involved in driving. 
Public vehicle drivers should be tested for numbness during medical examinations for 
their driver‟s licenses, to mediate in reducing human error caused accidents on the 
national roads. Previous studies have indicated that splinting and protective padding 
may be used for protecting the feet (Ites, et al., 2011). However this may be difficult 
in cases where the individual complains of allodynia, which is also known to affect 
sleep. Ownby and Dune (2007), applying a grounded theory approach concur with 
these findings adding that there is need for the health care workers to research more 
on the problems associated with DSP so as to develop effective strategies for 
reducing associated activity limitation and participation restrictions. Whereas the 
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association between pain and quality of life may be deemed natural associations 
between health-related quality of life, pain and the elements of POMA will now be 
discussed.  
 
Health related quality of life  
 
As discussed previously, health related quality of life changes in the experimental 
and control groups after the intervention, when measured using the utility score 
showed no differences between the groups (p=0.79). Considering the multi-faceted 
context of quality of life (Rusch, et al., 2004), the difference in the quality of life 
values found between the experimental and control group in this study will be 
discussed in the context of its relationships with the other variables. When the 
relationships between the levels of performance-oriented mobility and health related 
quality of life in participants were analysed using generalized estimating equations a 
positive significant association was found between the changes in health related 
quality of life and gait, odds ratio 1.01 (95%CI 1.00 – 1.04), with balance odds ratio 
0.68, (95%CI 0.52 – 0.93), pain odds ratio 0.98 (0.97 – 0.99), and peripheral 
neuropathy odds ratio 0.91 (0.82 – 1.01) and gait (p=0.001), balance (p=0.03) pain 
(p=0.02), and the muscle strength of the left quadriceps muscles (p=0.02). The 
results demonstrate strong associations with variables which form the 
dimensions/domains, an integral part of quality of life (Miners, et al., 2001).   
Therefore, since utility score showed no difference between the groups this validates 
the internal consistency of the quality of life, since gait, balance and pain, form 
integral components of quality of life, (Jelsma, et al., 2005). 
 
However the health related quality of life changes in the experimental group and 
control groups after the intervention measured using the state of health visual 
analogue score showed a difference between the groups where p=0.04. Considering 
that this measure focuses on individual participants‟ understanding of their own 
quality of life, this may be a complex issue to discuss. Robberstad and Olsen (2010), 
concur with this viewpoint in their review on quality of life, and recommend that 
quality of life research must focus on economic evaluations. The possible reasons for 
differences may be similar in nature to the reasons alluded to in the discussion on the 
aspect of pain such as the socio-environmental issues affecting these participants. 
The baseline visual analogue scale score or state of health measure of 68.6 (95% CI 
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63.5, 73.8) reflect a moderate self-perception value which is consistent with the 
values in Jelsma, et al., (2005). 
The health related quality of life profile shows that 42% (n=67) of the participants had 
some problems with mobility as well as completing usual activities. Washing or 
dressing presented as a problem in 9% (n=14) of the participants. Participants 
perceived themselves to be in a better state of health as shown by the state of health 
median score of one (1). Rusch, et al., (2004) and Miners, et al., (2001) found similar 
outcomes while using the ICF in a study in Canada, and the EQ5D in United 
Kingdom respectively for a sample of PLWHA. Myezwa, et al., (2009)‟s study using 
the ICF and Jelsma, et al., (2005) using the EQ5D, both assessed for problems 
experienced by PLWHA in South Africa  and found similar pattern of proportions of 
PLWHA who had these problems. Hence 56% (n=35) of participants in Myezwa, et 
al., (2009)‟s study had mobility problems while 9% (n=8) of the participants had self-
care problems in Jelsma, et al., (2005)‟s study. Since quality of life is a personal 
matter, the clinical characteristics of the participants will now be discussed. 
  
Clinical characteristics of the participants 
  
The participants in this study showed similarities in the characteristics tested for 
including: age, gender, education level, period of diagnosis and period on ARVs, 
CD4+ count and the peripheral neuropathy scores for the experimental and control 
groups. HIV related information of the participants summarized in Table 4.2 shows 
that of the sample under study 45% (n=72) of the participants had known their HIV 
status for more than two years. The results show that 70% (n=112) of the participants 
had a CD4+ count of less than 300 cells per cubic mm. However 45% (n=72 of the 
CD4+ count results were stale, as they were more than a year old. An explanation is 
found in the National Drug and Therapeutics Policy Advisory Committee, NDTPAC 
(2010) protocol which provides for a repeat CD4+ count after one year. Combination 
antiretroviral therapy of stavudine, lamivudine and nevirapine, which comprises of the 
dideoxynucleosides , known for their neuro-toxic effects (Keswani, et al., 2002),  was 
used by 59% (n=94) of the participants. This first line protocol is currently being 
phased out in Zimbabwe and a new protocol requires a change in the antiretroviral 
therapy used depending on the reporting of adverse clinical response (NDTPAC 
2010). Menez, et al., (2011) in a South African study with 9040 participants on 
HAART showed that stavudine is associated with co-morbidities which seem to 
outweigh the drugs benefits, concurring with the WHO position. This is consistent 
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with the findings in Van Griensven, et al., (2010), where in a cohort in which 2190 
participants who had used stavudine were re-assessed for a variety of toxic effects 
after its substitution.  
The study also brought out a need for the policy makers to consider offering 
rehabilitation services in the same package as other services for a token fee to 
PLWHA. As a result of the preliminary results, the study team convinced the 
Department of Rehabilitation at the College of Health Sciences, University of 
Zimbabwe to approach the Municipal of Harare seeking to collaborate in setting up 
Rehabilitation departments at all municipal clinics. This was done and currently the 
two partners are working on a memorandum of agreement (at the time of writing), 
which entails a pilot will be trialed before a full implementation is accomplished.  
5.3 Limitations of the findings of the study 
 
The study findings may not be generalized to all individuals living with HIV/AIDS who 
have DSP as the participants were from a particular demographic setting. There was 
a high level of participant withdrawal, which reduces the actual sample size and 
compromises the quality of the study even when intention to treat analysis is the 
method used. Thus the high withdrawal rate discussed earlier certainly cannot be 
ignored as a limitation in that the actual effect of intervention becomes compromised 
by the reduced sample size. However the intention to treat analysis is realistic and 
approximates the results more for use in clinical practice where the behavior of the 
participants is unpredictable as it is practical. There was high staff turnover and 
newly qualified physiotherapist, who were therefore inexperienced with regards to 
HIV care, were recruited as the research assistants. While clinical reports indicate 
significant changes within groups, the low adherence to exercise does not rule out 
the effects of other variables like group support becoming a confounding variable.. 
Walking, which was used by the control group had a significant effect as shown by 
within group results, when compared with the effects of the exercise intervention 
done in the experimental group. However the study could not suspend the usual 
method as this was unethical. The timing of the staging of the study might have been 
made more appropriate to eliminate interference by participants‟ personal adjustment 
issues. The study setting made the study difficult to implement as the participants 
were experiencing a challenging socio-economic situation.  
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CHAPTER 6  
6. CONCLUSION 
 
This study asked what the effect of progressive resisted exercises was on the 
performance oriented mobility and health related quality of life of people living with 
HIV and AIDS related distal symmetrical poly-neuropathy (DSP), a common 
neurological condition associated with HIV complications (Nicholas, et al., 2007b). 
People with DSP commonly have problems with mobility, altered gait and balance 
affecting their quality of life (Ites, et al., 2011) and progressive resisted exercises 
have been reported to attenuate these impairments (O‟Brien, et al., 2008).  
 
This study was an assessor-blind randomized controlled trial design. It consisted of 
two studies because the initial study had a high dropout rate. For the analysis the 
results from the two studies that used the same method were pooled and the sample 
size was n=160. In Study 2 participants were sourced from ten family care clinics and 
antiretroviral therapy dispensing clinics in Harare. The experimental group (n=80) 
had an intervention program of PRE while the control group (n=80) had usual 
treatment. The results on gait and balance scores using the POMA did not show 
differences in effect between the intervention and the control group (95%CI 0.00-0.02 
p = 0.8). Similarly there were no differences of effect for muscle strength (95%CI 
0.00-0.08) p=0.13-0.8) and pain (95%CI 0.0-0.06 p>0.13). However the effect on 
quality of life changes were significantly different between the two groups (95%CI 
0.00-0.12 p= 0.04). Quality of life was strongly and positively associated with gait, 
odds ratio 1.01 (95%CI 1.00 – 1.04), strongly negatively associated with pain odds 
ratio 0.98 (0.97 – 0.99), and peripheral neuropathy odds ratio 0.91 (0.82 – 1.01). 
There was significant relationship between the level of pain and level of balance and 
the, odds ratio 0.64 (0.46 – 0.83), and level of peripheral neuropathy, odds ratio 1.17 
(1.04 – 1.13). Results of this study demonstrate consistence with the findings by 
previous studies which show that PRE improves muscle strength, gait and balance in 
peripheral neuropathy.  
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6.1 Recommendations for further research 
 
The results of this study suggest the need to do a follow-up study on the participants 
who have had their drug regimen changed from stavudine to other new drugs as this 
would assist the community to determine the rate/and recovery of people who have 
been exposed to toxic antiretroviral drugs like stavudine. There is need to also 
analyse the results of the brief peripheral neuropathy so as to establish the 
implications of painless neuropathy or numbness. Walking may also be used as an 
management approach on its own or in combination with a simple exercise 
programme as the results of this study established.  
 
Future studies may need to profile the participants‟ motivation levels with regards to 
predicting their compliance behavior. This may be made feasible if the programme 
utilises the recommendations based on Basta, Reece and Wilson (2008)‟s study, 
where they used the trans-theoretical model to predict the stages of change on the 
path to compliance. Using such a model implies the factoring in of motivation as a 
crucial factor in behavior modifications to start and continue exercise. This approach 
would greatly enhance the use of intention to treat analysis for practical 
environments. The participants would then be invited to explain their self-care 
strategies to get an understanding of their coping mechanisms. Further studies could 
apply these findings on DSP to other co-morbidities like diabetes mellitus and 
alcoholic DSP where quality of life evaluations should focus on economic 
evaluations.  
 
Carrying out this study under the 2009-2011 socioeconomic situations in the country 
(MoHCW, 2009) of the study was a challenging exercise on its own. Hence, although 
the ethical procedure systems were in place, it took longer, up to two months, to get 
clearance at each level as there were few reviewers available for this purpose 
following the brain-drain which had occurred in the preceding 2003- 2008 period. The 
financial system was recovering and accessing funds for implementing the trial was 
very difficult where most donor agencies had now limited their operations to what 
they considered as essentials only. Thus the research team was left with funds from 
the school and from the scholarship for reimbursing the research team and the 
participants for their time and for transport purposes.  As it was a difficult time there 
was a high loss to follow up in Study 1 as participants could not afford transport 
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fares, as well as movements and relocations as the participants sought livelihood. 
The study also suffered a lot from expectations to provide food and money by the 
participants to reimburse for time lost away from their business and as the 
participants left the study. Having outlined the problems encountered as a 
consequence of the socioeconomic circumstance; the discussion will now attempt to 
recommend possible approaches to such scenarios. Firstly the responsibility of 
completing the study rests squarely with the research team and as such, the team 
must be aware of the reality and set a realistic plan of action with enough time to 
offset for unforeseen events. We recommend that when faced with such a situation it 
may be advisable to set the study nearer to the participant i.e. in the community. If 
possible a plan to reimburse the participants must be made within the ethical 
boundaries. 
 
6.2 Conclusion  
 
This research study established that progressive resisted exercises have positive 
effects on the health related quality of life in subjects with HIV/AIDS related distal 
symmetrical poly-neuropathy. However this study did not show a difference of the 
effects of progressive resisted exercises on performance oriented mobility, measured 
through the effect on gait, balance and gait and muscle strength in subjects with 
HIV/AIDS related distal symmetrical poly-neuropathy when compared to advice to 
exercise at home.  
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APPENDICES 
Appendix A: Brief Peripheral Neuropathy Screen 
 
Appendix A1 
 
Subjective Peripheral Neuropathy Screen Questionnaire (by the participant) 
 
 
Code:_______________________________________ Date __________ 
 
 
Please take a few minutes to answer the following questions about the feeling in your 
legs and feet. Check yes or no based on how you usually feel. Thank you. 
 
1. Do you ever have legs and/or feet that feel numb?    
 
2. Do you ever have any burning pain in your legs and/or feet?   
 
3. Are your feet too sensitive to touch?      
 
4. Do you get muscle cramps in your legs and/or feet?    
 
5. Do you ever have any prickling or tingling feelings 
 in your legs or feet?        
 
6. Does it hurt at night or when the covers touch your skin?   
 
7. When you get into the tub or shower, are you unable able to  
    tell the hot water from the cold water?      
 
8. Do you ever have any sharp, stabbing, shooting pain 
 in your feet or legs?       
 
9. Have you experienced an asleep feeling or loss of  
 sensation in your legs or feet?      
 
10. Do you feel weak when you walk?     
 
11. Are your symptoms worse at night?      
 
12. Do your legs and/or feet hurt when you walk?     
 
13. Are you unable to sense your feet when you walk?    
 
14. Is the skin on your feet so dry that it cracks open?    
 
15. Have you ever had electric shock-like pain in your feet or legs?  
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Appendix A2 
Physicians Checklist / Questionnaire for Screening of Peripheral Neuropathies 
related to HIV and ART (To be assisted by nurse working at the ART clinic) 
 
Demographic characteristics and General health Status of the Patient 
 
1. Gender:           Female               Male  
 
2. Age ----------------------------------------years 
 
3. Highest level of education 
a) Tertiary education (University, Institution of higher learning --- 
b) Secondary school education (S4 – 6) ------------------------------- 
c) Secondary school education (S1 – 3) ------------------------------- 
d) Primary education -------------------------------------------------------- 
e) Any other (please specify) --------------------------------------------- 
 
4. Occupation 
a) Public (government) service ----------------------------------- 
b) Peasant (farmer, or livestock) --------------------------------- 
c) Self – employed (business) ------------------------------------ 
d) Private organisation (NGO, bank, insurance etc) --------- 
e) Unemployed (do not have a job for the last 3 months)--- 
f) Any other (please specify) -------------------------------------- 
 
5. Marital status 
a) Single ------------------------------------------------------------------------------ 
b) Married ---------------------------------------------------------------------------- 
c) Divorced -------------------------------------------------------------------------- 
d) Separated -------------------------------------------------------------------- 
e) Widow / widower ----------------------------------------------------------- 
f) Cohabitating (live together with a temporally male/female partner- 
g) Any other (please specify) --------------------------------------------------- 
6. Place of residence -----------------------------------------(write it in here) 
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7. When the patient’s HIV was diagnosed: 
a) 1 – 6 months ago---------------------------------------------------            
b) 6 – 12 months ago------------------------------------------------- 
c) 1 – 3 years ago----------------------------------------------------- 
d) 4 – 6 years ago------------------------------------------------------ 
e) 7 – 9 years ago------------------------------------------------------ 
f) 10 – 15 years ago-------------------------------------------------- 
g) More than 15 years ago------------------------------------------- 
 
8. Clinical HIV staging: 
1. Clinical stage I -------------------------------------------    
2. Clinical stage II ------------------------------------------    
3. Clinical stage III ------------------------------------------     
4. Clinical stage IV ----------------------------------------   
9. Is the patient on Anti-retroviral treatment?  
        1. Yes    2.                               No   
10.    If yes, please specify the type (s) of ARVs ---------------------------------------------
-----------------------------------------------------------------------------------------------------------------
-------------------------------------------------------------------------------------------------- 
 
11.     For how long the patient has been on ARVs treatment? 
a) 1 – 6 months---- ------------------------------------------------------ 
b) 6 – 12 months----- -------------------------------------------------- 
c) 1 – 3 years---- ------------------------------------------------------- 
d) 4 – 6 years---- ------------------------------------------------------- 
e) 7 – 9 years ----------------------------------------------------------- 
f) 10 – 15 years----- --------------------------------------------------- 
g) More than 15 years------------------------------------------------- 
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12. Please indicate if the patient has the following conditions: (Tick  that 
apply) 
a) Diabetes mellitus ------------------------------------------------------    
b) Vitamin B deficiency ---------------------------------------------------- 
c) Cancer ----------------------------------------------------------------------  
d) Multiple sclerosis ---------------------------------------------------------   
e) Spinal cord disorders and cognitive problems -------------------- 
f) Hypothyroidism ------------------------------------------------------------   
g) Uraemia ---------------------------------------------------------------------    
h) Toxic exposure ------------------------------------------------------------   
i) Hereditary neuropathy----------------------------------------------------- 
j) A history of neoplasm -----------------------------------------------------   
k) Any other (please specify) ---------------------------------------------- 
 
13. Please indicate if the patient present the following symptoms:(Tick all 
that apply) 
a) Pain:   Hand and arms        Feet and Legs    
b) Paraesthesia: Hand and arms        Feet and Legs    
c) Numbness: Hand and arms         Feet and Legs   
 
14. If the patient presents any of the above symptoms, when did the 
symptoms start? (If remember/recorded) 
a) Before start ARVs      
b) After starting ARVs  
 
15. If after start ARVs, after how long on ARVs did the symptoms commence (if 
remember or recorded) 
 
a) 1 – 6 months---- ---------------------------------------------------- 
b) 6 – 12 months----- -------------------------------------------------- 
c) 1 – 3 years---- ------------------------------------------------------- 
d) 4 – 6 years---- ------------------------------------------------------- 
e) More than 6 years -------------------------------------------------- 
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Appendix A3: ACTG Brief Peripheral Neuropathy Screening Tool  
 
INSTRUCTIONS FOR RECORDING SUBJECTIVE ELICITED SYMPTOMS 
  
Ask the subject to rate the severity of each symptom listed in question 1 on a scale of 
01 (mild) to 10 (most severe) for right and left feet and legs. Enter the score for each 
symptom in the columns marked R (right lower limb) and L (left lower limb). If a 
symptom has been present in the past, but not since the last visit, enter „00-Currently 
Absent‟. If the symptom has never been present, enter „11-Always Been Normal‟  
 
Always been 
normal 
Currently 
absent 
 
Mild__________________________________Severe  
 
11 00 01 02 03 04 05 06 07 08 09 10 
 
 
1. SYMPTOMS          R      
L     
a. Pain, aching, or burning in feet, legs ………………                               
 
 b. “Pins and needles” in feet, legs ………………………………  
 
c. Numbness (lack of feeling) in feet, legs ……………………………… 
 
INSTRUCTIONS FOR GRADING SUBJECTIVE ELICITED SYMPTOMS  
Use the single highest severity score from question 1. above to obtain a subjective 
sensory neuropathy score. If all severity scores are ‟00‟ or „11‟, the subjective 
sensory neuropathy score will equal „0‟  
Presence/Severity Score of: 
01 – 03 = Grade of 1 
04 – 06 = Grade of 2 
07 – 10 = Grade of 3 
11 or 00 = Grade of 0 
 
2. Subjective sensory neuropathy grade …………………………………….. R      L 
 
3. Location of symptoms  
Use Score of:  
0 = None  
1 = feet only  
2 = extends to ankles  
3 = extends above ankle but not to knee  
4 = extends to knees  
5 = extends above knees  
R      
L  
 
a. Pain, aching, or burning in feet, legs ………………                               
 
b. “Pins and needles” in feet, legs ………………………………  
 
c. Numbness (lack of feeling) in feet, legs ……………………………… 
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INSTRUCTIONS FOR EVALUATING PERCEPTION OF VIBRATION  
 
Compress the ends of a 128 Hz tuning fork just hard enough that the sides touch. 
Place the vibrating tuning fork on a bony prominence on the subject‟s wrist or hand to 
be sure that they can recognize the vibration or “buzzing” quality of the tuning fork. 
Again, compress the ends of the tuning fork just hard enough so that the sides touch. 
Immediately place the vibrating tuning fork gently but firmly on the top of the distal 
interphalangeal (DIP) joint of one great toe and begin counting the seconds. Instruct 
the subject to tell you when the “buzzing” stops. Repeat for the other great toe.  
 
4. Vibration Perception  
R      
L  
a. Great toe DIP joint perception of vibration in seconds  
  
 
      
b. Vibration perception score       R     
L 
0 = felt > 10 seconds  
1 = felt 6-10 seconds  
2 = felt < 5 seconds  
3 = not felt  
8 = unable/did not evaluate  
 
INSTRUCTIONS FOR EVALUATING DEEP TENDON REFLEXES  
 
With the subject seated, the examiner uses one hand to press upward on the ball of 
the foot, dorsiflexing the subject‟s ankle to 90 degrees. Using a reflex hammer, the 
examiner then strikes the Achilles tendon. The tendon reflex is felt by the examiner‟s 
hand as a plantar flexion of the foot, appearing after a slight delay from the time the 
Achilles tendon was struck. Use reinforcement by having the subject clench his/her 
fist before classifying the reflex as absent.  
 
Ankle reflexes  
0 = absent  
1 = Hypoactive  
2 = Normal deep tendon reflexes  
3 = Hyperactive  
4 = Clonus  
8 = unable/did not assess  
R      
L  
5. Ankle reflexes ………………………………………………….. 
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Appendix A4: Bepa rekukukokai 
 
Shona version of the Subjective Peripheral Neuropathy Screen Questionnaire 
(by the participant) 
 
Runhare rwenyu      Code  Date   
  
 
Tinokumbira kuti mutore nguva shomanana kupindura zvamunonzwa mumakumbo 
uye mutsoka dzenyu. Nyorai pana hongu kana kuti pana kwete zvichienderana 
nezvamunowanzo kunzwa. Tatenda. 
- 
1. Munombo nzwa chiveve mumakumbo nemutsoka here?   
 
2. Munonzwa kupiswa here mutsoka kana mumakumbo?   
 
3. Makumbo enyu anoteta kubatwa here?    
 
4. Munomboita kuoma kwamarunda here mumakumbo kana mutsoka? 
 
5. Munombonzwa kunenge kubayiwabayiwa mumakumbo enyu here kana 
mutsoka?        
6. Munorwadziwa here usiku kana kuti kana magumwa ganda renyu 
nemachira?         
 
7. Kana muchindogeza munotadza here kunzwa kuti mvura iri kupisa here kana 
kutonhora?        
 
8. Munomboita here kunzwa kubaiwabayiwa mutsoka kana mumakumbo? 
 
9. Munombonzwa here kunge makumbo kana tsoka dzenyu dzarara, kana 
kushaiwa kunzwa makumbo kana tsoka dzenyu?   
 
10. Munonzwa kushaiwa simba here kana muchifamba ?  
 
11. Zvamunonzwa zvinonyanya usiku here?    
 
12. Makumbo kana tsoka dzenyu kana zvose zvinorwadza here kana mofamba? 
 
13. Munotadza here kunzwa tsoka dzenyu kana muchifamba? 
 
14. Ganda renyu remutsoka rakaomara here kana kuita man‟a? 
 
15. Munombonzwa here kurwadziwa kunge munogwinhwa nemagetsi mutsoka 
kana mumakumbo enyu?      
Kwete 
 
Generic Screening Tools for Peripheral Neuropathy, (Neurology Working Group of 
the National Centre in HIV Epidemiology and Clinical Research, 2004)  
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Appendix B:  Performance–Oriented Mobility Assessment 
 
 
 
 
 
Adapted from Kegelmeyer, et al., (2007) and Faber, et al., (2006). 
 
 
Balance 
 
Instructions: The subject is seated on a hard, 
armless chair.  
 
The following maneuvers are tested 
 
 Gait 
Instructions: The subject stands with the 
examiner, walks down the hallway or room at 
the usual pace. The subject is asked to walk 
down the walkway’ turn’ and walk back after 
being instructed to go.(using the usual walking 
aids.) 
 
1. Sitting balance 
Leans or slides on the chair, 
Steady, safe 
2. Arising 
Unable to arise without help 
Able but uses arms to help 
Able without using arms 
3. Immediate standing balance (first 5 
seconds) 
Unsteady, swaggers, moves feet, marked 
trunk sway,  
Steady but uses walker or other support 
Steady without walker or other support 
4. Standing balance (after 5 seconds 
Unsteady 
Steady but wide stance (heels 10 cm apart 
and uses cane or other support 
Narrow stance without support 
5. Nudged (Light push on the sternum, 
subject with feet as close together 
as possible) 
Begins to fall, 
Staggers, grabs, catches self 
Steady  
6. Eyes closed (feet as close together 
as possible) 
Unsteady 
Steady 
7. Turning 360º 
Discontinuous steps 
Continuous 
Unsteady (grabs staggers) 
Steady 
8. Sitting down 
Unsafe (misjudged distance, falls onto chair) 
Uses arms or not a smooth motion 
Safe smooth motion 
 
Balance score 
 
0 
1 
 
0 
1 
2 
 
 
 
0 
1 
2 
 
 
0 
 
1 
2 
 
 
 
0 
1 
2 
 
 
0 
1 
 
0 
1 
0 
1 
 
 
0 
1 
2 
 
/16 
1. Initiation of gait (immediately after go) 
Any hesitancy or multiple attempts to start 
No hesitancy to start 
2. Step length and height  
Right swing foot does not pass left stance foot 
with step 
Passes left stance foot  
Left swing foot does not pass right stance foot 
with step 
Passes right stance foot  
Right foot does not clear floor completely with 
step 
Right foot completely clears floor. 
Left foot does not clear floor completely with 
step 
Right foot completely clears floor 
3. Step symmetry 
Right and left step lengths not equal 
Right and left steps appear equal 
4. Step continuity 
Stopping or discontinuity between steps 
Steps appear continuous 
5. Path (estimated in relation to floor 
tiles 30cm in diameter observe 
excursion of 1 foot over about 3 
meters of the course) 
Marked deviation 
Mild /moderate deviation or uses walking aid 
Straight without walking aid 
6. Trunk 
Marked sway or uses walking aid 
No sway but flexion of knees or back or 
spread arms 
No sway no flexion, no use of arms, and no 
use of walking aid 
7. Walking stance 
Heels apart 
Heels almost touching while walking 
Gait score 
 
 
 
0 
1 
 
 
0 
1 
 
0 
1 
 
0 
1 
0 
 
1 
 
0 
1 
 
0 
1 
 
 
 
 
0 
 
1 
2 
 
0 
 
1 
 
2 
 
0 
1 
/12 
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Appendix C: South African English version of the EQ-5D 
 
By placing a tick in one box in each group below, please indicate which statements 
best describe your own state of health TODAY. 
 
Mobility 
I have no problems in walking about  
I have some problems in walking about  
I am confined to bed  
 
Self-Care 
I have no problems with self-care  
I have some problems washing or dressing myself  
I am unable to wash or dress myself  
 
Usual Activities (e.g. work, study, housework, family or 
leisure activities) 
I have no problems with performing my usual activities  
I have some problems with performing my usual activities  
I am unable to perform my usual activities  
 
Pain/Discomfort 
I have no pain or discomfort  
I have moderate pain or discomfort  
I have extreme pain or discomfort  
 
Anxiety/Depression 
I am not anxious or depressed  
I am moderately anxious or depressed  
I am extremely anxious or depressed  
 
Compared with my general 
level of health over the past 12 months, 
my state of health today is: 
 
Better   PLEASE TICK 
Much the same  ONE 
Worse  BOX 
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To help people say how good or bad their state of 
health is, we have drawn a scale on which the 
best state you can imagine is marked 100 and the 
worst state you can imagine is marked 0. 
 
We would like you to indicate on this scale, in your 
opinion, how good or bad your own health is 
today. Please do this by drawing a line from the 
box below to whichever point on the scale 
indicates how good or bad your state of health is 
today. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Your own 
state of health 
today 
9 0 
8 0 
7 0 
6 0 
5 0 
4 0 
3 0 
2 0 
1 0 
100 
Worst 
imaginable 
state of 
health 
0 
Best  
imaginable 
state of health 
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Because all replies are anonymous, it will help us to understand your answers better 
if we have a little background data from everyone, as covered in the following 
questions. 
 
1. Have you experienced serious illness? Yes No 
  yourself   
  in your family   
  while caring for others   
 
2. What is your age in years? 
 
3. Are you male or female? Male Female 
     
 
4. I smoke  
  I used to smoke  
  I have never smoked  
 
5. Do you now, or did you ever, work in Yes No 
 health services or social welfare?   
 
 If so, in what capacity? ..........................................................................  
 
6. Which of the following best describes your main activity? 
  self employed  
  in formal employment   
  retired  
  homemaker/domestic worker  
  student  
  seeking work  
  other (please specify)   ............................................  
 
    
7. What was the highest grade that you attained at school? 
  Yes No 
8. Do you have a diploma or equivalent?   
 
9. State the area/suburb in which you stay,  Please write it 
here................................. 
 
 
 
 
 
PLEASE TICK 
APPROPRIATE 
BOXES 
PLEASE TICK 
APPROPRIATE 
BOX 
PLEASE TICK 
APPROPRIATE 
BOX 
PLEASE TICK 
APPROPRIATE 
BOX 
PLEASE TICK 
APPROPRIATE 
BOX 
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Appendix D: Shona Version of the EQ-5D 
 
Muchikwata chimwe nechimwe chemhinduro dzinotevera, isa mucherechedzo  
mukabhokisi kari kumucheto seizvi            pamhinduro imwe chete yaunofunga kuti 
ndiyo inonyatsotsanangura utano hwako PARINHASI.  
Kugona kufamba 
Handinetseki kufamba  
Kufamba kunondinetsa  
Handigone kana nekufamba kose  
 
Kuzvishambidza 
Ndinogona zvangu kuzvishambidza  
Handinyatsogona kuzvigezesa kana kuzvipfekedza  
Handigone kuzvigezesa kana kuzvipfedza   
 
Mabasa enguva dzose (Akafanana ne: kushanda, kudziidza  mabhuku,  
kuita basa remumba kana repamba, kutandara kana kuvaraidzana nemhuri) 
Handinetseki nokuita mabasa angu andinowanzoita nguva dzose  
Ndinonetseka kuita mabasa angu andinowanzoita mazuva ose  
Handichagoni kuita mabasa angu andaiwanzoita mazuva ose  
 
Kurwadziwa/ Kusagadzikana 
Handisi kurwadziwa  
Ndinorwadziwa zwangu zvishoma  
Ndinorwadziwa zvakanyanya.  
 
Kunetsekana mupfungwa / Kuremerwa  
Hapana zvinondinetsa mupfungwa  
Ndine zvinodinetsa zwakati kuti  
Ndirikushushikana zvakanyanya  
 
Kana ndichienzanisa utano hwangu pamwedzi gumi nemiviri yapfuura neparinhasi,  
ndingati zvangu nhasi: 
 
Zvava nani  SARUDZA 
Zvakangofanana  BHOKISI 
Zvatonyanya  RIMWE CHETE 
 
 
 
 
 
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Kuti tibatsire vanhu kuti vaone kunaka kana 
kushata kwakaita utano hwavo  parinhasi, takupa 
chikero ichi chekupimisa nacho utano hwako. 
Chine nhamba dzinobvira pasi pana 0 kusvika 
kumusoro kuna 100. 0 anoratidza utano 
hwakadzikira hwemunhu anorwara zvakasvoipisa. 
100 anoratidza utano hwakaisvonakisa 
hwemunhu asingarware. 
Tinokumbira kuti unongedze nhamba pachikero 
apa yaunofunga kuti ndiyo inoratidza ipo chaipo 
pane utano hwako nhasi uno. Ita izvi nokunyora 
mutsetse unotangira kubva pachibhokisi chiri 
pazasi icho wakananga nechekurudyi uko 
kunechikero uchinoguma ipo chiapo pane 
nhamba yawasarudza yaunofungira kuti ndiyo 
chaiyo inoratidza pava neutano hwako nhasi. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Utano  
hwako nhasi 
 uno. 
 
9 0 
8 0 
7 0 
6 0 
5 0 
4 0 
3 0 
2 0 
1 0 
100 
Utano 
hwakaisvoipisa 
0 
Utano 
hwakaisvona
kisa 
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Sezvo mhinduro dzako dzichange dzisina zita rako, tinokumbirawo kuti  utiudzewo 
zvimwe zvemagariro aka neupenyu hwako kubva muneizvi zvinotevera. Isa 
mucherechedzo mukabhokisi seizvi                 pamhinduro yaunenge wasarudza . 
 
1. Wakamboona here munhu achirwara zvakaipisisa? Hongu Kwete 
  Ndiwe here iwe pachako?           
  Mumwewo here wemumhuri menyu?       
  Mumwewo here wawakaona mubasa reutano  
  kana mukubatsira vanhu kwawaiita?      
 
2. Une makore mangani?    
3. Uri murume kana kuti mukadzi here?    Murume Mukadzi 
     
4.    Unoputa fodya here? 
 Ndinoputa.  
  Ndaimboputa  
  Handina kugara ndamboputa  
 
5. Unoshanda basa reutano kana rekubatsira  
vanhu here izvozvi,  kana kuti wakamboshanda  Hongu Kwete 
basa  reutano  kana rekubatsira vanhu here?   
Kana zviriizvo, waishanda uri pachinzvimbo chipi? ......................................  
6. Pane zvirikutevera izvi, tiudze chaungati ndicho  
chaicho chinhu chikuru chauri kuita: 
  basa rekuzvishandira   
  basa rekubairwa chitupa  
  pamudyandigere         
  basa remumba kana pamba       
  mwana wechikoro         
  kutswaka basa      
  Chimwewo chatasiya (tiudze kuti chii)   .............................................  
  
7. Wakasvika pagwaro ripi nekufunda kwako kuchikoro? 
 
8.   Une dhipuroma here kana kuti  Hongu Kwete 
imwewo kosi zvayo yakafanana nedhipuroma?    
 
9.    Kana uchiziva nzvimbo/rukesheni raunogara tinyorerewo apa 
………………………. 
 
 
 
SARUDZAI BHOKISI 
RIMWE CHETE 
SARUDZAI BHOKISI 
RIMWE CHETE 
 
SARUDZAI BHOKISI 
RIMWE CHETE 
 
SARUDZAI BHOKISI 
RIMWE CHETE 
SARUDZAI BHOKISI 
RIMWE CHETE 
SARUDZAI BHOKISI 
RIMWE CHETE 
 
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Appendix E:  Wong Baker Faces 
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Appendix F:  Scoring EQ-5D health states 
 
(Based on A1 TARIFF BASED ON UK SURVEY (1993)) 
 
Values for the 243 health states defined by the EuroQoL classification have been 
calculated using a regression model. The following worked example indicates how 
these coefficients are to be used so as to compute the estimated values for each 
state. 
 
Calculating EQ-5D state scores - a worked example 
 
 
EuroQoL dimension Level 2  Level 3 
Mobility 0.069   0.314 
Self-care 0.104   0.214 
Usual activity 0.036   0.094 
Pain / discomfort 0.123   0.386 
Anxiety / depression 0.071   0.236 
 Constant = 0.081   N3 = 0.269 
 
             
The arithmetic needed to recover the estimated value for any health state from this 
table of decrements is given by the following example:  
 
Taking health state 1 1 2 2 3 
 
Full health ( 1 1 1 1 1) = 1.0 
 
Constant term (for any dysfunctional state) (subtract 0.081) 
 
Mobility.. level 1(subtract 0) 
Self-care.. level 1(subtract 0) 
Usual activity.. level 2(subtract 0.036) 
Pain / discomfort.. level 2(subtract 0.123) 
Anxiety / depression.. level 3(subtract 0.236) 
 
Level 3 occurs within at least 1 dimension (subtract N3 parameter 0.269)  
 
Hence the estimated value for state 1 1 2 3 3 is given by 
 
1.0 - 0.081 - 0.036 - 0.123 - 0.236 - 0.269 = .2      
 
 
- 0.081 - 0.036 - 0.123 - 0.236 - 0.269 = .255 
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Appendix G:  Per protocol analyses of post intervention 
results between the experimental group and the control group  
 
 
Introduction 
The results of the study were analysed to establish the effect of progressive resisted 
exercises on gait, balance and pain as outlined in the objectives using per protocol 
analysis. The analysis will establish if there was a difference in the muscle strength 
change between the control group and the experimental group post intervention and 
within the control group and within the experimental group post intervention. 
 
Muscle strength difference between the combined control group and 
combined experimental group 
The mean muscle strength difference between the combined control group and 
experimental group post intervention is summarized in Table 4.9 below. 
 
Table 4.9 Mean muscle strength difference between the control group and 
experimental group after intervention (n=64) 
Muscle Mean muscle  
strength difference 
Standard 
error 
 (CI) p 
value 
Right quadriceps -0.01 1.15 -2.31- 2.28 1.0 
Left quadriceps 0.89 1.14 -1.39- 3.16 0.44 
Right hamstrings -0.13 0.67 -1.47- 1.20 0.84 
Left hamstrings -0.35 0.67 -1.69- 0.98 0.60 
Right gastrocnemius 
muscle 
-0.38 1.07 -2.51- 1.76 0.72 
Left gastrocnemius 
muscle 
-0.10 1.11 -2.33- 2.13 0.93 
Right tibialis anterior 1.01 1.01 -1.00- 3.01 0.32 
Left tibialis anterior 0.87 0.94 -1.01- 2.76 0.36 
 
There was no difference in the mean muscle strength change between the combined 
control group and the combined experimental group, p range of p =0.32 to p =1.0. 
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Gait, balance and pain differences between the combined control group 
and combined experimental group after intervention 
These results answer the objectives 1, 2 and 3 on the effects of progressive resisted 
exercises. The differences in the gait score, balance score and pain score between 
the control group and the experimental group after intervention are summarized in 
Table 4.10. 
 
Table 4.10 Difference in the gait score, balance score and pain score between 
the control group and the experimental group after intervention  
Variable  z scores p value 
Gait -0.60 0.55 
Balance -1.08 0.28 
Pain scores -2.38 0.02 
 
There was no difference in the changes in the gait scores of the performance 
oriented mobility assessments between the experimental and control groups p=0.55. 
The balance scores of the performance oriented mobility between the experimental 
and control group after the intervention were similar p=0.28.  There was a difference 
in the pain score change between the control group and the experimental group 
p=0.02. 
 
Health related quality of quality differences between the combined 
groups after intervention 
The difference in the quality of life score between the control group and the 
experimental group after intervention is shown in Table 4.11 
 
Table 4.11 Difference in the quality of life score between the control group and 
the experimental group after intervention 
 QOL utility 
 score change 
Standard 
Error 
 (Confidence 
Interval) 
p 
value 
QOL utility 
score 
12 7.40 -2.76 - 26.81 0.11 
 
The changes in the health related quality of life in the combined experimental group 
and combined control groups after the intervention were similar p=0.11. 
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The relationships between the changes in gait, balance, pain and quality 
of life 
 
The fourth objective that sought to establish if there is a relationship between the 
levels of performance-oriented mobility and health related quality of life in participants 
with HIV/AIDS related DSP will be explored in this section based on the per protocol 
analysis.  
 
Gait relationships 
 
Gait relations with quality of life are presented in Table 4.12a, below. Gait was also 
related with the level of neuropathy, level of education and muscle strength of the 
right tibialis muscle as presented in Table 4.12a, Table 12b and Table 12c below. 
 
Table 4.12a Univariate model showing the correlation between gait and quality 
of life, level of neuropathy, level of education and muscle strength of the right 
tibialis muscle 
Variable Odds 
ratio 
Confidence 
interval 
z p value 
Right tibialis anterior 
muscle strength 
1.17 1.04-1.31 2.69 0.007 
Quality of life 1.03 1.02- 1.05 1.03 0.00 
Level of neuropathy 0.82 0.67- 1.0 -1.96 0.05 
Level of education 0.70 0.50- 0.98 -2.08 0.05 
 
The results of the models depicted in table 4.12a demonstrate significant association 
between the changes in gait and quality of life (p=0.001). There is also a significant 
association between gait and the level of neuropathy (p=0.03), level of education 
(p=0.02) and muscle strength of the right tibialis anterior muscle (p=0.02). 
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Table 4.12b Adjusted model showing the correlation between gait and the 
quality of life, level of neuropathy, level of education and muscle strength of 
the right tibialis muscle after adjusting for time and group 
 Odds ratio Confidence 
interval 
z p value 
Right tibialis anterior 
muscle strength 
1.28 1.1- 1.5 3.22 0.001 
Quality of life   1.03 1.02- 1.06 3.76 0.00 
Level of neuropathy 0.80 0.66- 0.98 -2.15 0.03 
Level of education 0.69 0.49- 0.97 -2.16 0.03 
 
 
Table 4.12c Multivariate model showing the relationship between gait and the 
quality of life, level of education and muscle strength of the right tibialis 
muscle 
 Odds ratio Confidence 
interval 
z p value 
Right tibialis anterior 
muscle strength 
1.22 1.03-1.45 2.27 0.02 
Quality of life 1.03 1.01- 1.06 3.29 0.001 
Level of education 0.60 0.39- 0.92 -2.16 0.02 
 
 
The results of the models depicted in table 4.12a and table 4.12b demonstrate 
significant relation in the changes in gait and quality of life (p=0.001). There is also a 
correlation between gait and the level of neuropathy (p=0.03), level of education 
(p=0.02) and muscle strength of the right tibialis anterior muscle (p=0.02). 
 
Balance relationships 
 
The relationship between balance and the level of pain, and muscle strength of the 
right and left hamstring muscle are described in Table 4.13a and Table 4.13b. 
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Table 4.13a Univariate model showing the correlation between balance and the 
quality of life, level of pain, and muscle strength of the right hamstring muscle 
 Odds 
ratio 
Confidence 
interval 
z p 
value 
Right hamstring muscle 
strength 
1.20 1.04- 1.38 2.45 0.01 
Left hamstring muscle 
strength 
1.18 1.02- 1.38 2.20 0.03 
Level of pain 0.51 0.37- 0.72 -3.83 0.00 
 
There was significant correlation between the level of balance and the level of pain 
(p=0.00) muscle strength of the right hamstring muscle p=0.01, muscle strength of 
the left hamstring muscle p=0.03. There was no correlation between balance and 
quality of life. 
 
Table 4.13b Adjusted model showing the correlation between balance, level of 
pain and the quality of life  
 Odds ratio Confidence interval z-score p value 
Level of pain 0.54 0.37- 0.77 3.38 0.001 
 
There was significant correlation between the change in balance and the level of 
pain, (p=0.001) as depicted by the adjusted model. The multivariate model showed a 
similar significant relationship between balance and the level of pain (p=0.002) 
 
 
 
 
 
Pain relationships 
 
The relationship between pain and the quality of life, level of neuropathy, and muscle 
strength of the left gastrocnemius muscle strength is shown in Table 4.14a and Table 
4.14b. 
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Table 4.14a Univariate model showing the correlation between pain and the 
quality of life, level of neuropathy, and muscle strength of the left 
gastrocnemius muscle  
 Odds 
ratio 
Confidence 
interval 
z-
score 
p 
value 
Left gastrocnemius muscle 
strength 
1.08 1.00- 1.17 1.95 0.051 
Quality of life 1.02 1.01- 1.03 2.82 0.005 
Level of neuropathy 0.88 0.76- 1.01 -1.81 0.07 
 
The correlation between pain and the quality of life was significant (p= 0.005) using 
the univariate model.  Pain was also trended to correlate with the level of peripheral 
neuropathy p=0.07. 
 
Health related quality of life relationships. 
 
The correlation between the quality of life and pain, the level of neuropathy, level of 
education level of health, muscle strength of the right and left quadriceps muscles is 
shown in Table 4.15a Table 4.15b and Table 4.15c below 
 
Table 4.15a Univariate model showing the correlation between the quality of 
life and pain, the level of neuropathy, level of education level of health, muscle 
strength of the right and left quadriceps muscles 
 Odds ratio Confidence interval z p 
value 
Muscle strength  right 
quadriceps 
1.08 1.0- 1.18 1.86 0.06 
Muscle strength  left 
quadriceps 
1.11 1.01-1.21 2.19 0.03 
Pain score 0.59 0.43- 0.81 -
3.27 
0.001 
Level of health  0.41 0.22- 0.76 -
2.85 
0.004 
Level of  neuropathy 0.86 0.76 0.97 -
2.42 
0.015 
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The correlation between quality of life and pain were similar p=0.001, the level of 
neuropathy p=0.01, level of health p=0.004, muscle strength of the right and left 
quadriceps muscles p=0.06 and p=0.03 respectively. 
 
Table 4.15b Temporal and group adjusted model showing the correlation 
between the quality of life, level of health, muscle strength of the right 
quadriceps muscle strength of the left quadriceps muscle and pain 
 Odds 
ratio 
Confidence 
interval 
z p 
value 
Level of health 0.39 0.21-0.73 -
2.92 
0.004 
Muscle strength  right 
quadriceps 
1.09 1.0-1.19 1.92 0.055 
Muscle strength  left 
quadriceps 
1.13 1.02- 1.25 2.32 0.021 
Pain 0.56 0.4- 0.79 3.35 0.01 
 
The correlation between quality of life and pain was significant p=0.001, and with the 
level of health p=0.004, muscle strength of the right and left quadriceps muscles 
p=0.06 and p=0.03 respectively in the temporal and group adjusted and the 
multivariate model. 
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Appendix H:  Post intervention results of Study 1 and Study 2 
 
 
The combined results of the reassessments done post intervention at week 12 of in 
Study 1 and Study 2 will be presented below. The results showing individual study 
results are presented in Appendix H 
 
Gait performance (Study 1 and Study 2 combined) 
Gait performance post intervention assessed using the performance oriented mobility 
(POMA) in the participants in Study 1 and Study 2 combined is presented in Table 
4.9 
Table 4.9 Gait scores post intervention in the participants (Study 1 and Study 
2) (n=64) 
Gait score Control group (n=29) n 
(%) 
Experimental group (n=16) n 
(%) 
Poor   (<9) 0 0 
Good (9-10) 3 (13.3) 6 (18.8) 
Excellent (11-
12) 
26 (86.7) 29 (71.2) 
 
Balance performance (Study 1 and Study 2 combined) 
Table 4.10 below presents the level of balance performance post intervention 
measured using the performance oriented mobility (POMA) in the participants in 
Study 1 and Study 2. 
Table 4.10 Balance scores post intervention in the participants (Study 1 and 
Study 2) (n=64) 
Balance score Control group 1 (n=15) n 
(%) 
Experimental group 1 (n=35) n 
(%) 
Poor (<10)  0 0 
Good (11-14) 7(33.3) 14 (50) 
Excellent(15-
16) 
22 (66.7) 21 (50) 
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Pain levels Study 1 and Study 2 combined 
Table 4.11 shows the pain levels of the participants in combined Study 1 and Study 2 
post intervention as assessed Wong baker faces. 
Table 4.11 Pain levels at post intervention in participants in (Study 1 and Study 
2 combined) (n=64) 
Pain level Control group 1 (n= 29) 
n (%) 
Experimental group 
(n=33) n (%) 
No hurt (0) 3 (10.3) 10 (6.2) 
Hurts a little bit (1)  8 (20) 14 (43.7) 
Hurts a little more (2) 8 (33.3) 4 (18.8) 
Hurts even more (3)  7 (26.7) 6 (25) 
Hurts whole lot (4) 3 (10.3) 1 (6.3) 
 
There was no difference in the pain level between the experimental and the control 
group, after the intervention for both Study 1, p=0.12 and study 2 p=0.17. 
 
Health related quality of life levels Study 1 and Study 2 
Table 4.12 below presents the health related quality of life levels of the participants in 
study 1 and study 2 post -intervention, as assessed by EQ5D  
 
Table 4.12 Health related quality of life levels post intervention of the 
participants in study 1  and study 2 (n=64) 
EQ5D level of 
health 
Control group (n=29) n 
(%) 
Experimental group (n=35) n 
(%) 
Better  25 (80) 29 (68.8) 
Same  3 (13.3) 4 (18.7) 
Worse  1 (6.7) 2 (12.5) 
VAS   
 
The health related quality of life visual analogue scale showed no difference between 
the groups at post intervention point p=0.68.  
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Appendix I:  Hand Held Dynamometer 
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Appendix J:  Approval of Title and Ethical Clearance Letters 
from Committees. 
 
 
 
 
134 
 
 
 
 
 
 
135 
 
 
 
 
 
 
 
 
136 
 
 
 
 
137 
 
 
 
 
 
 
 
 
138 
 
 
 
 
 
 
 
139 
 
 
 
 
 
 
140 
 
 
 
 
 
 
 
 
141 
 
 
 
 
 
 
 
 
142 
 
 
 
 
 
 
 
 
143 
 
 
Appendix K:  Participant Consent Information Sheet 
 
 
 
APPENDIX 23A: SUBJECT INFORMED CONSENT 
 
PROTOCOL TITLE: 
THE EFFECTS OF RESISTED EXERCISES ON PERFOMANCE ORIENTED 
MOBILITY IN PERSONS WITH HIV RELATED POLY-NEUROPATHY 
PROGRESSIVE  
 
NAME OF RESEARCHER: Khumbula Mkandla, BSc. Physiotherapy (Hons) 
 
PHONE: 011 874 996 Tel: 263-4-797800 
 
PROJECT DESCRIPTION: 
 
Hallo. I am a postgraduate student (MSc), in the Physiotherapy Department at the 
University of the Witwatersrand, Johannesburg, South Africa. I am conducting a 
study in Zimbabwe in the field of HIV/AIDS care.  I am inviting you to take part in this 
study on the effects of exercises on mobility in persons with HIV related poly-
neuropathy.  
You are one of the 78 people whom we expect to participate in this study to be done 
in the Harare area in Zimbabwe. You were selected as a possible participant in this 
study because you are an adult living with HIV-related poly-neuropathy. 
 
YOUR RIGHTS  
 
Before you decide whether or not to volunteer for this, study you must understand 
purpose, how it may help you, the risk to you, and what is expected of you .This 
process is called information consent. 
 
PURPOSE OF RESEARCH STUDY 
  
The aim of this study is to find out the effects of exercise on mobility and health 
related quality of life in people living with HIV. As part of this study, I need to make 
sure I find what effect exercises have on gait, balance and pain levels in people with 
HIV/AIDS related poly neuropathy. The study also wishes to see if the effect on 
mobility changes the health related quality of life in people with poly neuropathy.  
 
Initials    
 
 
 
 
144 
 
 
Page 2 [of 4].       MRCZ No. MRCZ/B/62. 
 
PROCEDURES INVOLVED IN THE STUDY 
  
 Permission from you to look at your medical records to get information on 
your diagnosis and treatment?   
 Permission from you to assess if you are having any problems with feeling 
and strength in your legs. I will test how well you move around and for 
strength a non-invasive dynamometer (a small machine to measure force 
exerted) will be used. I will also use a set of activities to test your balance and 
the will ask you how much pain you have because of your condition.  
 You will be required to answer some questions for about 30 minutes to find 
out what other difficulties/troubles you have that may be caused by any 
disturbance in movement. There will be questions on how you feel about 
yourself and the quality of life you have now. 
 Following this all names will be put in a hat and you may be chosen to be in a 
group which will do exercises or you may be chosen to be in a group that 
does what is normally done in Zimbabwe. The exercises will be done in a gym 
in Harare where the group will not be identified as a group of participants with 
HIV but an exercise group. You will exercise for 50 minutes twice a week. The 
reason of exercises is to strengthen the muscles so as to improve the way 
they work.  
 At the beginning of the exercise programme and after four months your 
sensation, strength of leg muscles and balance will be tested 
 
RISKS AND DISCOMFORTS 
  
Except for working hard and getting body aches initially from exercising, we do not 
expect you to have any ill effects from this exercise. Normally in Zimbabwe the 
doctors and nurses offer you advice on home exercise. All potential participants will 
receive this standard care whether or not s/he participates in the research study. 
 
BENEFITS AND/OR COMPENSATION 
 
We expect that if you are in the group that does exercises you may become fitter, 
improve your gait and balance as well as reduce your pain and get a better quality of 
life. However we cannot and do not guarantee or promise that you that this will 
certainly happen from this study. Your transport costs will be covered but there are 
no costs involved in taking part in the exercise sessions. 
  
CONFIDENTIALITY OF RECORDS 
  
Care will be taken to ensure that no names are recorded. You will be given a code on 
the records and only I and the research assistants will have access to the list that 
links your name to the code. Under some circumstances, the ethics council and my 
examiners may need to look at patient records to check if the study is being done 
properly. However the information that is obtained in connection with this study that 
can be identified with you will remain confidential and will be made known only if you 
agree. 
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STUDY WITHDRAWAL  
 
If you feel you do not want to take part in the study for any reason you are free to do 
so. The normal treatment and services that you would need will not be affected in 
any way. If you should choose to participate, please sign the attached consent form 
and be assured you are free to stop at any time. 
 
IN THE EVENT OF INJURY 
 
 The risk of injury during this study is low. However should any injury occur 
during exercise such as a strain or sprain; treatment will be made available at 
Parirenyatwa Hospital. You should understand that we will not be able to pay for your 
treatment so the costs of such treatment will be paid by you. 
In the case that you get an injury, contact Anne Butau 0912 831 018 who will assist 
you. 
 
 
PROBLEMS/QUESTIONS 
 
 Before you sign this form, please ask any questions on any aspect of this 
study that is unclear to you. You may take as much time as necessary to think it over. 
 
If you have any questions concerning this study or consent form beyond those 
answered by the investigator, including questions about the research, your rights as 
a research subject or research-related injuries; or if you feel that you have been 
treated unfairly and would like to talk to someone other than a member of the 
research team, please feel free to contact the Medical Research Council of 
Zimbabwe on telephone 791792 or 791193. 
 
AUTHORIZATION 
 
 You are making a decision whether or not to participate in this study.  Your 
signature indicates that you have read and understood the information provided 
above, have had all your questions answered, and have decided to participate. 
 
 The date you sign this document to enroll in this study, that is, today‟s date, 
MUST fall between the dates indicated on the approval stamp affixed to each page.  
These dates indicate that this form is valid when you enroll in the study but do not 
reflect how long you may participate in the study.  Each page of this Informed 
Consent Form is stamped to indicate the form‟s validity as approved by the MRCZ. 
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AUTHORIZATION 
 
I have read this paper about the study or it was read to me. I understand the possible 
risk and benefits of this study. I know being in this study is voluntary. I choose to be 
in this study: I know I can stop being in the study and will not lose any benefits 
entitled to me. I will get a copy of this consent form. (Initial all the previous pages of 
the consent form) 
 
           
  
Client Signature                                                            Date 
 
        
Client Name (Printed) 
 
           
  
Research Signature                                                         Date 
 
           
  
Witness Signature     Date 
 
                                                                                        Initials    
 
 
 YOU WILL BE GIVEN A COPY OF THIS CONSENT FORM TO KEEP. 
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APPENDIX 23B:  GWARO REKUBVUMA KWAKAZIVISWA 
 
MUSORO WECHIDZIDZO 
THE EFFECTS OF RESISTED EXERCISES ON PERFOMANCE ORIENTED 
MOBILITY IN PERSONS WITH HIV RELATED POLY-NEUROPATHY 
PROGRESSIVE  
 
ZITA REMUTSVAGIRIDZI: Khumbula Mkandla, BSc. Physiotherapy (Hons) 
 
RUNHARE: 011 874 996 Tel: 263-4-797800 
 
RONDEDZERO YECHIDZIDZO 
 
Makadii Ini ndiri kuita dzidzo yepamusoro (MSc), muDepartment rePhysiotherapy 
paUniversity yeWitwatersrand, muJohannesburg, South Africa. Ndiri kuita chidzidzo 
chetsvagiridzo muZimbabwe maererano nezve kubatsirwa kweavo vaneutachiona 
hwe shuramatongo (HIV/AIDS). Ndinokukokai kuti mubatane nesu muchidzidzo ichi 
chinoongorora zvingaitika kumafambiro emunhu ane utachiona hweHIV uye 
achirwadziwa nemakumbo kana achinge aita zvekusimbisa muviri wake. Muri 
mumwe wevanhu makumi manomwe nesere avanhu vatiri kutarisira kuti vapinde 
muchidzidzo ichi chichaitwa munharaunda yeHarare muZimbabwe. Imi 
makasarudzwa semumwe angangopinda mutsvagiridzo iyi nekuti muri munhu 
abvazera anorarama neutachiona hwe HIV uye muchirwadziwa nemakumbo.  
 
KODZERO DZENYU 
 
Musati mafunga kuti mupinde here kana kuti kwete muchidzidzo ichi munofanira 
kunzwisisa chinangwa chechidzidzo, kuti munogona kubatsirika sei, zvinogona 
kukukuvadzai, uye zvinotarisirwa kwamuri. Maitire awa ndiwo anonzi kubvuma 
kwakaziviswa. 
 
CHINANGWA CHECHIDZIDZO 
 
Chinangwa chechidzidzo ichi ndechekutsvagiridza kuti chii chinoitika kana munhu 
aita urongwa hwekusimbisa muviri pakugona kwake kufamba uye magariro ane 
chekuita neutano muupenyu hweavo vari kurarama neHIV. Ndinoda kubata chokwadi 
maererano nezvinoitika kana munhu ane utachiona hweHIV uye achirwadziwa 
nemakumbo achinge aiita zvekusimbisa nyama maererano nemafambiro ake, 
mutsigo pakumira neudzamu hwemarwadzo. Chidzidzo ichi chinodawo kuwona 
zvinoitika kana mafambiro emunhu ane marwadzo emakumbo asanduka maererano 
nemanakiro ehupenyu hwake.  
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MATANHO EZVIITWA HWECHIDZIDZO 
 
 Mvumo kubva kwamuri yekuti ndigone kutarisa mumagwaro akanyorwa 
nezveutano hwenyu kuti ndiwane ruzivo maererano nekuti munechirwere 
chipi uye kuti makamborapwa sei? 
 Mvumo kubva kwamuri yekunyatsoongorora kana muine dambudziko 
maererano nekubatwa kana kushaya simba mumakumbo. Ndichaongorora 
kuti munofamba zvakanaka here uye ndichapima simba ririmumakumbo 
ndichishandisa kamuchina kadiki kano shandiswa kupima simba rinenge 
richishandiswa (dynamometer). Ndichazenge ndichishandisa zviitwa 
zvakasiyana siyana kuitirakuona kuti munomira makatsiga here uye 
ndichakubvunzai mushure mechiitiko chega chega kana pane kurwadziwa 
kwamunenge muchinzwa nekuda kwedambudzo ramuinaro. 
 Muchange muchizotarisirwa kupindura mibvunzo kwenguva ingangoita 
maminitsi anokwana makumi matatu kuti titsvage kana paine mamwe 
matambudziko kana kunetseka kwamungadaro muinako kuchikonzerwa 
nenekukanganisika kwakaitika pamusoro pamafambiro enyu. Pachaitawo 
mibvunzo pamusoro pezvamunonzwa pamusoro penyu uye kunaka 
kweupenyu hwamuri kurarama parizvino. 
 Mushure meizvi mazita ose achaiswa munguwani (hat) uye munozogona 
kuiswa muboka kana muchikwata chevachazo ita maexercise kana kuti 
muboka rinoita zvinosingoitwa muZimbabwe. Zviitwa zvekusimbisa muviri izvi 
zvichaitwa munzvimbo iri muHarare apo boka revanege vari muchirongwa 
ichi vanenge vachizivikanwa seboka rekuzvisimbisa muviri chete. Muchaita 
zvekusimbisa muviri izvi kwemaminitsi makumi mashanu kaviri pasvondo. 
Chikonzero chekusimbisa muviri kuti nyama dzemuviri dzivandudzwe 
mashandiro adzo. 
 Pamavambo nepekupedzisira pechirongwa mushure memwedzi mina 
muchaongororwa manzwiro enyu, simba remakumbo nekutsiga pakumira. 
 
MARWADZO KANA ZVINGANGOIPA 
 
Kunze kwekushanda zvine simba nekungorwadziwa nenyama dzemuviri mushure 
mekushanda muzviitwa zvekusimbisa muviri hapana zvimwe zvakaipa zvatinotarisira 
kuti zvingakonzerwe nechirongwa ichi. Kazhinji muZimbabwe vana chiremba 
nevakoti vanokunyeurirai chete kuti munoita zvekusimbisa muviri muri kumba. Vose 
vangangopinda muchidzidzo ichi vachapihwa nyeuriro iyi zvisinei kuti vapinda kana 
kuti varegera kupinda muchidzidzo chetsvagiridzo iyi. 
 
ZVAMUNGANGO BATSIRIKA NAZVO 
 
Tinotarisira kuti kana muri muchikwata chichange chichiita zvekusimbisa muviri 
muchagwinya uye kufamba nemutsigo wenyu zvichiva nani ukuwo marwadzo enyu 
oderera imi muchivawo neraramo yeupenyu yakavandudzwa. Zvisinei hatigoni kuti 
tikuvimbisei kuti izvi ndizvo zvichaitika zvechokwadi nekuda kwechidzidzo ichi. 
Muchapihwa muripo wemari yamunenge mashandisa kufambisa iyo muchadzorerwa 
asi hapana dzimwe mari dzamunozoripiswa kuti muite zvekusimbisa muviri 
nevamwe. 
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KUBUDA MUCHIDZIDZO 
 
Munogona kusarudza kuregera kupinda muchidzidzo kana kubuda muchidzidzo 
panguva ipi zvayo pasina kurasikirwa nezvamakakodzera kubatsirikana nazvo. 
Kurapwa kwenyu kwemazuva ose nezvimwe zvamunoitirwa zvamunoda 
hazvizokanganiswi nenzira ipi zvayo. Kana masarudza kuva mumwe wevari 
muchidzidzo, tapota isai runyorwa pabepa remvumo rakanamirirwa pamberi muine 
idi rekuti makasununguka kuregera chero ipi nguva zvayo. 
 
KUCHENGETEDZWA KWERUZIVO PAMUSORO PENYU  
 
Tichanyatso cherechedza kuti hapana mazita anonyorwa pasi. Muchapihwa imwe 
nzira yekucherechedza kuti ndimi (code) mune zvichanyorwa pamusoro penyu uye 
ini neve boka rangu ndisu tichange tichiziva kuti imi ndimi vapi. Pane dzimwe 
nhambo kanzuru inopa mitemo nemashandiro atinoita patsvagiridzo 
nevachaongorora basa rangu vanogona kutarisa magwaro atinonyora aneruzivo 
rwamunenge matipa vachida kuona kuti chidzidzo ichi chiri kuitwa nemazvo. 
Zvichakadaro, ruzivo rwamunenge matipa maererano nechidzidzo ichi rwunogona 
kukunongedzai kuti ndimi ani rwucharamba rwakachengetedzwa uye ruchabudiswa 
kanemi chete muchibvuma. 
Zvisinei ruzivo urwu rwungango budiswa kana zvichidikanwa nemutemo. 
 
KANA MUCHINGE MAKUVARA  
 
Mukana wekukuvara muchidzidzo ichi mushoma. Zvisinei zvazvo, kana 
muchinge makuvara zvakaita sekuminyuka, kanawo kudhonzeka kwenyama, 
munokwanisa kuzorapiwa pachipatara che Parirenyatwa. Tinokumbira kuti 
munzwisise kuti hatikwanise kunge tichizokubhadharirai kuchipatara nekudaro imi 
muchazokumbirwa kuti mubhadhare mari yekurapwa mega. Kuri kuti makuvara 
chayayi nhare kuna Anne Butau panhamba dzinoti 0912 831 018 iye anozo 
kubatsirai. 
 
MATAMBUDZIKO/MIBVUNZO 
 
Tapota bvunzai zvenyu nyangwe ipi zvayo mibvunzo pamusoro pechidzidzo ichi 
kana gwaro remvumo iyi iye zvino.  
Kana muine imwe mibvunzo mune ramangwana munogona kuzondifonera panhare 
dzinoti 011 874 996 / 263-4-797800 
 
Kana muine mibvunzo pamusoro pechidzidzo ichi kana kuti gwaro rekupamvumo iri 
pamusoro peiyo yapindurwa, nemusori ,kusanganisira mibvunzo ine chekuita 
netsvagiridzo iyi kana pekodzero dzenyu semunhu achange arimuchirongwa kana 
kukuvara kunechekuita nechidzidzo ichi. Kana kuti kana maona sekuti mabatwa 
zvisina kururama uye muchida kutaura nemumwe munhu asiri muboka 
revatsvagiridzi  sunungukai kuona ve Medical Research Council of Zimbabwe 
panhare idzi 791792 or 791193 
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MVUMO YENYU 
 
 Mavakuita sarudzo yekuti munoda here kana kuti hamudi kubatidzana nesu 
muchidzidzo ichi. Kuisa runyorwa kwenyu kucharatidza kuti maverenga 
mukanzwisisa tsananguro yatakupai pamusoro pechidzidzo uye kuti mibvunzo yenyu 
yose yapindurwa uye kuti mafunga kubatidzana nesu. 
 
 Zuva ramunoisa runyorwa rwenyu pagwaro iri rekupinda muchidzidzo ichi 
rinova zuva ranhasi, RINOFANIRA kuwira pakati pemazuva akaratidzwa pachitambi 
chemvumo chakaiswa pabepa regarega. Mazuva awa anoratidza kuti bepa iri ndere 
chokwadi apo munopinda muchidzidzo asi izvi hazviratidzi kuti muchange muri 
muchidzidzo kwenguva yakadii. Rimwe nerimwe remapepa awa emvumo 
akadhindwa kuratidza kuti zvechokwadi bepa iri rakabvumidzwa neve MRCZ. 
 
MVUMO YENYU 
 
Ndaverenga bepa iri pamusoro pechidzidzo ichi kana kuti ndaverengerwa nemumwe 
munhu. Ndanzwisisa zvingangoipa nekubatsirikana kungaitika muchidzidzo ichi. 
Ndinoziva kuti kuva muchidzidzo ichi kuda changu. Ndinoda kuva muchidzidzo ichi: 
Ndinoziva kuti ndinogona kuregera kuva muchidzidzo ichi pasina kurasikirwa ne izvo 
ndinofanira kubatsirikana nazvo. Ndichawana mapepa akafanana neandapa mvumo 
yangu awa. (Nyorai mavara ekutanga pamazita renyu pamapepa ose egwaro 
remvumo iri) 
 
           
  
Runyorwa rwenyu      Date 
 
        
Zita renyu (nyorai zvinoverengeka) 
 
           
  
Runyorwa rwemutsvagiridzi     Date 
 
           
  
Runyorwa rwemufakazi     Date 
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 MUCHAPIWA RIMWE BEPA REKUBVUMA KWENYU KUTI MUCHENGETE. 
 
 
 
